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Abstract
Lipids are important for the structural and physiological functions of neuronal cell 
membranes. Alterations in their lipid composition may result in membrane dysfunction 
and subsequent neuronal deficits that characterise various disorders. This study 
focused on profiling lipids of aged and LPS-treated rat brain and liver tissue with a view 
to explore the effect of atorvastatin in neuroinflammation, and examining lipid changes 
in different areas of rat brain of the Flinders Sensitive Line (FSL) rats, a genetic model 
of depression.
Lipids and other analytes extracted from tissue samples were analysed with proton 
nuclear magnetic resonance spectroscopy (1H-NMR), gas chromatography (GC) and 
liquid chromatography-tandem mass spectroscopy (LC/ESI-MS/MS).
Changes in the lipid profiles suggested that brain and liver responded differently to 
ageing and LPS-induced neuroinflammation. In the aged animals, n-3 PUFA were 
reduced in the brain but were increased in the liver. However, following treatment with 
LPS, these effects were not observed. Nevertheless, in both models, brain 
concentration of monounsaturated fatty acids was increased while the liver was able to 
maintain its monounsaturated fatty acid concentration. Atorvastatin reversed the 
reduction in n-3 PUFA in the aged brain without reducing brain and liver concentration 
of cholesterol. These findings further highlight alterations in lipid metabolism in age-
related neuroinflammation and show that the anti-inflammatory actions of atorvastatin 
may include a modulation of fatty acid metabolism.
When studying the FSL model, there were differences in the lipid profile of different 
brain areas of FSL rats compared to Sprague-Dawley controls. In all brain areas, 
arachidonic acid was increased in the FSL rats. Docosahexaenoic acid and ether lipids 
were reduced, while cholesterol and sphingolipids were increased in the hypothalamus 
of the FSL rats. Furthermore, total diacylglycerophospholipids were reduced in the 
prefrontal cortex and hypothalamus of the FSL rats. These results show differences in 
the lipid metabolism of the FSL rat brain and may be suggestive of changes occurring 
in the brain tissue in depression.
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11.0 INTRODUCTION
1.1 Lipids
Lipids are biologically important molecules that generally have a wide variety of 
structures. This has resulted in different ways of classifying them. One general 
classification is based on grouping them together according to their solubility 
characteristics as either neutral or polar lipids (Christie, 2003). Neutral lipids 
have a small or weak polar region and a dominant hydrocarbon region while 
polar lipids have a hydrocarbon region and a strong polar region. Cholesterol, 
cholesteryl esters and triacylglycerols are examples of neutral lipids and polar 
lipids include monoacylglycerols, diacylglycerols, glycerophospholipids, 
sphingolipids and glycolipids. 
Lipids function within cells as constituents of the cell membranes and energy 
storage molecules. Their distribution within the cell membrane is highly 
organized and this organization is crucial for the many roles that they are 
associated with. For example diacylglycerols are key signalling molecules in 
cellular functions and polyunsaturated fatty acids interact with other biological 
molecules such as proteins and genes and modulate their functions 
(Samochocki and Strosznajder, 1995).
1.2 Fatty acids
Fatty acids are a class of carboxylic acids that have a hydrocarbon chain of 
varying length. The carboxylic group is reactive and readily forms ester linkage 
with alcohol groups.
21.2.1 Classification and nomenclature
Fatty acids are broadly classified into saturated and unsaturated groups. The 
unsaturated fatty acids are further categorized into monounsaturated and 
polyunsaturated fatty acids. Saturated fatty acids are those that contain no 
double bonds in their hydrocarbon chains. Although most saturated fatty acids 
are straight chained and contain an even number of carbon atoms, there are 
also branch-chained, substituted and odd numbered saturated fatty acids. 
These are found mainly in bacteria, and are also present at low concentrations 
in sheep and goats (Duncan and Garton, 1978, Valero-Guillen et al., 1985). 
Saturated fatty acids are mostly found in triacylglycerols associated with energy 
storage and are abundant in oily seeds and the adipose tissue (Zancanaro et 
al., 1994). 
Fatty acids are given systematic chemical names based on the number of 
carbon atoms and the number and position of double bonds in the hydrocarbon 
chain. For instance: an 18-carbon straight-chained saturated fatty acid is 
therefore termed octadecanoic acid. The presence of a double bond changes 
the suffix from anoic to enoic, therefore the 18-carbon unsaturated fatty acid is 
octadecenoic acid. However, naming unsaturated fatty acids is further 
complicated by geometric and positional isomerism. Therefore, the terms cis or 
trans is used to denote the projection of the double bond. For example 
octadecenoic acid with two cis double bonds between carbons 9 and 10 and 
between carbons 12 and 13, is termed cis-9, cis 12-octadecenoic acid.
In addition, a shorthand nomenclature, which consists of two numbers 
separated by a colon, is commonly used. The number before the colon gives the 
3Shorthand Common name Systematic name
C14:0 Myristic acid n-Tetradecanoic acid
C16:0 Palmitic acid n-Hexadecanoic acid
C16:1n-7 Palmitoleic acid cis-9-hexadecenoic aid
C18:0 Stearic acid n-Octadecanoic acid
C18:1n-7 Vaccenic acid cis-11-octadecenoic acid
C18:1n-9 Oleic acid cis-9-octadecenoic acid
C18:2n-6 Linoleic acid cis,cis-9,12-octadecadienoic acid
C18:3n-3 α-Linolenic acid All-cis-9,12,15-octadecatrienoic acid
C18:3n-6 γ-Linolenic acid All-cis-6,9,12-octadecatrienoic acid
C20:0 Arachidic acid n-Eicosanoic acid
C20:3n-6 di-Homo-γ-linolenic All-cis-8,11,14-eicosatrienoic acid
C20:3n-9 Mead acid All-cis-11,14,17-eicosatrienoic acid
C20:4n-6 Arachidonic acid All-cis-5,8,11,14-eicosatetraenoic acid
C20:5n-3 Eicosapentaenoic All-cis-5,8,11,14,17-eicosapentaenoic acid
C22:1n-9 Erucic acid cis-13-docosenoic acid
C22:4n-6 Adrenic acid All-cis-7,10,13,16-docosatetraenoic acid
C22:4n-9 Docosatetraenoic All-cis-4,7,10,13-docosatetraenoic acid
C22:5n-6 Osbond acid All-cis-4,7,10,13,16-docosapentaenoic acid
C22:5n-3 Docosapentaenoic All-cis-7,10,13,16,19-docosapentaenoic acid
C22:6n-3 Docosahexaenoic All-cis-4,7,10,13,16,19-docosahexaenoic acid
Table 1.1 Fatty acids commonly found in micro-organisms, plants and animals 
4carbon chain length while the number after the colon denotes the number of 
double bonds. Thus, an 18-carbon chained fatty acid with two double bonds 
(9,12-octadecadienoic acid) is denoted as C18:2. The position of the last double 
bond can also be denoted as (n-x) which describes the position of the last 
double bond (when measured from the carboxylic end), in reference to the 
methyl end (n) of the carbon chain. Thus, C18:2(n-6) indicates that the last 
double bond is positioned 6 carbons away from the methyl end of the chain. 
This nomenclature is also used to classify unsaturated fatty acids into the n-3, 
n-6 and n-9 families. 
Fatty acids are also known by their common names. A list of the common, 
systematic and shorthand designations of fatty acids commonly found in micro-
organs, plants and animals is shown in Table 1.1.
1.2.2 Fatty acid biosynthesis
Fatty acids are obtained by endogenous synthesis and from the diet. The diet is 
important for supply of those fatty acids that cannot be synthesized de novo by 
animals.
1.2.2.1 Saturated fatty acids
The de novo synthesis of fatty acids is based on the availability of the precursor 
molecule acetyl coenzyme A (acetyl CoA) obtained from the degradation of 
amino acids and sugars. This is activated by acetyl CoA carboxylase (ACC) to 
give malonyl CoA. In most biological systems, it is generally considered that the 
multi-enzyme complex known as Fatty Acid Synthase (FAS) initiates the 
sequential lengthening of malonyl CoA by two carbon units. This gives rise to 
5palmitic acid (C16:0) as the major saturated fatty acid. The actions of ACC and 
FAS occur in the cytosol of animal cells. Longer chained fatty acids are formed 
by the action of elongases. Most eukaryotic cells have the capacity to form 
longer chained fatty acids [reviewed in (Leonard et al., 2004)]. For example, 
stearic acid (C18:0) and longer carbon chained fatty acids such as lignoceric 
acid (C24:0) are found in the myelin of nervous tissue (Bourre et al., 1977). In 
mammalian tissues such as the liver and brain, there are two elongation 
systems located in the mitochondria and endoplasmic reticulum respectively 
(Bernert and Sprecher, 1977, Cook, 1996).
1.2.2.2 Unsaturated fatty acids
Unsaturated fatty acids are synthesised from saturated fatty acids following the 
introduction of double bonds in saturated fatty acids. This process, which is also 
known as desaturation, occurs in the endoplasmic reticulum. This pathway has 
been identified in bacteria, yeasts, algae, higher plants, protozoa and animals. 
Sometimes an elongation of the hydrocarbon chain of the precursor fatty acids 
occurs before desaturation [reviewed in (Leonard et al., 2004)]. An overview of 
the relevant biosynthetic pathways is shown in Figure 1.1.
Most monounsaturated fatty acids are synthesised by the introduction of a 
single double bond between carbons 9 and 10 of the saturated fatty acid chain 
by the action of delta (Δ) 9 desaturase enzyme (Cook and Spence, 1973). 
Polyunsaturated fatty acids (PUFA) are synthesized by the insertion of 
additional double bonds. In plants, the precursor fatty acid is oleic acid (C18:1n-
9) because they have Δ12 and Δ15 desaturases that can introduce double 
bonds beyond carbon 9 in the acyl chain (Cook, 1996). The products of the 
6action of Δ12 and Δ15 desaturases are linoleic acid (C18:2n-6) and α-linolenic 
acid (C18:3n-3) respectively. 
Animal enzymes normally introduce a new double bond between an existing 
double bond and the carboxyl group (Cook, 1996). Thus they introduce double 
bonds between carbons 4-5 (Δ4 desaturase), carbons 5-6 (Δ5 desaturase) and 
carbons 6-7 (Δ6 desaturase) respectively but not carbon 9 and beyond. As a 
result, C18:2n-6 and C18:3n-3 are not synthesised by animals. C18:2n-6 and 
C18:3n-3 act as precursors for the synthesis of longer chained PUFA of the n-6 
and n-3 families (Voss et al., 1992). As they are not synthesised de novo in 
mammalian cells yet are required by mammalian cells, they need to be 
supplemented in the diet and thus they are termed essential fatty acids 
(Sprecher, 1981).
The Δ6 desaturase enzyme is responsible for the desaturation of the precursors 
of n-9, n-6 and n-3 fatty acid families (Figure 1.1) (Cook, 1996). Thus, these 
precursors compete for the same Δ6 desaturase. C18:3n-3 is the substrate that 
is utilized the fastest, followed by C18:2n-6 and then oleic acid C18:1n-9. In 
mammalian tissues when docosatetraenoic acid (C22:4n-6) and 
docosapentaenoic acid (C22:5n-3) are produced they are not metabolised by a 
Δ4 desaturase but are chain elongated instead to tetracosatetraenoic acid 
(C24:4n-6) and tetracosapentaenoic acid (C24:5n-3) respectively. The process 
takes place in the endoplasmic reticulum (Baykousheva et al., 1994, Voss et al., 
1991, Voss et al., 1992). C24:4n-6 and C24:5n-3 are subsequently desaturated 
7Figure 1.1. Schematic showing the biosynthetic pathway of n-9, n-6 and n-3 
fatty acids in mammals
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8to yield tetracosapentaenoic acid (C24:5n-6) and tetracosahexaenoic acid 
(C24:6n-3), that are then moved to peroxisomes where they undergo chain 
shortening by two carbons through partial β-oxidation (Caruso et al., 1994). This 
is followed by the transfer of docosapentaenoic acid (C22:5n-6) (osbond acid) 
and docosahexaenoic acid (Allen et al.) back to the endoplasmic reticulum 
(Sprecher et al., 1995). This pathway is termed the Sprecher pathway (Voss et 
al., 1991).
1.2.3 Fatty acids as source of energy
Fatty acids are a source of energy in mammalian cells (Hegardt, 1999). When 
the energy content of an animal diet is low, or when there is high demand of 
energy such as during growth and reproduction, long chain fatty acids are 
mobilised from triacylglycerol stores in adipose tissue. β-Oxidation is the main 
metabolic pathway in which a fatty acid is progressively broken down by the 
sequential removal of two carbon atoms, as acetyl-CoA, from the carboxyl end 
of the acyl-CoA (Hegardt, 1999). The chemical energy stored up in the fatty 
acids is then released and used to generate adenosine triphosphate (ATP) 
needed for biochemical processes. The cellular site of this pathway is the 
mitochondria, although long chain fatty acids can also be β-oxidized in 
peroxisomes (Caruso et al., 1994).
Different tissues have different capacities to utilise fatty acids as a source of 
energy for their normal functions. For instance, the heart utilises free fatty acids 
as a source of energy supply in such activities like myocardial cellular 
respiration (Vuorinen et al., 1995). The brain relies mainly on glucose for its 
energy supply (Ximenes da Silva et al., 2002). However in prolonged starvation, 
9the brain can take up and make use of fatty acid metabolites known as ketone 
bodies, namely β –hydroxybutyrate, acetoacetate and acetone, for energy 
supply (Edmond et al., 1987). It has been shown that the brain may have the 
capacity for ketogenesis as has been demonstrated in cultured astrocytes 
(Edmond et al., 1987, Guzman and Blazquez, 2004).
The importance of the utilization of fatty acids as a source of energy in normal 
tissue function has been demonstrated in a number of different studies. 
Evidence shows that impaired fatty acid oxidation may affect the utilization of 
carbohydrates (glucose) for energy requirement (Schulz, 1994). Moreover it has 
been reported that n-3 PUFA deficiency alters glucose transport and utilization 
in the brain (Levant et al., 2007, Ximenes da Silva et al., 2002). In addition, 
ketone bodies have been shown to protect the brain in models of acute stroke 
(Suzuki et al., 2002) and hypoglycaemia associated hypoxic ischemic damage 
(Vannucci et al., 1996). Furthermore, an earlier study showed that Alzheimer’s 
disease patients without the apolipoprotein E-ε4 allele (an apoliprotein E 
genotype) show cognitive improvements in response to an acute increase in the 
levels of serum β–hydroxybutyrate after an oral administration of medium chain 
triacylglycerol (Reger et al., 2004).
1.2.4 Fatty acid-derived bioactive lipid mediators
Polyunsaturated fatty acids are precursors of biologically active lipid mediators 
such as the eicosanoids. These lipid mediators are generated via three main 
enzymatic pathways as well as some non-enzymatic pathways. Each enzymatic 
pathway is named after the enzyme(s) that catalyse the first committed step: 
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namely cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450 
epoxygenases (CYP450) (Figure 1.2). 
1.2.4.1 Cyclooxygenase pathway 
The COX pathway generates prostanoids, a subclass of eicosanoids that 
includes prostaglandins (PG), prostacyclins and thromboxanes (TX). COX is 
also known as prostaglandin H or prostaglandin endoperoxide synthase (Morita
et al., 1995). Initially, phospholipase A2 (PLA2) catalyse the release of a PUFA 
from the sn-2 position of membrane phospholipids. The free fatty acid is then 
converted to an unstable intermediate, prostaglandin endoperoxide H (PGH). 
PGH is precursor to a number of prostanoids including the arachidonic acid 
(AA) prostaglandins PGD2, PGE2, PGF2α, prostacyclin, PGI2 and thromboxane 
A2 (TXA2) through a series of tissue specific synthases (Figure 1.3). 
There are two main isoforms of the COX enzyme namely COX-1 and COX-2. 
While COX-1 is constitutively expressed in most cells for the production of 
prostaglandins that maintain homeostasis, COX-2 is inducible (Mitchell et al., 
1993). COX-2 is upregulated in inflammatory cells in response to inflammatory 
stimuli such as cytokines and lipopolysaccharide. It can therefore generate 
prostaglandins at inflammatory sites (Mitchell et al., 1993). In addition to 
inflammation, COX-2 induction has been implicated in various physiological 
states such as cell death (Bizik et al., 2004), oxidative stress (Wang et al., 
2004), ageing (Han et al., 2004) and carcinogenesis (Liu et al., 2001). A third 
isoform of COX namely COX-3 has been identified (Chandrasekharan et al., 
2002). This isoform is sensitive to analgesics that have antipyretic effects but 
have low anti-inflammatory activity such as paracetamol.
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Cyclooxygenase oxygenates carbon-20 fatty acids including AA, di-homo-γ-
linolenic acid (DHGLA, C20:3n-6) and eicosapentaenoic acid (Repa et al.). AA 
is the precursor of the 2-series (carrying two double bonds in the alkyl chain) of 
prostanoids. DHGLA and EPA are the precursors of the 1-series (carrying one 
double bond in the alkyl chain) and the 3-series (carrying three double bonds in 
the alkyl chain) of prostanoids respectively (Figure 1.2). Both DHGLA and EPA 
compete with AA and can reduce the production and efficacy of AA products 
(Hung et al., 2000). Eicosanoids derived from DHGLA and EPA are considered 
to have anti-inflammatory and vasodilatory properties (Hung et al., 2000, Weiss
et al., 2002).
Cyclooxygenase metabolites have various physiological functions in various 
tissues including the brian, blood, kidney. In addition, these metabolites 
influence biological systems such as gastrointestinal tract and reproductive 
system [reviewed in (Gurr et al., 2002, Nicolaou, 2004)]. Depending on their 
specific receptors and signal transduction pathways prostaglandins can have 
synergistic or opposing effects. Prostaglandin E2 (PGE2) has been shown to be 
both pro-infammatory and anti-inflammatory (Akundi et al., 2005, Candelario-
Jalil et al., 2007). Furthermore PGE2 when coupled to prostanoid E1 (EP1) or 
prostanoid E3 (EP3) receptors, has vasoconstrictive effects but when coupled 
to prostanoid E2 (EP2) or prostanoid E4 (EP4) receptors it has vasodilatory 
effects (van Rodijnen et al., 2007). In addition PGI2 and PGD2 have vasodilator 
and antiproliferative actions and are potent inhibitors of platelet aggregation, 
while TXA2 has vasoconstrictive and pro-coagulant activities (Cheng et al., 
2006, Golino et al., 1990, Gwozdz et al., 2007, van Rodijnen et al., 2007, Wong
et al., 2002)
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Figure 1.2. Schematic showing lipid mediators derived from DHGLA, AA, EPA and DHA. AA, aracidonic acid; COX, cyclooxygenase; 
CYP450, cytochrome P450; DHA, docosahexaenoic acid; DHGLA, di-homo-γ-linolenic acid; DT, docosatriene; EPA, eicosapentaenoic 
acid; 5(S)-HETE, 5(S)-hydroxyeicosatetraenoic acid; 5-HETE, 5-hydroxyeicosatetraenoic acid; HEPE, hydroxyeicosapentaenoic acid; 
HPETE, hydroperoxyeicosatetraenoic acid; HPEPE, hydroperoxyeicosapentaenoic acid; LOX, lipoxygenase; LT, leukotriene; LX, lipoxin; 
NP, neuroprotectin; PG, prostaglandin; RV, resolvins; TX, thromboxane. 
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1.2.4.2 Lipoxygenase pathway
The LOX pathway generates hydroperoxy fatty acids from PUFA. In mammals 
different LOX are found including 5-, 12- and 15-LOX (Lewis et al., 1980, 
Tornhamre et al., 2000). LOX are found in the brain, heart, spleen, lungs and in 
cells such as mast cells and monocytes (Lewis et al., 1980, Phillis et al., 2006). 
Lipoxygenase acts on PUFA including AA, EPA and DHA to generate 
hydroperoxy eicosatetraenoic acids (HPETEs), hydroperoxy eicosapentaenoic 
acids (HPEPEs) and hydroperoxy docosahexaenoic acids (HPDHAs) (Figure 
1.2) (Bazan et al., 1984, Marcheselli et al., 2003, Morita et al., 1983, VanRollins
et al., 1984). HPETEs can undergo the following three reactions: reduction to 
yield hydroxyeicosatetraenoic acid (HETE) (eg. 5(S)-HETE), a second 
lipoxygenation to yield dihydroxy eicosatetraenoic acid (eg. 5(S)-dihydroxy 
eicosatetraenoic acid) or dehydration to yield an epoxy fatty acid (eg. 
leukotriene A4 (LTA4). Likewise, HPEPEs can undergo three reactions to yield 
hydroxyeicosapentaenoic acid (HEPE) (eg. 5(S)-HEPE), a second 
lipoxygenation to yield dihydroxy eicosapentaenoic acid (eg. 5(S)-dihydroxy 
eicosapentaenoic acid) or dehydration to yied an epoxy fatty acid (eg. 
leukotriene B5 (LTB5) (Hung et al., 2000, Morita et al., 1983). HPDHAs are also 
converted by LOX to dihydroxy docosahexaenoic acids (diHDHAs) or 
docosatrienes (eg 10,17(S) diHDHA) (Hong et al., 2003).
5-Lipoxygenase converts AA to HPETE. Its actions also generate 7(S),17(S)-
diHDHA and 4(S),17(S)-diHDHA from 17(S)-HPDHA (Hong et al., 2003). 5-LOX 
is responsible for the generation of LTA4 from AA (Morris et al., 1982). 
Leukotrienes (LT) derive their name from leukocytes where they were originally 
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found (Borgeat and Samuelsson, 1979). LTA4 is the precursor from which other 
leukotrienes namely LTB4, LTC4, LTD4 and LTE4 are synthesised (Morris et al., 
1982, Murphy et al., 1979). LT are not stored in cells, but their synthesis and 
release from cells are rapid events following cellular activation (Tornhamre et 
al., 2000). 
Another LOX isoenzyme is 12-LOX which is of two types namely; the leukocyte 
type and platelet type 12-LOX. These are distinguishable by their substrate 
specificity and cellular distribution (Hamberg and Samuelsson, 1974, Yoshimoto
et al., 1990). The leuckocyte type 12-LOX is closely related to 15-LOX 
(Yoshimoto et al., 1990). 12-LOX converts AA to 12-HPETE, which is also 
reduced to 12(S)-HETE. 12-LOX also catalyses the conversion of EPA to 12-
HPEPE (Morita et al., 1983) and converts DHA to 11-HDHA and 14-HDHA 
(Bazan et al., 1984). 12-LOX is also involved in the biosynthesis of lipoxins (LX) 
from AA by converting LTA4 to LXA4 and LXB4 (Figure 1.2) (Romano et al., 
1993, Serhan et al., 1984, Yamamoto et al., 2005).
The action of 15-LOX, another form of LOX, generates 15(S)-HPETE from AA 
and 15(S)-HPETE is further reduced to 15(S)-HETE (Levy et al., 1993). A 15-
LOX-like reaction converts DHA first to 17(S)-HPDHA and then to 10,17(S)-
docosatriene (Lukiw et al., 2005). It has been shown that 15-LOX acts 
sequentially with 5-LOX to produce lipoxins such as LXA4 and LXB4 from the 5-
LOX generated LTA4 (Levy et al., 1993, Tornhamre et al., 2000).
Some of the physiological effects of LOX metabolites such as LTC4, LTD4 and 
LTE4 include bronchoconstriction in asthma (McMillan, 2001), 
neuroinflammation and stroke (Jatana et al., 2006), cell proliferation and cancer 
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(Vincent et al., 2008). LX have been reported to be active in the resolution of 
acute inflammation (Schottelius et al., 2002). LOX derived metabolites of DHA 
have neuroprotective effects and are termed neuroprotectins, e.g. 
neuroprotectin D1 (10, 17S-docosatriene) (Lukiw et al., 2005).
1.2.4.3 Cytochrome P450 epoxygenase pathway
The epoxygenase pathway refers to the oxidation of fatty acids by cytochrome 
P (CYP) 450 mixed-function oxidases to produce hydroxylated and epoxidised 
fatty acids (Hamberg and Bjorkhem, 1971). Two types of epoxygenase products 
generated from AA are epoxy-eicosatrienoic acids (EETs) and their less active 
hydroxylated forms dihydroxyeicosatrienoic acids (DHETs) and/or mono-
hydroxyeicosatetraenoic acids (HETEs) [reviewed in (Spector et al., 2004)]. The 
EETs are formed by CYP epoxgenases and the DHETs are formed by CYP ω-
oxidases at or near the ω-terminus of the PUFA (Capdevila et al., 2000). 
Examples of EETs formed from AA include 8,9-EET, 11,12-EET, and 14,15-
EET that have been found in tissues such as liver, kidney, plasma and heart 
(Karara et al., 1989, Karara et al., 1993, Karara et al., 1992, Wu et al., 1997). 
They have been shown to inhibit PGE2 production in vascular smooth muscles, 
decrease cytokine-induced cell adhesion in the endothelium and inhibit platelet 
COX activity (Spector et al., 2004). 
Other PUFA that are metabolised by CYP450 include EPA, docosapentaenoic 
acid (C22:5n-3) and DHA as have been shown in animal and human studies 
(Harmon et al., 2006, VanRollins et al., 1984). Rat microsomal liver oxidation of 
EPA by CYP450 monooxygenases yields 17,18-, 14,15-, 11,12- and 8,9-
dihydroxyeicosatetraenoic acids as well as 20-hydroxyeicosapentaenoic acid 
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and 19-hydroxyeicosatetraenoic acid (Van Rollins et al., 1988). Furthermore, 
20-hydroxyeicosapentaenoic and 19-hydroxypentaenoic acids were also 
generated by CYP450 oxidation in the rat kidney (Van Rollins et al., 1988). 
These EPA derived EETs are also found in vascular smooth muscles were they 
act as vasodilators (Lauterbach et al., 2002). Epoxy docosapentaenoic acids 
(EDPs) and their hydroxylated metabolites are generated from DHA (VanRollins
et al., 1984, Ye et al., 2002). Examples of EDPs include 7,8-, 10,11-, 13,14-, 
16,17- and 19,20- epoxy-EDP (Ye et al., 2002). They have hypotensive effects 
that may be attributed to their ability to potently dilate coronary microvessels 
(Ye et al., 2002). Furthermore it has been shown that the epoxygenase 
metabolites of EPA, DHA and docosapentaenoic acid (C22:5n-3) may inhibit the 
formation of AA epoxygenase metabolites such as 20-HETE which has 
vasoconstrictive effects (Harmon et al., 2006).
1.2.4.4 Non-enzymatic oxidation
Peroxidation of the free fatty acids by free radicals or reactive oxygen species 
(ROS) generates LOX- or COX-like products. When AA is the substrate it can 
be converted to prostaglandin F2-like compounds known as isoprostanes (F2-
IsoPs) (Morrow et al., 1990) (Figure 1.2). Formation of these compounds 
proceeds through the generation of PGH2-like intermediates that are reduced to 
F2-IsoP or undergo rearrangement to PGD2 and PGE2-like compounds (D2/E2-
IsoPs) (Morrow et al., 1994) and thromboxane-like compounds 
(isothromboxanes) (Morrow et al., 1996). Their formation increases markedly in 
animal models of oxidant injury (Gao et al., 2003). 
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Oxidation of EPA in vitro has also been demonstrated to yield prostaglandins 
F3-like (F3-IsoP) (Gao et al., 2006). F4-like (F4-IsoP) have been derived from in
vitro peroxidation of DHA (Nourooz-Zadeh et al., 1998) and F4-dihomo-IsoP 
from C22:4n-6 have been reported as biomarkers of free radical damage of 
myelin (VanRollins et al., 2008). 
1.3 Membrane lipids
Membrane lipids include acylglycerols, glycerophospholipids, ether lipids, 
sphingolipids and cholesterol. These lipids are asymmetrically organised within 
the membrane. This confers stability, fluidity and permeability to the membrane 
and regulates cellular function. Membrane structure is crucial for normal cell 
and alterations in this asymmetry can induce different cellular responses such 
as apoptosis and platelet coagulation (Ikeda et al., 2006).
1.3.1 Mono-, di-, and tri-acyl glycerols
Mono-, di-, and triacylglycerolipids are members of a class of membrane lipids 
called glycerolipids. A typical glycerolipid has a 3-carbon glycerol backbone, 
which functions as a base for the attachment of hydrophobic fatty acids and/or a 
polar alcoholic group that determine the characteristics and functions of these 
acylglycerols. 
Monoacyglycerols are esters of glycerol that have one of the hydroxyl groups 
esterified with a long fatty acid. They can be derived from diacylglycerols, 
triacylglycerols and glycerophospholipids. An example of a monoacylglycerol is 
2-arachidonylglycerol, which is also an endocannabinoid (Kondo et al., 1998). 
As cellular AA is esterified primarily at the sn-2 position of glycerophospholipids, 
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2- arachidonylglycerol is normally a major component of the cell's 
monoacylglycerols (Kerwin et al., 1994). 2-arachidonylglycerol occurs in trace 
amounts in mammalian tissues including brain, heart, liver, spleen, kidney and 
platelets (Berdyshev et al., 2001, Kondo et al., 1998, Schmid et al., 2000). 
Increased concentrations have been reported in conditions of membrane 
degeneration, phospholipid degradation and in models of neurodegeneration 
(Baker et al., 2001). Studies have demonstrated that 2-arachidonylglycerol can 
mediate a large number of immunoregulatory and neurobiological effects such 
as alleviation of symptoms of autoimmune diseases (Cabranes et al., 2005) and 
inhibition of the production of cytokines (Gallily et al., 2000).
Diacylglycerols (DAG) (sn-1,2-diacylglyecrols) are esters of glycerol in which 
two of the hydroxyl groups are esterified with long chain fatty acids. 
Diacylglycerols are generated in the cell at the endoplasmic reticulum from the 
biosynthesis of triacylglycerols and glycerophospholipids. Under normal 
conditions cell membranes contain no significant amounts of DAG. However, 
they are important intermediates in the biosynthesis and degradation of 
triacylglycerols, glycerophospholipids and glyceroglycolipids (Becker and 
Hannun, 2004)
As a crucial mediator of cellular signalling, alterations in DAG metabolism such 
as those induced by age may predispose to brain and liver dysfunction 
(Pasquare et al., 2001). For instance as a potential source of AA for the 
production of LT and prostanoids and as the direct precursor of 2-
arachidonylglycerol, DAG which can be generated from phosphatidylinositol that 
has a high content of AA at the sn-2 position (Kerwin et al., 1994), is implicated 
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in various pathological conditions mediated by these lipids such as neurological 
disorders (Tyeryar et al., 2008), autoimmune diseases (Cabranes et al., 2005)
and diabetes (Das Evcimen and King, 2007). 
Finally, triacylglycerols are esters of glycerol with three fatty acids and are the 
major components of natural fats and oils. They are the principal neutral 
glycerolipids found in mammals and are abundant in adipose tissue where they 
act as a source of fatty acids for energy production. 
1.3.2 Glycerophospholipids
Glycerophospholipids are esters of glycerol, fatty acids and phosphate. They 
have a polar headgroup (X) attached to the phosphate group esterified to the 
glycerol backbone at the sn-3 position (Figure 1.3). A saturated fatty acid is 
usually esterified at the sn-1 position of the glycerol backbone while an 
unsaturated fatty acid is usually esterified at the sn-2 position, however, a 
saturated fatty acid may also be esterified at this position (Wood and Harlow, 
1969).
The polar group is the functional group that determines which class a 
phospholipid belongs to and the fatty acids distinguish the individual 
phospholipid molecular species within each class (Metz and Dunphy, 1996). 
These different structural combinations allow for a large variety of physical and 
chemical properties including surface charge of the membrane, permeability, 
fluidity and regulation of membrane bound enzymes (Ridgway et al., 1999).
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Figure 1.3. Representative structure of glycerophospholipid (A) and resulting 
classes (B). X denotes the head group, R1, R2, R3 and R4 represent fatty acid 
chains.
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1.3.2.1 Phosphatidic acid
Phosphatidic acid (PA) or phosphatidate or 1,2-diacyl-sn-glycerol-3-phosphate 
is the simplest phospholipid as it has only phosphoric acid attached to 
diacylglycerol. It is located mostly in the inner membrane and found in trace 
amounts only in cell membranes under normal circumstances, but it has 
metabolic importance as the biosynthetic precursor of most other glycerolipids 
(Smith et al., 1957, Zachowski, 1993). It regulates some membrane trafficking 
events and acts as a signalling molecule in tissue damage during inflammation, 
against infection and oxidative stress (Viani et al., 1990, Yurkova et al., 2008).
1.3.2.2 Phosphatidylcholine
Phosphatidylcholine (PC) is represents about 32-55 % weight of total 
phospholipids and is the most abundant animal phospholipid (Christie, 1985). 
Most of the PC in mammalian cell membranes is located in the outer membrane 
(Bollen and Higgins, 1980). There are many molecular species of PC but the 
most abundant is composed primarily of C16:0 or C18:0 at the sn-1 and 
C18:2n-6, AA, C18:3n-3 or DHA at the sn-2 position (Kerwin et al., 1994). PC is 
generated in mammalian cells from choline via the cytidine diphosphate base 
pathway (Kennedy pathway) (Kennedy and Weiss, 1956). Choline cannot be 
synthesized in animal cells but is obtained from dietary sources or from the liver 
mediated methylation of phosphatidylethanolamine by 
phosphatidylethanolamine N-methyltransferase and subsequent hydrolysis of 
the choline moiety from PC (Walkey et al., 1997). As an integral component of 
cellular membranes it acts as a reservoir of bioactive lipid mediators such as AA 
and regulates the activities of enzymes (Zhyvoloup et al., 2003). In addition PC 
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participates in the biosynthesis of other membrane lipids such as 
sphingomyelin, a role that is implicated in the glycerophospholipid and 
sphingomyeline signalling pathway, suggested to be involved in cell membrane 
organization, cell proliferation, differentiation and apoptosis (Flores et al., 2000, 
Li et al., 2007). In addition alterations in PC metabolism have been implicated in 
inflammatory diseases (Farber et al., 2000), liver failure (Li et al., 2005) and 
cancer (Iorio et al., 2005).
1.3.2.3 Phosphatidylethanolamine 
Phosphatidylethanolamine (PE) is the second most abundant animal (19-33 % 
weight of total phospholipids) and plant phospholipid and is a major building 
block of membrane bilayers (Christie, 1985). Most of the PE in mammalian 
tissue is located in the inner membrane (van Meer et al., 1981). Esterified at the 
sn-1 position of PE is mainly C16:0 or C18:0 and at the sn-2 position is DHA or 
AA (Kerwin et al., 1994). Ethanolamine is the amino alcohol attached to 
phosphate. PE has various functional roles in addition to its structural role. In 
mammalian liver it actively participates in the endogenous synthesis of PC and 
choline via the action of phosphatidylethanolamine N-methyltransferase. PE has 
also been shown to modulate a number of cellular functions such as the 
regulation of membrane proteins (Zhyvoloup et al., 2003), immune regulation 
and inflammatory signalling (Maskrey et al., 2007). In addition, it was shown 
that an abnormal metabolism of PE in rat liver mitochondria may result in 
mitochondria dysfunction and that this might be associated with depression and 
bipolar disorder (Modica-Napolitano and Renshaw, 2004). 
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1.3.2.4 Phosphatidylinositol 
Phosphatidylinositol (PI) is an acidic phospholipid. PI is located in the inner 
membrane (Butikofer et al., 1990) and contributes about 3-4 % weight of 
phospholipids in mammalian cells (Christie, 1985). However, it is particularly 
abundant in brain tissue were it participates in essential metabolic processes 
and cell signalling. A characteristic feature of PI in animals is its high content of 
stearic acid (18:0) at sn-1 and AA at the sn-2 position of the glycerol backbone 
(Kerwin et al., 1994). It regulates the membrane associated protein kinase C 
(PKC) activity through calcium ion mediated phosphoplipase C or D dependent 
synthesis of DAG (Wang et al., 1999). Thus, it plays a prominent role in a 
number of cellular signalling pathways including membrane trafficking, cell 
growth, lipid metabolism and energy control (Vicinanza et al., 2008). It is also 
implicated in neuropsychiatric disorders like depression, schizophrenia and 
bipolar disorder (McNamara et al., 2006). 
1.3.2.5 Phosphatidylserine 
Phosphatidylserine (PS) is a weakly acidic phospholipid. It has three ionizable 
groups, a phosphate moiety, an amino group and a carboxyl functional group. 
The main type of fatty acid esterified at the sn-1 position is C18:0 and DHA is 
mostly esterified at the sn-2 position of PS (Kerwin et al., 1994). PS is mostly 
located in the inner membrane than in the outer membrane but appears in the 
outer membrane in cells undergoing apoptosis (Bratton et al., 1997, Zachowski, 
1993). Its appearance in the outer membrane causes recognition of the 
apoptotic cell for phagocytosis during the resolution of inflammation or during 
tissue remodelling (Bratton et al., 1997). It is widely distributed in mammalian 
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cells but contributes to about 3 % weight of total phospholipids (Christie, 1985). 
It is also known to be involved in a number of physiological processes, such as, 
inhibition of proinflammatory cytokines and nitric oxide (NO), and synaptic 
transmission (Kodas et al., 2004).
1.3.2.6 Phosphatidylglycerol
Phosphatidylglycerol (PG) is another acidic phospholipid. It is predominantly 
esterified at the sn-1 position with C16:0 and C18:0 and at the sn-2 position by 
C18:1n-9, AA and DHA. It is mainly present in the inner membrane of the 
mitochodria (Schlame et al., 2000). PG accounts for less than 1 % weight of 
total phospholipids, although it accounts for about 2-5 % weight of the 
phospholipids in the lungs and about 11 % weight of total phospholipids in lung 
surfactant (Hallman and Gluck, 1975, Schlame et al., 1986). Although not 
abundant in many tissues, it is important for the generation of cardiolipin and as 
an essential constituent of lung surfactant material, it is important for respiration 
and lung function (Schlame et al., 1986). However in optimal conditions, cells 
can respire in the absence of cardiolipin if PG is present (Schlame et al., 2000). 
Its ability to act as a biochemical indicator of pulmonary maturity of new borns 
has been shown to be affected by diabetes in pregnancy (Moore, 2002).
1.3.2.7 Cardiolipin
Cardiolipin or diphosphatidylglycerol is related structurally to PG and is mainly 
localised in the inner membrane of the mitochondria where it interacts with a 
large number of mitochondrial proteins (Schlame et al., 2000, Yurkova et al., 
2008). It is unique among common phospholipids in containing four acyl side 
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chains in comparison to more typical phospholipids, which have two acyl 
chains. In animal tissues, cardiolipin contains exclusively 18 carbon fatty acids 
and 80% of this is typically 18:2n-6, which is crucial in cardiolipin functions 
(Yamaoka et al., 1988). However in mouse brain, it has been shown that C18:0, 
C18:1n-9, DHA and AA each contribute to about 20 % of acyl side chains of 
cardiolipin (Ellis et al., 2005), while C18:2n-6 contributes only about 5 % (Bayir
et al., 2007). This distribution in the brain can predispose cardiolipin to 
peroxidation and may play a role in neurodegeneration as has been shown in
Parkinson’s and Alzheimer’s disease (Ellis et al., 2005, Guan et al., 1994). 
Furthermore, cardiolipin plays an active role in mitochondria respiratory function 
(Schlame et al., 2000).
1.3.2.8 Lysophospholipids
Lysophospholipids are products of enzymatic hydrolysis of phospholipids. Cell 
membrane phospholipids undergo continuous deacylation/reacylation. This 
means that they can be hydrolysed to lysophospholipids by the action of 
specific phospholipases and lysophospholipids can be re-acylated by 
acyltransferase to produce new glycerophospholipids. 
Figure 1.5 shows the different positions at which intracellular phospholipases 
cleave a phospholipid to release free fatty acids and form lysophospholipids. 
Although lysophospholipids are not abundant in biological membranes they 
increase in certain conditions such as inflammation (Rao et al., 2003). They are 
also involved in cell growth and differentiation, cell survival, migration, apoptosis 
and adhesion which in turn are responsible for biological processes such as 
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platelet aggregation (Sano et al., 2002), wound healing (Demoyer et al., 2000)
and smooth muscle contraction (Cremers et al., 2003).
1.3.3 Ether lipids
Ether lipids are glycerophospholipids that have ether links mainly on the sn-1 
position. They are found in mammals, lower animals, some plants and many 
bacteria. In mammals most of the ether linkages are in choline and 
ethanolamine glycerophospholipids. There are two groups of ether lipids in 
mammals namely alkenylacyl- and alkyacyl-glycerophospholipids (Figure 1.5). 
Alkenylacyl glycerophospholipids (Figure 1.5A) are also known as 
plasmalogens. At the sn-1 position there is a vinyl ether (enol ether) linkage with 
palmitic acid (C16:0), C18:0 and C18:1n-9 acyl chain fatty acids (Farooqui and 
Horrocks, 2004).
Figure 1.4 Sites of action of phospholipases A, B, C and D. PLA; phospholipase 
A, PLB; phospholipase B, PLC; phospholipase C and PLD; phospholipase D. 
Adapted from (Gurr et al., 2002).
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Figure 1.5 Structures of ether glycerophospholipids. (A) Alkenylacyl-
phospholipid (plasmalogens), (B) Alkylacyl-phospholipid. R1 and R2; acyl 
groups, X; phospholipid headgroup. 
At the sn-2 position an ester bond links either AA or DHA (Favrelere et al., 
2000). At the sn-3 position there is either a phosphocholine or 
phosphoethanolamine but mostly the latter. These are termed plasmenylcholine 
and plasmenylethanolamine respectively (Nagan and Zoeller, 2001).
Plasmalogens are mostly found in all mammalian tissues including the brain, 
liver, heart and muscle and in immune cells, neutrophils and macrophages. 
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Less than 5 % of the ethanloamine phospholipids in the liver is in the form of 
plasmalogens (Nagan and Zoeller, 2001).
In the central nervous system, their primary function is structural and it has 
been shown that plasmenylethanolamine constitute more than 80 mol % of the 
ethanolamine phospholipid pool in non-neuronal brain membranes and more 
than 60 mol % in neurons and synaptosomes (Han et al., 2001). Plasmalogen-
deficient cells exhibit decreased transmembrane protein function and 
membrane-related intracellular and extracellular cholesterol transport (Munn et 
al., 2003). This has been linked with Niemann-Pick Type C disease, a
cholesterol-storage disorder characterized by liver dysfunction, 
hepatosplenomegaly, and progressive neurodegeneration (Garver et al., 2007)
and in which levels of plasmenylethanolamine are reduced in the brain and liver 
(Han et al., 2001, Schedin et al., 1997). The vinyl ether linkage at the sn-1 
position of plasmalogens is suggested to protect against oxidation of the more 
susceptible PUFA esterified in the sn-2 position (Strokin et al., 2006, Zoeller et 
al., 1999). This property has therefore been associated with cellular functions 
such as neuroprotection where lipid oxidation contributes to the initiation of 
inflammation characteristic of neurodegeneration (Strokin et al., 2006). 
Platelet activating factor is a representative of alkyacyl glycerophospholipids 
(Figure 1.5B). Like most lipid mediators, platelet activating factor is not stored in 
large amounts in cells. Although synthesized de novo for physiological 
functions, platelet activating factor biosynthesis can be activated during 
inflammation and other hypersensitivity responses (Aihara et al., 2000). Platelet 
activating factor is a potent activator of platelets (Suzuki et al., 1998) and has 
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biological effects on a variety of other types of cells and tissues. In the central 
nervous system it induces hippocampal long-term potentiation (Wieraszko et al., 
1993), enhances memory task performance (Izquierdo et al., 1995), and has 
been suggested to be relevant to brain development (Yoshida et al., 2005). 
Platelet activating factor is also associated with post-ischemic neuronal death, 
stimulates intracellular increases in calcium and AA release in microglia and is 
involved in tumor growth and angiogenesis (Ferreira et al., 2007). 
1.3.4 Sphingolipids
Sphingolipids are a class of lipids that have a common sphingoid base. The 
sphingoid base contains a chain with 18-20 carbon atoms, with C18 being the 
most common (Pruett et al., 2008). For most mammalian sphingolipids, 
sphingosine (D-erythro-2-amino-trans-4-octadecane-1,3-diol) is the prevalent 
base (Figure 1.6A). Sphingosine has a trans double bond between carbon 4 
and carbon 5 near the polar end of the molecule thus the chain behaves like a 
saturated fatty acid (Figure 1.6A). Another sphingoid base is 
dihydrosphingosine (sphinganine) in which the double bond is saturated (Figure 
1.6B). A third sphingoid base from which sphingolipids are generated is 
phytosphingosine (Figure 1.6C). The sphingoid base can be attached to a fatty 
acid, carbohydrate or a phosphate unit through an amide bond. Based on 
different combinations of sphingoid bases, fatty acids and head groups, 
sphingolipids may be classed as phosphosphingolipids, ceramides and 
glycosphingolipids (Figure 1.7).
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Figure 1.6 The structures of C-18 sphingoid bases. (A) sphingosine, (B) 
dihydrosphingosine (sphinganine), (C) pytosphingosine
Sphingolipids are irregularly distributed in the cell membranes in both the lateral 
and vertical direction. In the lateral direction they form membrane lipid micro 
domains (lipid rafts) with cholesterol and vertically, they are differentially packed 
with phospholipids (Kihara et al., 2007). This distribution contributes to the 
maintenance of the lipid asymmetry in biological membranes (Ikeda et al., 
2006). In addition the synthesis and metabolism of sphingolipids has been 
shown to play a role in many pathological conditions such as cancer, Niemann–
Pick disease and Alzheimer’s disease, (Colombaioni and Garcia-Gil, 2004, 
Huwiler et al., 2000).
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Figure 1.7 The sphingolipid cycle. GalCer, galactosylceramide; GlcCer, 
glucosylceramide; galactose linked to N-acetyl-neuraminic acid.
1.3.4.1 Ceramides
Ceramides or N-acyl sphingosines are the simplest forms of sphingolipids. They 
have no head group and are generated from de novo synthesis through N-
acylation of sphingosine by ceramidases or by ceramide synthase (Yavin and 
Gatt, 1969). They are also synthesized via the dephosphorylation of ceramide-
glucosylceramide
galactosylceramide
sphingomyelin
ceramide
sphingosine
sphingosine-1-phosphate
GalNac-GalGlcCer
ganglioside
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1-phosphate or catabolism of complex sphingolipids like sphingomyelin, 
glucosylceramide, galactosylceramide and gangliosides by the action of 
sphingomyelinases or other specific gangliosidases (Kopaczyk and Radin, 
1965, Sribney and Kennedy, 1958). 
Ceramides are degraded by ceramidases to yield sphingosine and free fatty 
acid. Sphingosine can be further phosphorylated by sphingosine kinases to 
yield sphingosine-1-phosphate, which in turn can be dephosphorylated by 
specific phosphatases to regenerate sphingosine. This cycle is summarised in 
Figure 1.7.
Ceramides are found in small amounts in intracellular membranes and are 
highly hydrophobic. Various reports support the role of ceramides in a variety of 
cellular processes such as, response to oxidative stress and programmed cell 
death that influence both physiological and pathological processes (Scurlock 
and Dawson, 1999).
1.3.4.2 Phosphosphingolipids
Phosphosphingolipids are phosphorylated sphingolipids and this class includes 
sphingomyelin, sphingosine-1-phosphate and ceramide-1-phosphate (Figure 
1.7). In mammals sphingomyelin is a major phosphosphingolipid. It contains a 
sphingosine base esterified to phosphorylcholine through an amide bond. PUFA 
such as DHA are not commonly found in sphingomyelin; this unique structural 
feature of sphingolipids has been suggested to contribute to their ability to resist 
oxidation (Sargis and Subbaiah, 2003). Sphingomyelin occurs in appreciable 
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amounts in the brain and is found in lipoproteins, lung surfactant and bile 
(Bagdade et al., 1990, O'Brien and Sampson, 1965, Schiller et al., 2001). 
Apart from its membrane structural role, sphingomyelin has a variety of 
functions. As a precursor for the synthesis of signalling molecules such as 
ceramides, sphingosine-1-phoshate, sphingoid bases and many other important 
bioactive sphingolipids, it regulates diverse cellular processes including 
apoptosis, cell growth and differentiation (Andrieu-Abadie and Levade, 2002, 
Galve-Roperh et al., 1997). Furthermore, it is an essential component of 
membrane rafts that are implicated in several cellular processes including 
neuronal adhesion, axon guidance, synaptic transmission, synapse loss or 
changes in nerve conduction characteristic of neurodegenerative diseases 
(Hering et al., 2003, Sjogren and Svenningsson, 2007). Evidence shows it acts 
as an antioxidant in plasma (Subbaiah et al., 1999) and its levels are altered in 
response to ageing, various age-related stress factors such as oxidative stress 
and age related diseases such as Alzheimer’s disease (Cutler et al., 2004). 
1.3.4.3 Glycosphingolipids
Glycosphingolipids are derivatives of ceramides and sugars. The carbohydrate 
moieties are linked via a β-glycosidic bond to the 1-OH group of a ceramide 
(Figure 1.7) and are found in mammals and bacteria cells (Krziwon et al., 1995). 
The simplest glycosphingolipids are the cerebrosides, also known as 
monoglycosyl ceramides (Figure 1.7). Glucosylcerebrosides and 
galactosylcerebrosides (Figure 1.7) are the most common glycosphingolipids. 
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Figure 1.8 Monosialo-ganglioside
Glucosylcerebrosides are found in relatively low levels in neurons, since they 
are metabolic intermediates in the synthesis of complex glycosphingolipids 
(Buccoliero and Futerman, 2003). Galactosylcerebrosides are the principal 
glycosphingolipids found in the central nervous system with high amounts in the 
brain and myelin sheath (Borner et al., 2006). 
Galactosylcerebrosides have been shown to form lipid microdomains with 
cholesterol in myelin where they regulate oligodendrocyte differentiation 
(Hayashi and Su, 2004). Myelin in turn provides insulation at axons crucial in 
the regulation of nerve conduction and neurotransmitter release. Other 
cerebrosides like cerebroside sulphates or sulphatides are also essential for 
axon structure and central nervous system function (Marcus et al., 2006). The 
deacylated product of galactosylcerebrosides, psychocine or 
galactosylsphingosine has been associated with Krabbe disease an inherited 
neurological disorder (Giri et al., 2006). Trace amounts of cerebrosides are also 
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found in lung, kidney, liver, spleen and plasma (Coles and Foote, 1974, Ho, 
1973, Sakakibara et al., 1981).
Gangliosides are acidic glycosphingolipids. They contain one or more units of 
an acidic sugar called N-acetyl-neuraminic acid or sialic acid attached via α-
glycosidic linkages to other sugars (Figure 1.8). They are also found in high 
amounts in the brain and central nervous system (O'Brien and Sampson, 1965)
and are linked with neuronal cell death (Sohn et al., 2006). Evidence also 
implicates them in neurological disorders such as Alzheimer’s disease where 
their levels are reported to be altered in the affected brain tissue (Cutler et al., 
2004).
1.3.5 Sterols
Sterols are essential components of the cellular membranes in all eukaryotes. 
They include cholesterol, ergosterol (found in yeast) and phytosterols such as 
stigmasterol and sitosterol that are both found in plants. Phytosterols are 
structurally related to cholesterol but unlike cholesterol they are present in trace 
amounts in human cells.
1.3.5.1 Cholesterol
Cholesterol is the most common sterol in mammalian cell membranes. The 
structure of cholesterol makes it uniquely suitable for the role of a structural 
membrane component (Figure 1.9A). The rigid planar structure of cholesterol 
reduces the fluidity of phospholipid bilayers and, thus, alters membrane 
permeability and the activity of integral membrane proteins (Ridgway et al., 
1999). 
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Figure 1.9  (A) cholesterol, (B) cholesteryl ester. R denotes the fatty acid chain.
The hydroxyl group located at carbon-3 facilitates the orientation of the 
cholesterol molecule in a membrane bilayer and can be esterified with a fatty 
acid to yield cholesterol esters (Figure 1.9B). 
Cholesterol is also a precursor of steroid hormones and bile salts and whilst in 
the skin degrades to 7-hydrocholesterol that yields vitamin D3 (the active form of 
vitamin D). Cholesterol exerts a regulatory function on metabolism of other 
lipids (Ridgway et al., 1999). This regulatory role has been demonstrated in cell 
culture studies of macrophages where increased cholesterol resulted in 
increased concentrations of PC, PE, PS and sphingomyelin (Schmitz et al., 
1990, Shiratori et al., 1994). In addition, it has been shown that inhibition of 
cholesterol synthesis downregulates Δ9 desaturase activity and upregulates Δ6 
desaturase and Δ5 desaturase activities in liver microsomes (Leikin and 
Brenner, 1988). 
(A)
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Lipid rafts are microdomains within cell membranes abundant in cholesterol and 
sphingolipids. These cholesterol-rich rafts are involved in protein trafficking, 
formation of signaling complexes and regulation of normal synapse density and 
morphology. These have been linked to the ability of cholesterol to promote 
synapse maturation (Mauch et al., 2001) and modulate serotonin binding and 
transport (Sjogren and Svenningsson, 2007). 
1.3.5.2 Cholesterol biosynthesis
Cholesterol is synthesized in the endoplasmic reticulum but very small amounts 
of cholesterol are found in this organelle (Brown et al., 2002). 3-hydroxy-3-
methyl-glutaryl-CoA (HMG-CoA) reductase is the rate-limiting enzyme of this 
biosynthestic pathway and it converts HMG-CoA to mevalonate. Mevalonate is 
in turn converted to cholesterol via a series of enzymatic reactions. Figure 1.10 
shows the cascade of enzymatic reactions by which cholesterol is synthesized. 
Thus inhibition of HMG-CoA reductase prevents the cascade of enzymatic 
reactions that eventually generate cholesterol and a target for drug 
development. This enzyme is competitively inhibited by cholesterol lowering 
agents collectively called statins.
1.3.5.3 Cholesterol transport
Lipoproteins are lipid-protein complexes that transport lipids in the blood from 
one tissue to another and help to supply the lipid needs of different cells. 
Lipoproteins include chylomicrons, very low density lipoproteins (VLDL), 
intermediate density lipoproteins (IDL), low density lipoproteins (LDL) and high 
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density lipoproteins (HDL). Furthermore, chylomicrons and VLDL transport 
dietary triacylglyerol and liver synthesized triacylglycerol respectively. 
Figure 1.10 Cholesterol biosynthetic pathway. ACAT: acyl CoA:cholesterol 
acyltransferase; CEH: cholesteryl ester hydrolase.
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Low density lipoprotein particles are the major carriers of plasma cholesterol in 
humans, rabbits, pigs and guinea pigs (Krause and Newton, 1995). They are 
derived from VLDL in the plasma by the removal of VLDL triacylglycerols and 
apolipoproteins E and C and leaving only apolipoprotein B. Although LDL 
receptors on cell surfaces mediate the transport of cholesterol from the liver to 
many extrahepatic tissues, the liver also serves as the major site for removal of 
LDL particles (Dietschy et al., 1993). This pathway of delivery of cholesterol to 
other tissues is regarded as forward cholesterol transport (Fielding and Fielding, 
1995). LDL receptors are also responsible for removing LDL particles from 
circulation and this removal is reported to be enhanced after treatment with 
cholesterol lowering agents such as mevinolin and cholestipol (Bilheimer et al., 
1983). 
High density lipoprotein particles are carriers of plasma cholesterol in 
herbivores and carnivores as well as in rats (Krause and Princen, 1998). In 
addition rat liver secretes VLDL particles and their LDL cholesterol is very low 
(Krause and Newton, 1995). HDL mediates the movement of cholesterol out of 
extrahepatic tissues and its transport into the liver and subsequent excretion in 
the bile. This is regarded as reverse cholesterol transport (Fielding and Fielding, 
1995).
1.3.5.4 Cholesterol regulation
The cholesterol pool in cells is maintained through endogenous synthesis, LDL 
receptor mediated cholesterol synthesis and exogenous supply by the diet. The 
LDL receptor mediated synthesis occurs after the LDL-receptor complex is 
dissociated and the LDL core of cholesteryl esters are hydrolysed by lysosomal 
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acid hydrolases to yield cholesterol (Gurr et al., 2002). An increase in the 
cholesterol pool modulates HMG-CoA reductase activity and the expression of 
LDL receptors. This modulation is achieved by a decrease of LDL receptor 
protein expression and a downregulation of the activities of the enzymes 
involved in cholesterol endogenous synthesis. These include HMG-CoA 
synthase, HMG-CoA reductase, squalene synthase and farnesyl diphosphate 
activity (Brown and Goldstein, 1999). In addition, cholesteryl esters may also be 
resynthesized from cholesterol by the action of acyl-CoA: cholesterol 
acyltransferase. Thus any further increase in cellular cholesterol is reduced. 
Conversely, in low concentrations of cellular cholesterol pool, the synthetic 
pathways are activated and acyl-CoA: cholesterol acyltransferase activity 
surpressed (Brown and Goldstein, 1999). 
1.4 Lipid metabolism in the liver
The liver is a major metabolic organ. Many important classes of lipids including 
triacylglycerols, cholesterol, sphingolipids, phospholipids and fatty acids are 
synthesized and metabolised in the liver. 
1.4.1 Fatty acid metabolism in the liver
Several studies have shown that the liver may be the main site of fatty acid 
metabolism (Mohrhauer and Holman, 1963, Rahm and Holman, 1964, Scott 
and Bazan, 1989, Su et al., 2001). The liver obtains fatty acids from both diet 
and de novo synthesis. Liver de novo synthesis follows the pathways of chain 
elongation, desaturation and partial β-oxidation (Cook, 1978). It is also regarded 
that the liver is the major site of fatty acid elongation and desaturation in 
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mammals (Su et al., 2001). Thus the liver is able to synthesize saturated and 
unsatured fatty acids.
The desaturase activity in the liver depends on individual species. In animals 
such as rat and mouse, liver Δ6 desaturase and Δ5 desaturase activities are 
quite high in comparison to other tissues such as the brain, kidney and heart 
(Youdim and Deans, 1999). In humans, liver Δ6 desaturase and Δ5 desaturase 
activities are reported to be low (Rodriguez et al., 1998). 
In mammals, the precursor essential fatty acids C18:2n-6 and C18:3n-3 
required for PUFA generation are present in much greater concentrations in the 
liver than in tissues such as the brain (Cook, 1978). However, there are major
variations in elongation and desaturation products. For example, DHA is known 
to be the major n-3 PUFA in carnivores and omnivores while docosapentaenoic 
acid (C22:5n-3) is the predominant n-3 PUFA in ruminants and herbivores 
[reviewed in (Gurr et al., 2002). Furthermore, among these classes of 
mammals, variations also exist, for instance, DHA was not found in the liver of 
domestic feline (Pawlosky et al., 1994)
It is generally accepted that quantitatively the most important metabolic pathway 
of essential fatty acids in the liver is that of the n-6 series while the least 
important is that of the n-9 series (Sheaff et al., 1995). When the diet contains 
sufficient C18:2n-6, and given that this fatty acid has a high affinity for the Δ6 
desaturase, its metabolism in the liver produces, DHGLA, AA, C22:4n-6 and 
docosapentaenoic acid (C22:5n-6) (Lin and Salem, 2007, Mohrhauer and 
Holman, 1963, Pawlosky et al., 1994, Rahm and Holman, 1964). The 
accumulation of mead acid (C20:3n-9) that normally occurs in tissues in trace 
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amounts, is an indication of dietary deficits of C18:2n-6 and C18:3n-3 (Rahm 
and Holman, 1964). C18:3n-3 in the liver is metabolised to eicosatrienoic acid 
(C20:3n-3), EPA, docosapentaenoic acid (C22:5n-3) and DHA (Lin and Salem, 
2007, Mohrhauer and Holman, 1963, Rahm and Holman, 1964) and can be 
supplied from the liver through circulation to other tissues including the brain, 
kidney and heart (Scott and Bazan, 1989, Youdim and Deans, 1999). 
There is competition by the different unsaturated fatty acid families (n-6, n-3 and 
n-9) for the desaturase activity and the favoured of this competition depends on 
the relative dietary supply of these acids (Rahm and Holman, 1964). Diets 
supplemented with safflower oil enriched in C18:2n-6 were shown to increase 
liver C18:2n-6, DHGLA, AA and docosapentaenoic acid (C22:5n-6), reduce 
palmitoleic acid (C16:1), C18:1n-9 and C20:3n-9 (Rahm and Holman, 1964). 
Yet it did not affect C18:3n-3 but reduced its metabolites C20:3n-3, EPA, 
docosapentaenoic acid (C22:5n-3) and DHA. In contrast, when diets were 
supplemented with C18:3n-3, n-3 PUFA were increased, monounsaturated fatty 
acids and C18:2n-6 were not affected but C18:2n-6 metabolites were 
significantly reduced (Mohrhauer and Holman, 1963). Thus C18:3n-3 inhibits 
the metabolism of C18:2n-6, and C18:2n-6 inhibits the metabolism of C18:1n-9. 
A similar trend is proposed for the conversion of C20-C22 PUFA: n-3 PUFA, for 
example, docosapentaenoic acid (C22:5n-3) and DHA may inhibit the 
conversion of AA to docosapentaenoic acid (C22:5n-6) (Mohrhauer and 
Holman, 1963).
Fatty acids are delivered to the liver to be catabolized for energy production and 
the production of bioactive metabolites such as eicosanoids (Guzman and 
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Blazquez, 2004, Morita et al., 1983). The liver is known to supply other tissues 
such as the brain with ketone bodies for energy during starvation (Guzman and 
Blazquez, 2004). Breakdown of fatty acids by β-oxidation occurs in the 
mitochondria and peroxisomes. Mitochondrial β-oxidation is primarily concerned 
with energy production but can also be used for fatty acid synthesis, while 
peroxisomal β-oxidation is concerned primarily with chain shortening of fatty 
acids such as erucic acid (C22:1n-9) (Clouet and Bezard, 1978). 
1.4.2 Cholesterol metabolism in the liver
The liver plays an important role in cholesterol balance across individual organs 
and in the whole body (Dietschy et al., 1993, Robins et al., 1985, Turley et al., 
1981). All animal tissues can obtain cholesterol via diet and are also able to 
synthesize cholesterol from acetyl CoA. However, the rate of synthesis depends 
on species, age and type of tissue (Dietschy et al., 1993). Liver synthesizes 
more cholesterol than it requires for its growth and contributes to a significant 
amount of cholesterol that accumulates in the whole body (Yao et al., 2007). 
Cholesterol from the diet reaches the liver from the small intestine by 
chylomicron remnant receptor pathway (Dietschy et al., 1993, Spady and 
Cuthbert, 1992). Healthy adult mammals are in the steady state because they 
are not growing, so their cholesterol requirement is determined by the need to 
compensate for the net loss of cholesterol in the form of bile salts, hormonal 
synthesis, biliary cholesterol and from sloughed cells (Dietschy et al., 1993). In 
contrast, young mammals, foetuses and neonates are in a state of rapid growth, 
therefore in addition to compensation for cholesterol loss in the pathways 
described above (Dietschy et al., 1993), they require cholesterol for membrane 
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formation (Cavender et al., 1995). The rate of cholesterol synthesis decreases 
with age in all mammals (Dietschy et al., 1993, Yao et al., 2007).
Conversion of cholesterol to bile salts provides the major pathway for 
cholesterol elimination from the body (Spady and Cuthbert, 1992). The liver is 
the only mammalian organ that can excrete cholesterol from the body, thus 
most mammalian extrahepatic cells that are unable to catabolise cholesterol 
export it to liver for catabolism and elimination in order to maintain cholesterol 
homeostasis (Lutjohann et al., 1996, Reiss et al., 2004). The initial and rate 
limiting step in cholesterol conversion to bile salts is the formation of 7α-
hydroxycholesterol catalysed by cholesterol-7α-hydroxylase (Shefer et al., 
1970). In adult animals in the steady state, the liver must excrete each day the 
amount of cholesterol that equals the amount of cholesterol synthesized in the 
various organs and obtained from the diet (Dietschy et al., 1993). Thus 
extrahepatic cells export cholesterol to the liver by reverse cholesterol 
transpsort for catabolism (Fielding and Fielding, 1995). When the hepatic 
cholesterol pool is increased, a compensatory upregulation of cholesterol-7α-
hydoxylase activity results, thereby increasing cholesterol degradation into bile 
salts and subsequent excretion in the form of fecal bile salts.
The liver also metabolises cholesterol carried in VLDL and LDL (Dietschy et al., 
1993). In addition to being a carrier of triacylglycerols, VLDL also carries 
cholesterol on its monolayer and cholesteryl esters in its core (Gurr et al., 
2002). Thus cholesterol is secreted from the liver in VLDL. During liver 
metabolism of VLDL, triacylyglycerols are removed and VLDL remnants are 
formed whilst a portion of VLDL is converted to LDL. LDL-cholesterol and VLDL 
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remnants are significantly cleared from the plasma by LDL receptors in the liver 
(Kita et al., 1982). When hepatic LDL receptor activity is low or surpressed, less 
VLDL remnants are cleared from plasma, LDL-cholesterol synthesis is 
increased with a corresponding increase in LDL-cholesterol in circulation 
(Dietschy et al., 1993). Conversely, when LDL receptor activity is increased in 
the liver, more VLDL remnants are cleared from the plasma and LDL-
cholesterol synthesis is decreased with a corresponding decrease in LDL-
cholesterol in circulation (Dietschy et al., 1993). Thus net cholesterol balance in 
the whole body, and the level of circulating LDL-cholesterol is dependent on 
what happens in the liver.
1.5 Lipid metabolism in the brain
1.5.1 Fatty acid metabolism in the brain
The brain demonstrates the alternating sequence of desaturation and chain 
elongation that occurs in the liver (Cook, 1978). The brain is able to synthesize 
saturated, and monounsaturated fatty acids and PUFA, through the metabolism 
of precursor essential fatty acids. In the brain α-linolenic acid (C18:3n-3) is the 
preferred substrate for the Δ6 desaturase (Cunnane et al., 1994). The PUFA 
found in the mammalian brain include C18:2n-6 (0.1-1.5 % weight of total fatty 
acid), C18:3n-3 (0.1-1.0 % weight of total fatty acid), AA (8-17 % weight of total 
fatty acid), DHA (13-29 % weight of total fatty acid) (Cook, 1996) . Appreciable 
amounts of C22:4n-6 have also been found whilst traces of C20:3n-3 have also 
been reported (Lin and Salem, 2007, Martinez, 1992). It is still not clear whether 
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EPA (C20:5n-3) and docosapentaenoic acid (C22:5n-3) are found in the brain 
(Li et al., 2006, Murthy et al., 2002). 
DHA and AA accumulate in the brain of animals during the period of rapid 
development (Martinez, 1992, Neuringer et al., 1986). DHA and AA are 
synthesized in the brain from C18:3n-3 and C18:2n-6 respectively (Scott and 
Bazan, 1989). Studies show that preformed AA and DHA may contribute to the 
accumulation of AA and DHA in the brain more than contribution from de novo
synthesis from the dietary essential fatty acid C18:3n-3 (Lefkowitz et al., 2005, 
Salem et al., 1996, Su et al., 2001). Moreover, it is reported that the brain 
depends not only on the diet for DHA but also on the liver since its ability to 
synthesize DHA from α-linolenic acid (C18:3n-3) is very low compared to that of 
liver (Igarashi et al., 2007, Scott and Bazan, 1989). Deficient n-3 PUFA diets 
have been shown to reduce DHA levels in the brain and cause a compensatory 
increase in some n-6 PUFA, especially docosapentaenoic acid (C22:5n-6) 
(Neuringer et al., 1986). 
Fatty acids in brain phospholipids function to maintain membrane fluidity and 
integrity which further influences other cellular activities such as neuronal 
differentiation (Kan et al., 2007) and signal transduction (Bazan, 2003). Analysis 
of cortical phospholipids has shown variations in the fatty acids that are 
esterified in the sn-1 and sn-2 positions (Kerwin et al., 1994). DHA is the 
predominant PUFA in the sn-2 position of PE and PS, PI is mainly esterified 
with AA in the sn-2 position, while PC is predominantly esterified with C16:0 in 
sn-1 position and C18:2n-6 and AA in the sn-2 position (Kerwin et al., 1994). 
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Metabolism of brain PUFA also depends on the activities of specific 
phospholipases that liberate them from the sn-2 position of phospholipids. DHA 
and AA are removed by the action of calcium independent and calcium 
dependent PLA2 respectively (Strokin et al., 2003). These free fatty acids can 
either be metabolised to bioactive lipid mediators or reacylated by acyl 
transferases into lysophospholipids, thereby forming new phospholipids. 
1.5.2 Cholesterol metabolism in the brain
Brain is able to synthesize de novo cholesterol to cover its requirements for 
development and function (Jurevics et al., 1997). During brain development in 
the foetus and newborn, cholesterol synthesis is high but declines with 
maturation of the animal (Spady and Dietschy, 1983). This decline in the adult 
animal brain tissue has been explained to be due to an efficient recycling of 
brain cholesterol (Bjorkhem and Meaney, 2004). However brain cholesterol 
synthesis continues at a slow rate after maturation and eventually its 
concentration becomes constant (Spady and Dietschy, 1983). 
Brain cholesterol is tightly regulated and the intact blood brain barrier prevents 
the uptake of cholesterol from circulation (Bjorkhem and Meaney, 2004). Thus 
cholesterol contents in the brain are independent of dietary uptake or hepatic 
synthesis (Farooqui et al., 2007). Since cholesterol levels are constant in 
maturity it means that the rate of synthesis is in equilibrium with the rate of 
degradation or elimination in adult animals. 
Several pathways for cholesterol degradation and elimination in the brain have
been reported (Zhang et al., 1997). These pathways metabolise cholesterol to 
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24-hydroxycholesterol, 25-hydroxycholesterol, 27-hydroxycholesterol, other 
cholesterol oxides such as, 7-ketocholesterol and cholesteryl esters that are of 
importance for cholesterol homoeostasis in the brain. The major pathway for 
efflux of brain cholesterol is the cholesterol 24-hydroxylase pathway, which 
converts cholesterol to 24-hydroxycholesterol (Bjorkhem et al., 1998). 24-
hydroxycholesterol, 25-hydroxycholesterol and 27-hydroxycholesterol can 
penetrate the blood brain barrier, exported in circulation and then transported by 
plasma LDL to the liver where they are excreted in bile (Bjorkhem and Meaney, 
2004). These metabolites also participate in brain cholesterol homeostasis 
through their ability to inhibit brain cholesterol synthesis (Bjorkhem and Meaney, 
2004). 
Cholesterol metabolism is altered with age and in neurodegenerative diseases. 
This altered brain cholesterol metabolism has been demonstrated in increased 
levels of cholesterol in the aged brain (Calderini et al., 1983). In addition, it has 
been shown that age increases the flux of 24-hydroxycholesterol from the 
human brain into the circulation (Lutjohann et al., 1996). In neurodegeneration, 
neuronal cell membranes are degraded and cholesterol is released (Bjorkhem 
and Meaney, 2004). Free cholesterol is subsequently available for oxidation to 
24-hydroxycholesterol and other hydroxyl cholesterol metabolites, and 
increased 24-hydroxycholesterol in the plasma is a peripheral marker of 
neurodegeneration and diseases such as Alzheimer’s disease and dementia 
(Lutjohann et al., 2000). 
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1.6 The role of lipids in neuroinflammation
Neuroinflammation is a response of brain cells to a disturbance in their normal 
function as a result of events such as infection and ischemia. 
Neuroinflammation can be acute or chronic. Lipids play an active role in the 
maintenance of normal brain structure and function and any disturbance in their 
metabolism may therefore contribute to neuroinflammation.
1.6.1 Fatty acids and their metabolites in neuroinflammation 
Neuronal membranes are rich in AA and DHA esterified mostly in the sn-2 
position of membrane phospholipids such as PE, PC, PI, PS (Kerwin et al., 
1994). AA and DHA are highly unsaturated and prone to oxidation. Their 
liberation from membrane phospholipids may result in the production of free 
radicals and reactive oxygen species both of which contribute to lipid 
peroxidation and oxidative damage of neural membrane proteins, ion channels 
and receptors (Pratico et al., 1998).
Enzymatic metabolism of AA by COX, LOX and/or CYP450 monooxygenases 
and epoxygenases yield eicosanoids with pro-and/or anti-inflammatory 
properties. PGE2 has been demonstrated to have neuroprotective functions 
(McCullough et al., 2004); however it is also associated with neuroinflammatory 
diseases such as Alzheimer’s disease (Liang et al., 2005). TXA2 is also 
released in the brain (Hou et al., 2004). In addition to initiating the inflammatory 
response, other mediators derived from AA such as lipoxins, may also mediate 
resolution (Gilroy et al., 2004). Free radical derived metabolic products of AA 
such as the isoprostanes are also involved in neuroinflammation and cause 
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vasoconstriction (Morrow et al., 1990). EPA and DHA can be non-enzymatically 
metabolised to neuroprostanes that inhibit F2-isoprostanes and serve as unique 
markers of oxidative neuronal injury (Gao et al., 2006, Nourooz-Zadeh et al., 
1998).
Eicosanoids are also reported to induce the release of proinflammatory 
cytokines in cells (Bagga et al., 2003). Cytokines such as the interleukins (IL), 
chemokines, tumour necrosis factors (TNF), interferons, and growth and cell 
stimulating factors; neurotrophins (Rothwell, 1999) are major effectors of the 
neuroinflammatory cascade and evidence demonstrates their contribution to 
neuroinflammation (Ching et al., 2005). 
Fatty acids also have anti-inflammatory properties. EPA and DHA are 
metabolised to resolvins and neuroprotectins. EPA is metabolised by aspirin-
treated COX-2 to generate 18R-HEPE and 15R-HEPE that are resolvins of the 
E series. DHA is metabolised by LOX to neuroprotectin D1 (10R, 17S-
docosatriene) which is a neuroprotective mediator (Lukiw et al., 2005, 
Marcheselli et al., 2003) and metabolised by COX-2 to yield 17R-hydroxy series 
of docosanoids also termed resolvins of the D series (Serhan et al., 2002). They 
antagonise the effects of eicosanoids, modulate leukocyte trafficking and 
downregulate the expression of cytokines in glial cells (Hong et al., 2003, 
Marcheselli et al., 2003, Serhan et al., 2002). EPA has also been shown to 
reduce inflammation in the human monocytic cell line by decreasing the TNF-α 
gene expression by preventing NF-κB, a nuclear transcription factor that 
induces inflammatory genes (including TNF-α, COX-2, IL-1β and IL-6) in 
response to inflammatory stimuli (Zhao et al., 2004). 
51
1.6.2 Phospholipids in neuroinflammation
Phospholipid metabolism is altered in neuroinflammation (Horrobin and Bennett, 
1999). The levels of PC, PE and PI are reportedly reduced in the brain in 
neuroinflammatory conditions such as cerebral ischemia, head injury and age 
(Calderini et al., 1983, Ramirez et al., 2003). In addition lyso-
glycerophospholipids, the products of PLA2 degradation of phospholipids, 
contribute to neuroinflammation. For instance lysophosphatidylcholine activates 
microglia and other immune cells (Schilling et al., 2004) and activated microglia 
in turn induce the release of pro-inflammatory cytokines (Stock et al., 2006). 
Moreover lysophosphatidylcholine is also a precursor of platelet activating 
factor, a potent pro-inflammatory lipid mediator. The acetyl group at the sn-2 
position of its glycerol backbone (Figure 1.5B) is essential for its pro-
inflammatory activity (Castro Faria Neto et al., 2005). Studies have shown that 
platelet activating factor enhances neuroinflammation by upregulating COX-2, 
TNF-α, and PGE2 in human neuronal cells (Boetkjaer et al., 2007) and 
astrocytes (Farooqui et al., 2007). In addition, platelet activating factor is known 
to modulate intracellular calcium stores in human microglia (Wang et al., 1999)
which in turn is related to the release of AA from phospholipids in the brain 
(Sergeeva et al., 2005).
Furthermore, phospholipid-related signal transduction has been associated with 
neuroinflammation (Wang et al., 1999). Activation of PLC leads primarily to the 
breakdown of PI to DAG and inositol triphosphate that are active signal 
transduction molecules. Inositol triphosphate in turn causes an increased 
release of calcium ions, which together with DAG lead to increased activity of 
PKC. Further to this, PLD and PLA2 contribute to the sustained action of PKC 
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by hydrolysing PC to yield PA, which in turn is converted to DAG while PLA2
hydrolyses PC to release AA and lysophosphatidylcholine all of which have 
been shown to potentiate the DAG mediated activation of PKC. PKC has been 
reported to mediate the induction of nitric oxide synthase implicated in 
inflammation (Paumelle et al., 2006).
1.6.3 Sphingolipids in neuroinflammation
Various studies suggest the involvement of sphingolipids in the modulation of 
neuroinflammation through the activation of PLA2, COX-2 and 
sphingomyelinase (Akundi et al., 2005, Singh et al., 1998). Specifically, it has 
been shown that ceramide can induce lipid peroxidation and lead to the 
accumulation of pro-inflammatory cytokines such as TNF-α in the brain 
(Alessenko et al., 2005). TNF-α and other cytokines in turn induce COX-2 and 
secretory PLA2 (El Alwani et al., 2006). In addition it has been shown that the 
sphingomyeline cycle and lipid peroxidation are induced in rat brain regions in 
neuroinflammatory diseases such as Alzheimer’s disease (Alessenko et al., 
2004). 
1.6.4 Cholesterol in neuroinflammation
Cholesterol has also been implicated in neuroinflammation. It has been shown 
that hypercholesterolemia can induce activated microglia which is a 
characteristic of neuroinflammation (Lutjohann et al., 2000). In addition 
increased cholesterol excretion from the brain was shown to decrease 
neuroinflammation and deactivate microglia in Niemann-Pick type C mouse 
(Repa et al., 2007). 
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Another way through which cholesterol may contribute to neuroinflammation is 
by its oxidized products. Cholesterol is a major component of the myelin sheath;
and cholesterol oxidized products such as 7β-hydroxycholesterol and 7-keto-
cholesterol exhibit cytotoxic effects on neurons (Chang and Liu, 1998) and this 
has been linked with demyelination and progressive neuronal damage (Diestel
et al., 2003). 7-ketocholesterol activates microglia (Diestel et al., 2003) and an 
accumulation of 7β-hydroxylcholesterol is reported to induce oxidative stress 
and neuronal loss observed in Alzheimer's disease (Nelson and Alkon, 2005)
and multiple sclerosis (Diestel et al., 2003). 
1.7 Lipids and neuropsychiatric disorders
Neuropsychiatric conditions include such disorders like Attention Deficit 
(hyperactivity) Disorders, Alzheimer's disease, schizophrenia and mood 
disorders such as major depression and bipolar disorder. 
1.7.1 Fatty acids in neuropsychiatric disorders
Abnormal PUFA metabolism has been linked to neuropsychiatry disorders. A 
study of drug naive first episode schizophrenic patients (average age, 22 years) 
and chronic treated schizophrenic patients (average age, 46 years) showed 
alterations in fatty acid levels typically with increased saturated fatty acids and 
reduced AA and DHA when compared to healthy controls of similar ages (Khan
et al., 2002). It has also been suggested that the distribution of PUFA in the red 
blood cell membrane may reflect the distribution in the central nervous system 
(Carlson et al., 1986) since the blood is a source of fatty acid supply to the brain 
(Connor et al., 1990, Lin and Salem, 2007, Scott and Bazan, 1989). 
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Omega 3 PUFA especially DHA are particularly depleted in the blood of 
schizophrenic and depressive patients compared to normal controls (Khan et 
al., 2002, Peet et al., 1998). In an animal study, it was shown that diets deficient 
in C18:3n-3 caused a major reduction in brain DHA and a compensatory 
increase in brain docosapentaenoic acid (C22:5n-6) in pregnant rats compared 
to non-pregnant controls (Levant et al., 2006). In pregnancy, the mother 
transfers AA and DHA from the placenta through the blood to the foetus liver 
and subsequently to the foetus brain (Campbell et al., 1998). This may put the 
mother at risk of AA and DHA depletion. However with a diet deficient of n-3 
PUFA, there is a tendency for n-6 PUFA to accumulate since they compete for 
the same metabolising enzymes (Neuringer et al., 1986). This potential risk of 
DHA depletion, along with the hormonal and other changes associated with 
pregnancy and childbirth may predispose the mothers to postparturm 
depression (Hibbeln, 2002). 
Arachidonic acid is involved in brain function and alterations in its levels may be 
involved in the pathology of neuropsychiatric disorders. This may occur via the 
formation of eicosanoids (Lee et al., 2007) and endocannabinoids like 2-
arachidonylglycerol (Melis et al., 2004), modulation of neurotransmitter levels as 
well as signal transduction (Maida et al., 2006) and gene expression (Bosetti 
and Weerasinghe, 2003). Moreover, it has been demonstrated that lithium and 
antimanic anticonvulsants such as carbamazepine and valproic acid target and 
reduce AA but not DHA and C16:0 incorporation and turnover within brain 
phospholipids of unanaesthesized rats (Bazinet et al., 2006, Rapoport and 
Bosetti, 2002). Lithium also caused a corresponding downregulation of COX-2 
activity and, cytosolic PLA2 that selectively liberates AA and not DHA from 
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phospholipids (Rapoport and Bosetti, 2002). These findings indicate that drugs 
that target enzymes in the AA cascade, such as COX-2 inhibitors, might be 
candidate treatments for some neuropsychiatric disorders.
Dysfunctions in neurotransmitter systems are thought to underlie 
neuropsychiatric disorders (Zangen et al., 1997, Zangen et al., 1999). For 
instance there is a marked reduction in dopamine concentration in the brains of 
dementia and Parkinson’s disease patients when compared to normal controls 
(Piggott et al., 1999). A postmortem study of schizophrenic patients showed that 
in the prefrontal cortex, the receptor site densities of serotonin 1A (5HT-1A) was 
significantly increased whereas that of serotonin 2A (5HT-2A) was significantly 
decreased when compared to that of healthy controls (Burnet et al., 1996). 
Animal studies have shown that dopaminergic, muscarinic M1/M4, 
serotoninergic, and α-adrenergic receptors stimulate the release of AA (C20:4n-
6) by activating calcium dependent PLA2 in neuronal cells (Felder et al., 1990, 
Vial and Piomelli, 1995). 
In rat brain regions such as nucleus accumbens, prefrontal cortex and 
hippocampus, n-6 PUFA have been shown to reduce muscarinic M2/M4 
receptor binding (du Bois et al., 2005). Additionally, it has been shown in the rat 
prefrontal cortex that a low n-3 PUFA level may induce a reduction in dopamine 
D2 specific binding associated with a reduction in endogenous dopamine levels 
(Delion et al., 1994). Furthermore, n-3 PUFA deficiency is reported to lower 
dopamine release in the rat frontal cortex and nucleus accumbens (Zimmer et 
al., 2002). These findings indicate that fatty acid deficiency may cause 
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variations in neurotransmitter binding which may possibly have an effect on 
their functions. 
It was also shown that in rats which have been fed a diet deficient in C18:3n-3, 
the levels of DHA decreased during brain development. This led to hyperactivity 
in adulthood, which is indicative of altered dopaminergic function that 
predispose to schizophrenia and Attention Deficit Disorder development (Levant
et al., 2004). During weaning some of the C18:3n-3 deficient rats were given a 
remediation diet enriched with DHA, and attention deficit associated 
hyperactivity was reduced in these rats, when compared to C18:3n-3 deficient 
rats not fed a remediation diet. The reduction in hyperactivity was also found to 
be comparable to that of controls fed C18:3n-3 sufficient diet (Levant et al., 
2004). These results demonstrate the important role DHA may play in brain 
development.
1.7.2 Phospholipids in neuropsychiatric disorders
The phospholipid hypothesis of mood and other neuropsychiatric disorders 
proposes that there is an alteration in phosholipid metabolism because of an 
increased rate of loss of dihomo-γ-linolenic acid (C20:3n-6), EPA, AA and DHA 
at the sn-2 position of phospholipids (Horrobin, 1998, Horrobin and Bennett, 
1999). This alteration is associated with induced abnormal phospholipid signal 
transduction (Horrobin, 2001, Pacheco et al., 1996) and altered activities of 
phospholipid metabolising enzymes (Ross et al., 2006, Ross et al., 1998, Ross
et al., 1999). Also, phospholipid levels have been shown to be decreased in 
neuropsychiatric disorders, for instance, it was shown that there are lower 
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amounts of PC and PE in the brains of schizophrenic patients when compared 
to subjects without schizophrenia (Yao et al., 2000).
From this hypothesis, studies of neuropsychiatric disorders have made 
correlations between alterations in the fatty acid composition of red blood cell 
membrane phospholipids and that of neuronal membrane phospholipids (Yao et 
al., 2002). It was demonstrated that a decrease in the AA composition of red 
blood cell membrane phospholipids in schizophrenic patients was in parallel to 
a decrease in the AA composition of the prefrontal cortex membrane 
phospholipids (Yao et al., 2002). Thus showing that in schizophrenia there may 
be an association between a decrease in red blood cell membrane phospholipid 
PUFA and a decrease in brain membrane phospholipid PUFA. In depression, 
decreases in the level of n-3 PUFA have been shown in serum cholesteryl 
esters with a concomitant increase in the AA/EPA ratio of serum cholesteryl 
esters and phospholipids of depressed patients (Maes et al., 1996, Peet et al., 
1998). In a recent post-mortem study of major depressed patients, it was shown 
that there were significant decreases in the DHA of the orbitofrontal cortex (a 
subregion of the prefrontal cortex), which was concomitant with increased n-6/n-
3 fatty acid ratio, specifically AA/DHA and docosapentaenoic acid (C22:5n-
6)/DHA ratios (McNamara et al., 2007).
In addition, the blood and brain activities of phospholipid metabolizing enzymes 
have been implicated in neuropsychiatric disorders (Gattaz et al., 1995, Ross et 
al., 2006, Ross et al., 1998, Ross et al., 1999). In platelets of schizophrenic 
patients it was shown that the activity of calcium independent PLA2 was 
significantly increased compared to normal controls (Gattaz et al., 1995). Post-
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mortem brain enzyme assays performed on the temporal cortex of 
schizophrenic patients showed a 45 % increase and a 27-42 % decrease in the 
activities of calcium independent PLA2 and calcium dependent PLA2
respectively when compared with normal controls (Gattaz et al., 1995, Ross et 
al., 1999). Furthermore, it has been shown in the autopsied brain of Alzheimer’s 
patients that the activities of calcium dependent PLA2, calcium independent 
PLA2 and glycerophosphocholine phosphodiesterase were reduced compared 
to that of neurologically and histopathological normal controls (Ross et al., 
1998). In contrast, the activities of lysophospholipid acyltransferase, which 
recycles lysophospholipids into intact phospholipids, and 
glycerophosphocholine phosphodiesterase, which returns phospholipid 
catabolites to be used in phospholipid resynthesis, were increased by 
approximately 50-70% in the same brain areas (Ross et al., 1998). Thus, it may 
be possible that compensatory phospholipid metabolic changes occur in the 
Alzheimer brain that may reduce the loss in phospholipids associated with this 
disease.
1.7.3 Animal models of neuropsychiatric disorders
Animal models have been used to study neuropsychiatric disorders. Some of 
these models include the Flinders Sensitive Line (FSL) and Wistar-Kyoto (WKY) 
rat models of depression, hypothesis based and susceptibility gene based 
models of schizophrenia, beta-amyloid precursor protein transgenic line models 
of Alzheimers disease and spontaneously hypertensive rats (SHR) for Attention 
Deficit Disorders (Chen et al., 2006, Overstreet et al., 2005, Pare, 2000, Russell
et al., 2005).
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The FSL rats were selectively bred from Sprague-Dawley rats for increased 
responses to the anticholinesterase diisopropyl fluorophosphates (DFP) 
(Overstreet et al., 1979, Russell et al., 1982). DFP causes delayed neurotoxicity 
which was shown to act through the phosphorylation of an esterase termed 
neuropathy target esterase (Johnson, 1969). Neuropathy target esterase is 
known to be involved in normal brain development and in membrane 
phosphatidylcholine homeostasis (Glynn, 2005, Glynn, 2006). The FSL rats 
have many similarities with depressive humans such as loss of weight, 
decreased appetite, increased rapid eye movement sleep and responds to 
antidepressants (Yadid et al., 2000). The FSL rat model has been used to study 
the cholinergic abnormalities in depression (Benca et al., 1996), brain fatty acid 
metabolism in depression (Green et al., 2005), neurochemical mechanisms of 
depression (Zangen et al., 2001), mode of action of antidepressants such as 
desipramine (Zangen et al., 1997) and to study emotional dysregulation in 
infants of depressive parents (Braw et al., 2008).
Another well studied animal model of depression is the WKY rat model (Pare, 
2000). The WKY rat model was inbred from Wistar strains. This animal model of 
depression also exhibits a hyper-responsiveness to stress and depressive-like 
behavior in multiple behavioral tests, including the forced swim test (Pare, 
1994). It has been applied in the study of investigatory behaviour in depression 
(Pare, 2000), emotional dysregulation in infants of depressive parents (Braw et 
al., 2008) and hormonal regulation in depression (Solberg et al., 2001). 
In the study of schizophrenia, different animal models have also been employed
(Chen et al., 2006). These include the susceptibility genes model such as the 
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disrupted-in-schizophrenia-1 (DISC1) gene. DISC1 gene model is based on the 
hypothesis that genes are critical risk factors for susceptibility to schizophrenia. 
DISC1 gene is a gene susceptible to schizophrenia which when disrupted due 
to a balanced chromosome translocation, results in schizophrenia (Millar et al., 
2000). DISC1 animal models display several behavioral abnormalities, including 
hyperactivity and an anhedonia/depression-like deficit similar to those reported 
in human schizophrenic patients (Hikida et al., 2007). Another model is the 
dopamine transporter (Hauss-Wegrzyniak et al.) knock out mouse, which is 
based on the hypothesis that hyperdopaminergic activity is characteristic of 
schizophrenia. This model has been applied in the screening of antipsychotic 
drugs (Chen et al., 2006). 
1.8 Statins
Statins are a family of drugs used to regulate cholesterol levels. They are 
competitive inhibitors of HMG-CoA reductase, the rate limiting step in 
cholesterol biosynthesis (Chong et al., 2001, Christians et al., 1998, Endo and 
Endo, 2004, Vaughan and Gotto, 2004).
1.8.1 Origin and types of statins
Statins were originally developed based on the search for microbial metabolites 
that would inhibit HMG-CoA reducase (Endo and Endo, 2004). The first statin, 
mevastatin, was isolated from the fungus Penicillium citrinium and this was 
followed by the isolation of lovastatin from Aspergillus terrus (Endo and Endo, 
2004). 
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Figure 1.11 Structures of some commonly used statins (A) Lovastatin, (B) 
Pravastatin, (C) Simvastatin, (D) Fluvastatin, (E) Atorvastatin, (F) Rosuvastatin, 
(G) Pitavastatin
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Figure 1.11 shows the structures of the seven statins currently available as 
medicines. These statins may be classified into two groups: natural and 
synthetic statins. The natural statins include mevastatin and lovastatin. 
Pravastatin and simvastatin are synthetic derivatives of mevastatin and 
lovastatin respectively. Other synthetic statins are atorvastatin, fluvastatin, 
pitavastatin, cerivastatin and rosuvastatin. 
Statins are administered as either inactive lactone pro-drugs or as salts of the 
active hydroxy acids. Lovastatin and simvastatin are inactive lactone pro-drugs 
that are converted by esterases to their respective active acid form in the liver. 
Atorvastatin, fluvastatin, pravastatin, rosuvastatin and pitavastatin are 
administered as salts of their active hydroxy acid forms. Figure 1.12 shows the 
active acid and inactive lactone forms of atorvastatin. The active acid form is 
unstable in vivo and undergoes interconversion mediated by the action of 
cytochrome P3A4 (CYP3A4) to produce two main active hydroxy acid 
metabolites namely ortho-hydroxyatorvastatin and para-hydroxyatorvastatin. 
These hydroxyl derivatives similarly to the parent compound are unstable and 
undergo further interconversion to inactive ortho-hydroxyatorvastatin lactone
and para-hydroxyatorvastatin lactone respectively. Interconversion of the active 
acid form has been shown to occur in the liver (Siedlik et al., 1999) and other 
tissues including plasma and brain (Chen et al., 2007).
Although statins have a common mechanism of action they differ in their 
cholesterol lowering efficacy, pharmacokinetics, and interactions with other 
drugs and food (Chong et al., 2001, Christians et al., 1998, Rise et al., 2003). 
Atorvastatin, lovastatin, simvastatin and fluvastatin undergo extensive first pass 
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Figure 1.12 Active and inactive forms of atorvastatin and its metabolites
metabolism in the liver by the CYP450 mixed function enzymes and as a result 
have very low bioavailability (Chong et al., 2001). Rosuvastatin and pitavastatin 
undergo minimal first pass metabolism in the liver by CYP450 mixed function 
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enzymes and therefore have a high oral bioavailability (Iglesias and Diez, 
2003). Pravastatin does not undergo first pass metabolism by CYP450 in the 
liver. It has a high bioavailability and is excreted unchanged in faeces and urine 
(Komai et al., 1992). 
It has been shown that most cholesterol is synthesized at night when dietary 
intake is low (Jones and Schoeller, 1990). For instance, in both humans and 
rats it has been shown that the rate of cholesterol synthesis in the liver shows 
diurnal periodicity, with production peaking at night time (Edwards and Gould, 
1972, Edwards et al., 1972, Jones and Schoeller, 1990). In rat liver, HMG-CoA 
reductase activity is at its peak at 24:00 h and lowest at 12:00 h (Edwards and 
Gould, 1972, Edwards et al., 1972). For this reason it is recommended that 
statins be administered at bedtime. It is also recommended that simvastatin be 
taken in the evening because when it is taken in the morning, it significantly 
increases total cholesterol and LDL-cholesterol (Lund et al., 2002, Wallace et 
al., 2003). Therefore patient compliance is very crucial for the cholesterol 
lowering effects of simvastatin. It is not yet clear when it is better to take 
fluvastatin, pravastatin, rosuvastatin and lovastatin (Plakogiannis and Cohen, 
2007) although evening intake has been reported to be more effective for 
lovastatin (Pappu and Illingworth, 2002). Atorvastatin can be taken at any time 
because of its longer duration of action (Cilla et al., 1996, Plakogiannis et al., 
2005). In general, statins with shorter half lives (1-5 h) such as lovastatin, 
simvastatin and fluvastatin are proposed to be more effective when taken in the 
evening whereas those with longer half lives (14-22 h) such as atorvastatin, 
pravastatin and rosuvastatin are effective when taken at any time (Plakogiannis 
and Cohen, 2007).
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1.8.2 The lipid lowering effects of statins
Statins have well documented serum cholesterol lowering effects, in most 
animal species and humans (Koga et al., 1992, Krause and Newton, 1995, 
Mabuchi et al., 1983, Parker et al., 1990, Shepherd et al., 1995). The 
mechanism by which statins achieve this effect is through the depletion of 
hepatic cholesterol by inhibition of cholesterol synthesis in the liver. This 
inhibition is reported to induce the upregulation of LDL receptors in the liver, 
resulting in the reduction of plasma LDL-cholesterol, and reduction of the 
availability of cholesterol for VLDL production and secretion from the liver (Kita
et al., 1980, Reihner et al., 1990). It has also been reported that statins do not 
increase LDL-cholesterol uptake in extrahepatic cells, suggesting that 
upregulation of LDL receptors induced by statin occurs mainly in liver cells 
(Chen et al., 2007).
Statins mainly reduce blood LDL-cholesterol (Shepherd et al., 1995). Many 
clinical trials have demonstrated their ability to prevent acute cardiovascular 
events and reduce mortality in primary and secondary prevention of ischemic 
heart disease (Amarenco et al., 2006, Jones et al., 2004, LaRosa et al., 2005). 
These diseases are characterised by elevated LDL-cholesterol and reduced 
HDL-cholesterol levels, which are well recognised coronary heart disease risk 
factors (Frost et al., 1996, Nissen et al., 2005). 
It is important to point out that experimental animals do not always respond to 
statins in the same manner as humans. In rats and mice under normo- or 
hypercholesterolemic conditions, some studies have shown that the serum 
cholesterol lowering effects of HMG-CoA reductase inhibitors are not observed 
66
(Endo et al., 1979, Fears et al., 1980). Studies have demonstrated that single 
and repeated administration of pravastatin to rats with either a 2 fold higher 
dose (500 mg /kg) or dose (250 mg/kg) at which cholesterol synthesis is 
completely inhibited in the liver, strongly induced HMG-CoA reductase activity in 
order to compensate for the cholesterol reduction in the liver (Fujioka et al., 
1995, Fujioka and Tsujita, 1997). Consequently, liver cholesterol level was 
increased and VLDL secretion of cholesterol from the liver was stimulated, 
resulting in an increased serum cholesterol level. These studies also showed 
that liver LDL receptor activity was not induced by pravastatin treatment 
(Fujioka et al., 1995), and that the induced HMG-CoA reductase activity was 
followed by a decrease in cholesterol-7α-hydroxylase activity (Fujioka and 
Tsujita, 1997).
The rat is a hyporesponder to increased cellular cholesterol because it is able to 
adapt to large fluctuations in cholesterol intake or loss with little change in 
plasma LDL levels (Horton et al., 1995). Conversely, humans and animals, such 
as hamsters and monkeys are hyper-responders; increased dietary cholesterol 
results in increased plasma cholesterol and a downregulation of liver LDL 
receptor activity (Glatz et al., 1993, Spady and Cuthbert, 1992). The rat also 
has a high basal level of cholesterol-7α-hydroxylase, which is induced in 
increased cholesterol intake thereby enabling the liver to increase bile acid 
synthesis for cholesterol elimination (Horton et al., 1995, Spady and Cuthbert, 
1992). If this were the case, a reduction in cholesterol from statin treatment 
would have an opposing effect in rat cholesterol-7α-hydroxylase activity. 
Additionally, it is reported that statins lower plasma triacylglycerols and not 
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cholesterol in chow fed rats and thereby reduce VLDL production and secretion 
in rats (Krause and Newton, 1995). 
Various studies have shown the relative potency of statins in lowering 
cholesterol in vitro and in vivo. One such study reported that in vitro simvastatin 
is the most potent, followed by atorvastatin then fluvastatin in cultured human 
monocytic cells (Rise et al., 2003). Another study reported that simvastatin is 
able to reduce cholesterol precursor lathosterol in 3 month old mouse brain, 
thereby affecting cholesterol synthesis in the brain while pravastatin has no 
effects (Thelen et al., 2006). Furthermore, it was shown that in the adult male 
guinea pig, total brain cholesterol level were not affected by equipotent high 
doses of simvastatin or pravastatin treatment that markedly reduced plasma 
cholesterol (Lutjohann et al., 2004). However, both statins significantly reduced 
cholesterol precursor lathosterol and its ratio to cholesterol in the adult guinea 
pig brain. In addition, only pravastatin significantly reduced 24S-
hydroxycholesterol in the guinea pig brain, suggesting that endogenous brain 
cholesterol biosynthesis was reduced and was balanced out by a reduced 
conversion of cholesterol to 24S-hydroxycholesterol. These findings therefore 
suggest that although cholesterol synthesis in the guinea pig brain may be 
affected by statin treatment, brain cholesterol homeostasis is maintained.
1.8.3 Tissue permeability and distribution of statins
Tissue permeability of statins is somewhat controversial in that different 
investigators class them differently. Atorvastatin, pitavastatin, simvastatin, 
fluvastatin and lovastatin are regarded as lipophilic while pravastatin and 
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rosuvastatin are regarded as hydrophilic (Liao, 2005, Serajuddin et al., 1991). 
However, other studies report fluvastatin as hydrophilic (Christians et al., 1998).
Lipophilic statins are more likely to enter extrahepatic cells such as those of the 
blood brain barrier by passive diffusion than are hydrophilic statins. Hydrophilic 
statins are primarily targeting the liver. However, statin transporters have been 
reported to facilitate the transport of hydrophilic statins into hepatic and 
extrahepatic cells (Kikuchi et al., 2004, Lau et al., 2006). Furthermore, the 
hydrophilic statin, pravastatin is taken up into the liver by active transport and 
although it does not undergo extensive first pass effect in the liver, its 
distribution in plasma is quite low. This is because it is eliminated unchanged in 
the liver and has low cellular uptake in peripheral cells. Due to its liver 
selectivity, it was shown to have no cholesterol lowering effects on 21 days old 
Sprague-Dawley rat lens (Mosley et al., 1989). It was also reported to have 
minimal cholesterol lowering effects in cells from male Wistar rat spleen and 
testes (Parker et al., 1990). This tissue distribution associated with the 
hydrophilicity and lipophilicity of statins has been linked to the observed 
differences in the peripheral side effects of statins (Kobayashi et al., 2008).
1.8.4 The pleiotropic effects of statins
Although initially introduced as cholesterol lowering agents, statins have been 
shown to possess biochemical effects beyond the simple inhibition of 
cholesterol synthesis. These lipid-independent actions are known as pleiotropic 
effects (Liao, 2002, Nissen et al., 2005, Topol, 2004). 
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Pleiotropic effects of statins have been shown in a number of studies. These 
include anti-inflammatory and anti-oxidant effects, which might contribute to
their beneficial effects on cardiovascular diseases, such as improvement of 
endothelial function (Landmesser et al., 2005) that is impaired in coronary artery 
disease (Heitzer et al., 2001). In addition, they have been shown to enhance the 
stability of atherosclerotic plaques (Mitani et al., 2003), reduce cell proliferation 
and differentiation (Choi and Jung, 1999), and inhibit platelet aggregation and 
thrombosis (Casani et al., 2005). They also have extra beneficial hepatic effects 
on the immune system (Weber et al., 2006), central nervous system (Clarke et 
al., 2008, Hauss-Wegrzyniak et al., 1999) and bone fracture healing (Skoglund 
and Aspenberg, 2007). Statins also modulate gene expression in the brain, 
endothelial cells and hepatocytes (Johnson-Anuna et al., 2005, Landrier et al., 
2004, Wagner et al., 2002). Additionally, they have been found to affect fatty 
acid synthesis in cell cultures of monocytes and hepatocytes (Harris et al., 
2004, Rise et al., 1997, Rise et al., 2003, Rise et al., 2005), and fatty acid 
composition in serum (Harris et al., 2004). It has also been shown that statins 
may modulate signal transduction pathways in macrophages by inhibiting PKC 
mediated induction of inducible nitric oxide synthase implicated in inflammation 
(Paumelle et al., 2006).
1.8.5 Neuroinflammatory effects of statins
Statins have been shown to possess neuroprotective effects that are believed to 
be mediated via their anti-inflammatory effects (Endres et al., 1998). They 
reduce ischemic brain injury by decreasing oxidative stress caused by reactive 
oxygen species on neurons (Hayashi et al., 2005). Atorvastatin was recently 
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shown to increase anti-inflammatory IL-4 in activated microglia of aged and 
lipopolysaccharide challenged brain, which inhibited pro-inflammatory cytokine 
interferon–γ and the subsequent cascade of inflammatory events (Clarke et al., 
2008). Statins also inhibit amyloid-β stimulated expression of cytokines and 
inducible nitric oxide synthase and the production of nitric oxide in microglia and 
monocytes (Clarke et al., 2007, Cordle and Landreth, 2005). Furthermore the 
anti-inflammatory effects of statins in the brain have been attributed to their 
ability to reduce the levels of isoprenyl intermediates produced during the 
biosynthesis of cholesterol; this is distinct from their cholesterol lowering effects 
since these anti-inflammatory effect were not reversed by exogenous 
cholesterol supplementation (Cordle and Landreth, 2005). 
1.8.6 Statins and the blood brain barrier
As a result of their high lipophilicity, simvastatin and lovastatin are reported to 
pass the blood brain barrier more efficiently than pravastatin and atorvastatin 
(Vuletic et al., 2006). Thus these statins may be able to go into the brain. 
However, their abilities to lower brain cholesterol is still unclear. A recent study 
reported that whole-brain cholesterol turnover does not seem to be affected by 
short-term, high-dose statin treatment, as levels of cholesterol and its 
metabolite, 24S-hydroxylcholesterol, remained unchanged (Thelen et al., 2006). 
However, other studies demonstrated that lovastatin and pravastatin 
significantly reduced brain cholesterol (Vecka et al., 2004). In addition, other 
reports have shown that statins may affect cholesterol microdomains in 
synaptosomal plasma membranes of mice brain tissue (Kirsch et al., 2003). 
Specifically lovastatin and simvastatin reduced the levels of free cholesterol, 
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while pravastatin along with simvastatin reduced cholesterol levels in the 
exofacial membrane leaflet (Kirsch et al., 2003). These findings suggest that 
different statins, regardless of their ability to cross the blood brain barrier and 
their prevalence in the brain, induce alterations in cellular cholesterol 
distribution.
1.9 Lipid analysis
Changes in lipid composition have been associated with various diseases 
including age related disorders, cardiovascular dieases, inflammatory diseases 
and neuropsychiatric disorders, (Cremers et al., 2003, Favrelere et al., 2000, 
Goodenowe et al., 2007). Lipid analysis is therefore a valuable tool that permits 
not just the comparison of lipid metabolism in health and disease (Noula et al., 
2000, Oostendorp et al., 2006) but may also provide valuable information for 
therapeutic targets and for drug development. Lipid analysis is based on a 
variety of methods including: nuclear magnetic resonance (NMR), gas 
chromatography (GC), high performance liquid chromatography (HPLC), thin 
layer chromatography (TLC) and mass spectrometry (MS).
1.9.1 Lipid analysis by Nuclear Magnetic Resonance Spectroscopy
Nuclear magnetic resonance (NMR) spectroscopy is an analytical technique 
based on the principle that nuclei of atoms have magnetic properties that can 
yield chemical information (Pavia et al., 2001). High-resolution NMR has been 
used extensively in lipid analysis. It is a useful tool as it provides a non-
destructive method for rapid and comprehensive assay of many classes of 
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lipids. The most popular nuclei used in lipid analysis are hydrogen atom (1H), 
carbon-13 (13C) and phosphorus-31 (31P).
1.9.1.1 1H-NMR spectroscopy in lipid anlaysis
Proton nuclear magnetic resonance (1H-NMR) spectroscopy provides an 
overview of the quantitatively most abundant hydrogen containing substances in 
a sample (Nicholson et al., 1984). This has been used to characterise lipids and 
investigate their metabolism in cells (Bartz et al., 2007). In addition, it has been 
used to analyse the lipid composition of various tissues in health and disease 
(Nicholson et al., 1984, Noula et al., 2000, Oostendorp et al., 2006, Wevers et 
al., 1994). 13C-NMR spectroscopy has been shown to be valuable in using 13C 
labelled substrates to study the origin and utilization of carbon in fatty acid, as 
well as cholesterol metabolism in developing rat brain (Cunnane, 1992, 
Cunnane et al., 1994, Likhodii and Cunnane, 1999). In addition 31P- NMR 
spectroscopy has been shown to provide an accurate qualitative and 
quantitative analysis of phospholipids in biological fluids and tissues (Meneses 
and Glonek, 1988, Metz and Dunphy, 1996, Sotirhos et al., 1986). This 
technique has been applied in various studies such as the qualitative and 
quantitative analysis of modifications of phospholipids induced in plasma by 
malignant tumors (Kriat et al., 1993), post-mortem brain analysis of 
phospholipid molecular species in schizophrenics (Pearce and Komoroski, 
2000). In the present study, the focus will be on 1H-NMR analysis of lipids in 
both the brain and, liver of rats. 
The usefulness of 1H-NMR in lipid analysis is due to the diagnostic peaks 
characteristic of each lipid class. These diagnostic peaks allow for qualitative 
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and quantitative analyses of lipid mixtures (Adosraku et al., 1994). In addition 
the acyl chain length and degrees of unsaturation can been determined by 1H-
NMR spectrometry (Adosraku et al., 1994, Noula et al., 2000). Sample 
preparation of lipid extracts for 1H-NMR analysis is straightforward and does not 
require sample derivatisation that results in sample destruction. Thus intact lipid 
molecules present in tissue are analysed.
However, 1H-NMR spectroscopy is not without its disadvantages. With this 
analytical technique it is difficult to determine the acidic phospholipids PI, PS, 
PG and PA because their headgroup resonances overlap with that of glycerol 
and headgroup signals from non-acidic phospholipids (Kriat et al., 1993). In 
addition, it does not give information about the phospolipid molecular species 
and provides only the relative abundance of different phospholipid classes, 
unlike 31P-NMR, which provides the detailed molecular species of phospholipids 
and absolute concentrations of phospholipid classes in a sample (due to the 
use of an internal standard triethyphosphate) (Kriat et al., 1993, Pearce and 
Komoroski, 2000). The inability of 1H-NMR spectroscopy to provide absolute 
concentrations of phospholipids is due to differences in the chemical shift, and 
thus resonance frequencies. These differences in resonance frequencies are 
very small. As a result it is not easy to measure exact resonance frequencies of 
any proton thus a reference standard known as tetramethysilane is used. This 
standard is added to the sample solution and the resonance frequency of each 
proton in the sample measured relative to the resonance frequency of the 
protons of the reference substance (Pavia et al., 2001). 
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1.9.2. Gas chromatography in lipid analysis
Gas chromatography is an analytical technique applicable to volatile 
compounds. It has been used extensively for the analysis of lipids (fatty acids, 
glycerolipids, phospholipids, sphingolipids, cholesterol) and is popular for fatty 
acid analysis (Hoving, 1995, Masood et al., 2005, Morrison and Smith, 1964, 
Myher et al., 1974, Zhu et al., 1989).
1.9.2.1 Fatty acid analysis by gas chromatography
Fatty acids cannot be separated by GC because of their high boiling points. 
Therefore they have to be chemically converted to their lower boiling point 
alcoholic esters (Morrison and Smith, 1964). A popular method is to derivatise 
fatty acids to their corresponding fatty acid methyl esters (FAME) (Destaillats 
and Cruz-Hernandez, 2007, Eder, 1995, Masood et al., 2005, Morrison and 
Smith, 1964). This procedure is however not very suitable for analysing short 
chain (less than carbon-12) fatty acids since the increased volatility of the 
corresponding FAME can lead to unquantifiable losses related to evaporation 
(Hallmann et al., 2008). Short chain fatty acids can be analyed by converting 
them to propyl, butyl or ethyl esters (Hallmann et al., 2008, Kulig et al., 2006, 
Salanitro and Muirhead, 1975, Sullivan et al., 1978). Thus, these alkyl esters 
due to their decreased volatility, allow for the simultaneous analysis of both long 
and short chain (less than carbon-12) fatty acids (Hallmann et al., 2008).
For the preparation of FAME from lipid extracts, the lipids are trans-esterified 
either by acid catalysis or base catalysis. In acid catalysis, the reagents 
commonly used are methanolic hydrochloric acid 5 % (w/v) or sulphuric acid 2 
% (w/v), and boron trifluoride-methanol (BF3) 14 % (w/v) (Eder, 1995, Gutnikov, 
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1995, Morrison and Smith, 1964). The reaction catalysed by these reagents 
cannot proceed at ambient temperature so they require heating at a 
temperature of 100 °C (Morrison and Smith, 1964). An anti-oxidant such as 
butylated hydroxytoluene is also required to prevent oxidation of the fatty acids 
during this process. The transesterification process can last from about 2-90 
min depending on the type of lipid being transesterified. The reaction is 
complete within 2 min for free fatty acids, whilst transesterification of complex 
lipids requires more time: 10 min for phospholipids, 30 min for triacylglycerols 
and ether lipids, 45 min for sterols and 90 min for sphingolipids (Morrison and 
Smith, 1964). In base catalysed reaction, the common reagents used are 
sodium methoxide and potassium hydroxide in methanol. In contrast to acid 
catalysed reaction, base catalysed reaction proceeds at ambient temperature 
and there is no risk of PUFA degradation so there is no need for antioxidants 
such as BHT. However, the disadvantage of base catalysed reaction is that it 
does not esterify free fatty acids and does not trans-esterify sphingolipids (Eder, 
1995).
One of the most popular and convenient detectors used in GC analysis of fatty 
acids is the FID (Eder, 1995, Gutnikov, 1995, McNair and Miller, 1998). With 
FID, fatty acids can be identified by their relative retention times. The relative 
retention times of fatty acids are usually based on the retention times of an 
authentic FAME standard that are commercially available. These standards 
usually cover the range carbon-4 to carbon-24, and include both saturated and 
unsaturated compounds. 
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Although popular, GC analysis of free fatty acids has some disadvantages. 
These include lengthy derivatisation steps that could be risky for PUFA, and 
long run times required to resolve all of the fatty acids that commonly occur in 
mammalian cells (Marangoni et al., 2004, Morrison and Smith, 1964). Various 
methods have been proposed to overcome these drawbacks such as the use of 
antioxidants such as BHT (Morrison and Smith, 1964), short and highly polar 
fast columns (Destaillats and Cruz-Hernandez, 2007).
1.10 Mass spectrometry in bioanalysis
Mass spectrometry is an analytical technique that identifies compounds based 
on the mass (m)-to-charge (z) ratio (m/z) of ionised molecules. A mass 
spectrometry system is composed of three main parts namely the ionisation 
source, the analyser and the detector. 
The initial step in mass spectrometry is the ionisation of samples prior to 
analysis in the mass spectrometer. The ions generated are transferred into the 
analysers where they are separated according to their m/z. Once the ions are
analysed by the mass analysers, the detector then identifies the separated ions 
and transforms them into signals. The signals are sent to a data system where 
the m/z ratios are stored together with their relative abundance for presentation 
in the form of a m/z spectrum. Mass spectrometers can be coupled to 
separation techniques such as high performance liquid chromatography (LC) or 
GC to give powerful tools of bioanalysis (Gutnikov, 1995, Hammarstrom et al., 
1970, Korfmacher, 2005). Thus samples can be separated into components 
prior to their sequential introduction into the ionisation source and subsequently 
into the mass spectrometer. However the method of sample introduction 
77
depends on the ionisation method being used, and the type and physical form 
of the sample. Samples can also be introduced by direct infusion into the ion 
source. 
1.10.1 Electrospray ionisation-liquid chromatography tandem mass 
spectrometry
Coupling of the LC to tandem mass spectrometry with ESI as the ionisation 
method (LC/ESI-MS) is a powerful technique in bioanalysis (Ho et al., 2003). 
ESI is a liquid phase ion source (de Hoffmann and Stroobant, 2002) were the 
analyte is in a solution. ESI uses a strong or high electric field (~2-5 kV) to 
produce ions that are attracted to the entrance of a mass analyser (Figure 
1.14). 
Figure 1.14 Schematic of the principles of electrospray ionisation (ESI). e-; 
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The ESI source can tolerate flows up to 0.2 ml/min thus is easily coupled to a 
HPLC (de Hoffmann and Stroobant, 2002). This soft ionisation technique 
produces molecular ion species and is the method of choice for polar to ionic 
compounds (de Hoffmann and Stroobant, 2002, Holcapek et al., 2008).
The use of ESI technique enables the analyses of both low and high molecular 
weight species because it is able to produce single and multiply charged ions 
(Ho et al., 2003). Thus it can be used in the analysis of drugs and/or drug 
metabolites (Nirogi et al., 2006, Wang et al., 2001). Matrix effects that may 
occur through competition between co-eluting undetected matrix components 
(eg. salts) which affect ionisation of the analyte of interest during the ionisation 
process, affect ESI negavtively (Schlusener and Bester, 2005).
1.10.2 Tandem mass spectrometry
Tandem mass spectrometry is defined as any general method whereby at least 
two stages of mass analysis is carried out either in conjunction with a 
dissociation process or a chemical reaction that causes a change in the mass or 
charge of an ion. The simplest form of MS/MS combines two mass analysers 
(Figure 1.15). 
Figure 1.15 The elements of a liquid chromatography electrospray tandem 
spectroscopy (LC/ESI-MS/MS).
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The first mass analyser selects or isolates a precursor ion of a particular mass 
from the sample. This ion passes into the collision cell where it undergoes either 
a spontaneous or activated fragmentation to yield product ions and neutral 
fragments. The second mass analyser then separates the ions according to 
their m/z ratio. There are four basic scan modes used in tandem mass 
spectrometry namely: product ion scan, precursor scan, neutral loss scan and 
selected or multiple reaction monitoring (Figure 1.16) (de Hoffmann and 
Stroobant, 2002):
i. Product ion scan consists of the first mass analyser selecting a precursor ion 
of chosen m/z and the second mass analyser determining all of the product ions 
resulting from collision induced dissociation (fragmentation) (CID). An inert gas, 
such as argon is used in the collision cell for this purpose and thus the 
fragmentation is termed collision-activated reaction (CAR). 
ii. Precursor ion scan consists of choosing a product ion and determining the 
precursor ions. The first mass analyser allows the transmission of all sample 
ions, whilst the second mass analyser is set to monitor specific fragment ions 
generated by CID. This type of scan is useful for monitoring groups of 
compounds that have similar structures that fragment to produce common 
fragment ions.
iii. Neutral loss scan consists of selecting a neutral fragment and detecting all 
the fragmentations leading to the loss of that neutral fragment. Here both 
analysers are scanning or collecting data, across the whole m/z range. 
However, the two are offset so that the second analyser allows only the ions 
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Figure 1.16 Schematic showing the basic scan modes used in tandem mass 
spectroscopy. (A) Product ion scan, (B) Precursor ion scan, (C) Neutral loss 
scan, (D) Multiple reaction monitoring scan. MS1 and MS2: mass analysers.
that differ, by a certain number of mass units, originating from the ions 
transmitted through the first analyser.
iv. selected or multiple reaction monitoring (MRM) is a scan mode whereby 
selected specific precursor ions are transmitted through the first analyser, and 
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after collision in the collision cell, specific fragments arising from these ions are 
measured by the second analyser. Prior to the MRM, the compound of interest 
must be known and previously well characterised. This scan mode is used to 
confirm the presence of a compound in matrices such as blood or urine 
samples. It is not only a highly specific method but also has very high sensitivity 
(de Hoffmann and Stroobant, 2002, Nirogi et al., 2006).
There are various applications of tandem mass spectrometry. For instance, it 
can be applied in the elucidation of structure, such as in the determination of 
isomers, determination of fragmentation mechanisms, eg. the neutral loss of the 
phenylaminocarbonyl group and phenylamino group in the fragmentation of 
para-hydroxyatorvastatin and ortho-hydroxatorvastatin respectively, selective 
detection of a class of compounds in a complex mixture such as biological fluids 
(de Hoffmann and Stroobant, 2002, Nirogi et al., 2006). Tandem mass 
spectrometry coupled to LC (LC-MS/MS) or GC (GC-MS/MS) is one of the 
preferred techniques for the simultaneous identification and quantitating of small 
molecule drugs and metabolites in biological matrices including plasma, blood, 
serum, urine, and brain tissue (De Meulder et al., 2008, Xu et al., 2007). It has 
therefore been applied successfully in drug development, pharmacokinetic 
studies and clinical trials (Holcapek et al., 2008, Jacobson, 2004). This 
analytical technique is also one of the methods of choice for sensitive and 
selective detection of proteins, lipids and carbohydrates in health and disease 
(Kawasaki et al., 2000, Little et al., 2007, Masoodi et al., 2008, Pettinella et al., 
2007, Zhang et al., 2008)
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1.11 Aims and objectives
The lipid composition of brain is pivotal to normal brain development and 
function and neuroinflammation resulting from infections, ageing and/or 
neuropsychiatric diseases may alter the brain lipid composition. Liver 
contributes to the regulation of the lipid profile of the brain through its role as the 
central organ of metabolism in the whole body. 
Statins are medicines that inhibit cholesterol biosynthesis in the liver and which 
are able to modulate fatty acid metabolism in mammalian cells. They have anti-
inflammatory actions that have been shown to be beneficial in 
neuroinflammation and in addition have been reported to provide 
neuroprotection in brain disorders such as ischemic stroke. The molecular 
mechanism of action is therefore of interest. 
The FSL rat is a genetic animal model of depression. Recently, an increase in 
the AA composition of its different brain areas was reported, thus, indicating an 
alteration in the fatty acid metabolism of the FSL rat brain. It is therefore of 
interest to investigate the total lipid composition of the different brain areas of 
the FSL rat.
The present study aimed to evaluate the changes in the brain and liver lipid 
profile of rat models of ageing and LPS-induced neuroinflammation with a view 
to investigate the effects of atorvastatin in neuroinflammation, and evaluate the 
changes in the lipid profile of different brain areas of the FSL rat model of 
depression.
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For the purposes of this study, a lipidomic approach was undertaken and the 
specific objectives were to:
1. Develop an LC/ESI-MS/MS-based method to measure atorvastatin and its 
metabolites, ortho-hydroxyatorvastatin and para-hydroxyatorvastatin in rat 
tissue samples.
2. Apply this method to examine levels of atorvastatin in the brain, liver and 
plasma of aged and LPS-treated rats in an attempt to understand the 
molecular mechanism of its anti-inflammatory actions.
3. Use 1H-NMR and GC to evaluate any alterations in the fatty acid and lipid 
profile of brain and liver in aged animals before and after treatment with 
atorvastatin.
4. Use 1H-NMR and GC to evaluate any alterations in the fatty acid and lipid 
profile of brain and liver in rats treated with LPS and atorvastatin.
5. Use 1H-NMR and GC to evaluate the brain fatty acid and lipid profiles in the 
FSL rat model of depression.
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2.0 MATERIALS AND METHODS
2.1 Materials
2.1.1 Lipid analysis by 1H-NMR spectroscopy
Chloroform-d1 (CDCl3), methanol-d4 (CD3OD, 99.8 %), phosphate buffered 
saline (PBS) tablets, butylated hydroxytoluene (BHT), anhydrous sodium 
sulphate (Na2SO4), were purchased from Sigma-Aldrich (Poole, Dorset, UK). All 
these reagents were analytical grade quality. Potassium chloride (KCl) was 
supplied by BDH (Poole, Dorset, UK). HPLC grade methanol and chloroform 
were purchased from Fischer Scientific (Leicestershire, UK). WILMARD ® NMR 
tubes, 5 mm, ultraimperial grade were purchased from Sigma-Aldrich (Poole, 
Dorset, UK).
2.1.2 Fatty acid analysis by gas chromatography
SUPELCO ® 37 component fatty acid methyl ester (FAME) in % weight 
standard [C4:0 (4 %), C6:0 (4 %), C8:0 (4 %), C10:0 (4 %), C11:0 (2 %), C12:0 
(4 %), C13:0 (2 %), C14:0 (4 %), C14:1 (2 %), C15:0 (2 %), C15:1 (2 %), C16:0 
(6 %), C16:1 (2 %), C17:0 (2 %), C17:1 (2 %), C18:0 (4 %), C18:1n-9t (2 %), 
C18:1n-9c (4 %), C18:2n-6t (2 %), C18:2n-6c (2 %), C20:0, (4 %), C18:3n-6 (2 
%), C20:1 (2 %), C18:3n-6 (4 %), C20:1 (2 %), C18:3n-3 (2 %), C21:0 (2 %), 
C20:2 (2 %), C22:0 (4 %), C20:3n-6 (2 %), C22:1n-9 (2 %), C20:3n-3 (2 %), 
C20:4n-6 (2 %), C23:0 (2 %), C22:2 (2 %), C24:0 (4 %), C20:5n-3 (2 %), C24:1 
(2 %), C22:6n-3 (2 %)], C22:5n-3, C18:1n-7, C22:4n-6, C20:2, C21:0, butylated 
hydroxytoluene (BHT), potassium carbonate (K2CO3) and 14 % boron trifluoride 
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(BF3) methanol solution were purchased from Sigma-Aldrich (Poole, Dorset, 
UK), HPLC grade dichloromethane and dimethyl ether were purchased from 
Fischer Scientific (Leicestershire, UK). Pesticide residual analysis grade (PRA) 
toluene and 2,2,4-trimethylpentatone were purchased from Acros Organics 
(Loughborough, UK). 
Pyrex ® borosilicate round bottom test tubes (5 ml) were purchased from 
Corning (Costar, UK). Deactivated glass flat bottom insert vials (1.5 μL), ivory 
PTFE/red silicon rubber septa and preassembled screw cap vials were 
purchased from Agilent Technologies (Berkshire, UK).                                                                                                                                                                       
2.1.3 Atorvastatin analysis by LC/ESI-MS/MS
Atorvastatin calcium salt (1.4 mg), ortho-hydroxyatorvatatin dihydrate 
monosodium salt  (1 mg) and para-hydroxyatorvastain disodium salt (1 mg) 
pure analytical standards purchased from Toronto Research Chemicals Inc. 
(North York, Ontario Canada) were used for the LC-MS/MS analysis of 
atorvastatin and its active metabolites in animal tissues. Atorvastatin (calcium 
salt) tablets (Lipitor TM) purchased from Pfizer-Parke Davies (Ireland) were used 
for animal studies. Analytical grade methaqualone hydrochloride (250 mg) was 
supplied by Sigma-Aldrich (Poole, Dorset UK). HPLC grade dichloromethane 
and dimethyl ether were purchased from Fischer Scientific (Leicestershire, UK). 
Analytical grade formic acid was supplied by Sigma-Aldrich (Poole, Dorset, UK), 
and analytical grade phosphoric acid was purchased from BDH (Poole, Dorset, 
UK) 
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2.1.4 Protein assay
Assay II lyophilised bovine serum albumin standard, DC protein assay kit (kit 
catalog number 500-0112) containing reagents A (alkaline copper tartrate 
solution), B (dilute Folin reagent) and S were supplied by Bio-Rad laboratories 
(Hertfordshire, UK). Analytical grade sodium hydroxide (NaOH) was supplied by 
Sigma-Aldrich (Poole, Dorset UK). 96 well plates were supplied by Corning 
(Costar, UK).
2.1.5 General laboratory supplies
Eppendorf tubes were supplied by Western Laboratory Services Ltd 
(Hampshire, UK). Wide necked glass vials (10 ml) were supplied by LSL 
Laboratory sales (UK) LTD. 9’’ and 6’’ Pasteur pipettes and disposable pipette 
tips were purchased from Western Laboratory Services Ltd (Aldershot, 
Hampshire, UK), amber glass vials (1.5 ml), screw caps, septa and insert vials 
(100 μl) were supplied by Kinesis (Berdfordshire, UK). Fixed needle glass 
syringes (10, 50 and 250 μl) were purchased from SGE (Milton Keynes, UK). 
Absorbent cotton wool was purchased from Robinson Healthcare Ltd (Walton, 
Chesterfield, UK). Full range pH (1-14) indicator strips were supplied by BDH 
(Poole, Dorset, UK). Milli-Q grade water was obtained by filtering with a 
minimum resistance of 18 Ω. Nitrogen gas was supplied by BOC gas, UK.
2.2 Equipment
A JEOL ECA600 NMR spectrometer (JOEL UK, Welwyn, UK) was used for 1H-
NMR analysis. 
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LC/ESI-MS-MS analysis was performed using a Waters Alliance 2695 HPLC 
coupled to a Micromass Quattro Ultima triple quadrupole mass spectrometer 
(Waters, Manchester, UK) equipped with electrospray ionisation (ESI) probe. 
Direct infusion analysis was performed using a harvard apparatus pump II 
coupled to the HPLC.
A Gemini C18 analytical column (5 µ, 150 x 2 mm) supplied by Phenomenex 
(Macclesfield, UK) was used to carry out HPLC separation of atorvastatin and 
its metabolites.
A 6850 series network gas chromatography system equipped with flame 
ionisation detector (FID), a 6850 network GC sytems autosampler and HG 2000 
hydrogen generator was supplied by CLAIND (UK). A BPX-70 forte GC capillary 
column (length 60 m, internal diameter 0.25mm and film 0.25 µm, serial no. 
9934A05) supplied by Phenomenex (Macclesfield, UK) was used for the 
separation of fatty acid methyl esters. System operation and data handling was 
achieved through Chemstation Revision software (B2.01) package supplied by 
Agilent Technologies (Berkshire, UK). 
A React-Therm® heating module used in the fatty acid derivatization procedure 
was supplied by ThermoScientific (Cramlington, UK). 
Protein content analysis data were recorded on a Labsystems Multiskan RC 
analytical plate reader supplied by Labsystems Oy (Helsinki, Finland). 
General laboratory equipment used in all experiments include a waterbath and 
WhirliMixerTM vortex purchased from Fisher (UK), Sorvall® RT6000B 
refrigerated centrifuge supplied by Dupont (UK) LTD (Stevenage, Herts, UK), a 
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SANYO Micro Centaur microcentrifuge supplied by MSE (UK) and a Ystral® D-
79282 blade homogeniser (Ballrechten-Dottingen).
2.3 Animal Studies
2.3.1 Atorvastatin study
All animals used for this study, their housing, treatments and tissue sample 
preparation described in sections 2.3.1.1 - 2.3.1.5 were carried out at the Bio 
Resources Unit, Trinity College, Dublin under the supervision of our collaborator 
Professor M. A. Lynch. In detail:
2.3.1.1 Housing of animals
Adult (3-4 months) and aged (22-24 months) male Wistar rats were housed in 
groups of either 2-6 under a 12 h light-dark schedule and ambient temperature 
was controlled between 22 ○C and 23 ○C under veterinary supervision. All 
animal experimentation was performed under a licence granted by the Minister 
for Health and Children (Ireland) under the Cruelty to Animals Acts, 1876 and 
the European Community Directive, 86/609/EC.
2.3.1.2. Atorvastatin supplement preparation 
Atorvastatin calcium tablets (Lipitor™; Pfizer-Parke Davis, Ireland) were ground 
to a fine powder by pestle and mortar and dissolved in sunflower oil (Dunnes 
Stores, Ireland). Sufficient chow was prepared for 2-3 days at a time. 
Atorvastatin in sunflower oil was then mixed with laboratory chow (5 ml/150g 
chow). 
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2.3.1.3 Atorvastatin supplementation in aged study
12 aged (22-24 months) and 12 adult (3-4 months) male Wistar rats served as 
subjects in this experiment. Laboratory chow (Red Mills, Ireland) and water 
were given to the animals for a week and these were assessed daily. After one 
week aged and adult rats were randomly divided into control and atorvastatin 
treatment groups. Each group consisted of 6 animals.
The control group continued to receive normal laboratory chow. The 
atorvastatin treatment group received the experimental diet of atorvastatin (5 
mg/kg/day). This was orally fed to the animals in laboratory chow with sunflower 
oil (5 ml/150 g chow) for 8 weeks. The atorvastatin treatment group were 
offered their full daily requirement each day with monitoring to ensure animals 
received their full daily dose of atorvastatin. Both control and atorvastatin 
treatment groups were examined daily and weighed regularly before, during and 
after treatment to ensure that similar weight changes were occurring in the 
different treatment groups. 
After the 8 weeks treatment period, aged and adult rats were anaesthetized by 
intraperitoneal injection of urethane (33 % w/v). Adult rats were administered 
1.5 g/kg and aged rats were initially given 1.2 g/kg with further increments to a 
maximum of 2.0 g/kg when required. All animals were kept warm whilst awaiting 
procedures. The absence of a pedal reflex was used to confirm deep 
anaesthesia and if needed a top-up dose was administered. Animals were then 
sacrificed by decapitation.
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2.3.1.4 Atorvastatin supplementation in lipopolysaccharide challenged rat 
study
24 adult male Wistar rats (2-3 months) were used in this experiment. Laboratory 
chow and water were given to the animals for a week and these were assessed 
daily. After a week the animals were randomly divided into control and 
atorvastatin treatment groups. Each group consisted of 12 adult rats.
The control group received normal laboratory chow. The atorvastatin treatment 
group received the experimental diet of atorvastatin (5 mg/kg/day). This was 
orally fed to the rats in laboratory chow with sunflower oil (5 ml/150 g chow) for 
3 weeks. The atorvastatin treatment group were offered their full daily 
requirement each day with monitoring to ensure animals received their full daily 
dose of atorvastatin. Both control and atorvastatin treatment groups were 
examined daily and weighed regularly before, during and after treatment to 
ensure that similar weight changes were occurring in the different treatment 
groups.
After the 3 weeks treatment period, all animals were administered 1.5 g/kg 
urethane (33 % w/v) by intraperitoneal injection and were kept warm whilst 
awaiting procedures. The absence of a pedal reflex was used to confirm deep 
anaesthesia. The control and atorvastatin treated animal groups were 
subdivided into those that received saline (0.9 % w/v) intraperitoneally and 
those that received lipopolysaccharide (100 µg/kg in sterile 0.9 % w/v saline) 
from Escherichia coli serotype 0111.B4 (Sigma-Aldrich, UK) intraperitoneally on 
the day of the experiment. Thus in the control group 6 rats received saline (0.9 
% w/v) while the remaining 6 rats received lipopolysaccharide. In the same way, 
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6 rats in the atorvastatin treatment group received saline (0.9 % w/v) and the 
remaining 6 rats received lipopolysaccharide. Three hours after intraperitoneal 
injection of saline and lipopolysaccharide, animals were sacrificed by 
decapitation.
2.3.1.5 Tissue sample preparation 
Brain tissue slices: After animals were sacrificed by decapitation the brains 
were rapidly removed, collected on ice and the cortex was dissected free. 
Freshly dissected brain tissue was cross chopped to a thickness of 350 µm 
using a McIlwain tissue chopper (Mickle Laboratory Engineering Co., Surrey, 
UK) and placed in eppendorf tubes containing 1 ml Krebs solution (NaCl 136 
mM, KCl 2.54 mM, KH2PO4 1.18 mM, MgSO4.7H2O 1.18 mM, NaHCO3 16 mM, 
glucose 10 mM) with added CaCl2 (2 mM final concentration) and 10 % dimethyl 
sulfoxide (DMSO) (v/v). The samples were stored at –80 ○C.
Liver tissue: Liver was removed and immediately flash-frozen in liquid 
nitrogen, wrapped in tin foil and stored at –80 ○C.
Serum: Trunk blood was collected following decapitation and the serum was 
isolated and centrifuged at 10,000 g for 10 min. The supernatant was then 
isolated and stored at -80 ○C.
All tissue samples were transported to Bradford on dry ice. Here, they were 
stored at -80 ○C awaiting analysis.
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2.3.2. Flinders Sensitive Line (FSL) rat study
All animals used for this study, their housing, treatments and tissue sample 
preparation were carried out at the Faculty of Life Sciences and the Leslie 
Susan Gonda (Goldschmied) Multidisciplinary Brain Research Centre, Bar-Ilan 
University, Ramat Gan, Israel. The work was supervised by our collaborator Dr. 
P. Green. In detail:
2.3.2.1 Housing of animals
6 adult male Flinders Sensitive Line (FSL) and 6 adult male Sprague-Dawley 
(control) rats (230-250 g) served as subjects in this study. Both groups were 
maintained under conditions of constant temperature (22 ○C) and humidity (50 
%) on a 12 h light – 12 h dark cycle (lights off at 07:00). Both groups were fed 
an identical diet: food and water available ad libitum. All animal procedures 
were approved by the Bar-Ilan University Animal Care and Use Committees and 
were carried out in accordance with the National Institutes of Health guidelines 
for the care and use of laboratory animals, and every effort was made to 
minimize trauma to the animals.
2.3.2.2 Brain tissue sample preparation
The rats were decapitated and punches were taken from four brain regions: 
hypothalamus, nucleus accumbens, prefrontal cortex and striatum. Tissue 
punches of each region were rapidly taken using stainless steel cannulas with 
an inner diameter of 1.1 mm. The dissected tissue samples were immediately 
frozen in liquid nitrogen, weighed and stored at –80 ○C. The tissue samples 
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were then transported to the UK on dry ice and stored at –80 ○C awaiting 
analysis. 
2.4 Sample preparation for lipid extraction
2.4.1 Brain tissue sample preparation- atorvastatin study
In the atorvastatin study, the brain tissue slices were stored in a DMSO-
containing solution, to allow for multiple experiments. To remove the DMSO-
containing solution, the following process was followed:
Tissue samples were removed from –80 ○C and transferred to an icebox. Brain 
tissues stored in DMSO-containing solution in eppendorff vials, were agitated in 
a water bath set at 37 ○C for 1 min to defrost. After agitation, they were kept in 
the icebox to cool for 1 min and then centrifuged for 30 s at 640 g (3000 rpm). 
The resulting supernatant was removed and discarded then 1 ml PBS solution 
was added to the residual tissue. The mixture was agitated for 10 s, placed in 
ice for 1 min and centrifuged for 30 s at 640 g (3000 rpm). The resulting 
supernatant was again removed and discarded. These steps for washing the 
brain tissue slices were repeated a further three times. The washed brain slices 
were processed as described in section 2.4.3.
2.4.2 Liver tissue sample preparation
Liver was removed from the –80 ○C, left to stand at room temperature for 5 min 
(tissue did not thaw) after which a small piece was cut off from the whole liver 
tissue and transferred into a clean extraction glass vial and kept in ice. 
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2.4.3 Homogenisation of solid tissue samples
Solid tissue samples (50-100 mg) were transferred into clean glass extraction 
vials (EV1) (5 ml), kept cool in ice and then homogenized with a Ystral® D-
79282 blade homogeniser (Ballrechten-Dottingen) for 10 pulses, five times in 
ice-cold water (1 ml). 
2.4.4 Lipid extraction
The homogenates were extracted according to a modification of the Folch 
method (Folch et al., 1957) as follows: 
Ice-cold chloroform-methanol mixture (2:1, v/v) (5 ml) was added to the 
homogenate in extraction vial (EV1) and the mixture was vortexed five times, for 
5 min at 1 min intervals. The extraction vial was kept cool in ice for at least 30 s 
in between vortexing. The mixture was then centrifuged in a refigerated 
centrifuge at 1000 g (3000 rpm) for 5 min at 4 ○C to separate the aqueous (top) 
and organic (bottom) layers. The organic bottom layer was transferred to a 
clean 5 ml glass extraction vial (EV2) and kept cool in ice. A further ice-cold 
chloroform-methanol mixture (2:1, v/v) (5 ml) was added to the aqueous layer 
retained in EV1 (this contained interface between the two layers and the 
denatured proteins) and cooled in ice. This vial was again vortexed and 
centrifuged as described above. The bottom organic layer was removed and 
transferred to EV2. 0.5 M Potassium chloride: methanol (50:50, v/v) (2 ml) was 
then added to the combined organic solvent extracts from both steps (EV2). 
The mixture was vortexed for 5 min and centrifuged at 4 ○C, 1000 g (3000 rpm) 
for 5 min. The top layer was removed and discarded while the bottom layer was 
retained in EV2. A further 0.5 M potassium chloride: methanol (50:50, v/v) (2 ml) 
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was added and the mixture vortexed and centrifuged as before. The bottom 
layer (organic solvent) was then transferred into a third clean extraction glass 
vial (EV3), and approximately 4 spatula tips of anhydrous sodium sulphate were 
added to it. Anhydrous sodium sulphate was used to remove any residual water 
from the extract. 6 “ Pastuer pipettes were tightly packed with glass wool (5 mm 
thickness) washed with chloroform-methanol mixture (2:1, v/v) (3 ml). The 
extract was then filtered through these pipettes into a fourth clean extraction 
glass vial (EV4), to remove the sodium sulphate, and a further 3 ml was used to 
rinse the pipettes. To ensure no lipid extracts were retained in the glass wool 
and pipettes the eluent was also collected in EV4. A stream of nitrogen was 
then used to evaporate the solvents from EV4 to dryness. The dry lipid extracts 
were analysed by NMR spectroscopy.
2.5 1H-NMR spectroscopy lipid analysis
2.5.1 Sample preparation
The lipid extracts were re-dissolved in 0.8 ml of CD3OD: CDCl3 (2:1, v/v). 6 “ 
Pastuer pipettes were tightly packed with glass wool and flushed with 0.5 ml 
CD3OD: CDCl3 (2:1, v/v). Following this, the lipid extracts re-dissolved in 0.8 ml 
of CD3OD: CDCl3 (2:1, v/v) were filtered through these pipettes and transferred 
into 5 mm NMR tubes. Samples were bubbled with nitrogen in order to remove 
oxygen, and were kept at –20 ○C until ¹H-NMR analysis (within 1 week). After 
analysis, the lipid extracts were taken to dryness under a gentle stream of 
nitrogen and dissolved in 1 ml methanol-chloroform (1:2, v/v) containing the 
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antioxidant BHT (0.01%, w/v) and stored at –80 °C. These solutions were used 
for fatty acid analysis.
2.5.2 NMR spectra acquisition
All NMR spectra were recorded at room temperature. The spectra were 
acquired in the Fourier transformation mode with 32 K data points, using a 45° 
pulse width, a relaxation delay of 1 and 29 s acquisition time. The residual HOD 
signal at approximately 4.7 ppm was suppressed by the application of a 
continuous and selective secondary irradiation during the relaxation delay. For 
each sample 1000 scans were recorded to obtain a good quality spectrum. 
Chemical shifts were referenced to the residual methanol peak at 3.31 ppm. 
2.5.3 Calculation of % mole ratio of lipids
Relative quantitation of the lipids present in each sample was based on 
diagnostic peaks (Little et al., 2007, Noula et al., 2000) and results were 
expressed as % mole of total lipid or total fatty acid chain. 
Diagnostic peak intensities were estimated by computerised integration and the 
integrals were related to the amount of each lipid. Relative concentrations were 
determined by the calculation of the percent of the signal areas. The sum of the 
total diacylglycerophospholipids, sphingosine lipids, plasmalogens and 
cholesterol was taken to represent the total lipid content (100 %) of the tissues. 
In detail:
Total diacylglycerophospholipids (DAGPLs): The glycerol sn-1 methylene 
protons of the diacylglycerophospholipids (phosphatidylcholine, 
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phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, 
phosphatidylglycerol) are magnetically equivalent and appeared at ~4.15 ppm 
(1H, upfield). The glycerol sn-2 proton appeared as a multiplet at ~5.2 ppm. The 
glycerol sn-3 methylene protons appeared at ~3.98-4.00 ppm. Thus the area of 
4.42 ppm was used for the quantification of the total diacylglycerophospholipids.
Sphingosine lipids: Identification of the shingosine lipids was by the specific 
vinyl proton resonances of the sphingosine moiety at ~5.44 ppm 
(CH2CH=CHCHOH) and ~5.70 ppm (CH2CH=CHCHO). The area at 5.70 ppm 
was used for the quantification of the total sphingolipids.
Ether phospholipids: Both the alkylacyl and alkenylacyl (plasmenyl) present, 
of the ether lipids were represented by the multiplet at 5.15 ppm arising from the 
glycerol sn-2 proton. This area was used for the quantification of total ether 
lipids. Plasmalogens gave characteristic resonances at 4.33 ppm 
(OCH=CHCH2) and at 5.92 ppm (OCH=CHCH2). The area at 5.92 ppm was 
used for the quantification of total plasmalogens. The integral difference 
between the 5.15 ppm and the 5.92 ppm areas directly measures the amount of 
alkylacyl phospholipids, which in most cases was almost zero, indicating their 
low concentration in rat brain and liver.
Total choline lipids: These were identified and quantified from their 
characteristic nine proton N+(CH3)3 signal at ~3.20 ppm. This resonance can be 
used to further calculate phosphatidylcholine from the resonance at 3.2085 ppm 
and sphingomyelin from the characteristic resonance at 3.196 ppm. The two 
head group methylene protons resonated at ~4.25 ppm (-OCH2CH2N(CH3)3+
and 3.60 ppm (-OCH2CH2N(CH3 )3+.
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Total ethanolamine lipids: The characteristic head group –CH2 NH2 methylene 
proton resonance at 3.10 ppm was used to identify and quantify the total 
ethanolamine lipids. The –OCH2 methylene protons resonated at ~3.98 ppm 
together with the sn-3 glycerol protons of the diacylglycerophospholipids.
Cholesterol: This was identified and quantified by its characteristic C-18 methyl 
singlet at 0.68 ppm. Other diagnostic cholesterol signals include the C-19 
methyl singlet at 1.00 ppm and the C-3 proton multiplet at 3.41 ppm.
Fatty acid chains: All fatty acid chains showed omega-CH3 (n-CH3) peaks at 
0.80-0.96 ppm; bulk methylene peaks ((CH3(CH2)n) were identified at ~1.30 
ppm; α-methylene (CH2COO) peaks at ~2.30 ppm, β-methylene (CH2CH2COO) 
peaks at 1.59-1.74 ppm; allylic methylene peaks (=CHCH2) peaks at 1.98-2.15 
ppm- this area was used to calculate the total unsaturated chains; diallylic 
methylene (=CHCH2CH=) peaks at 2.74-2.84 ppm and olefinic (CH=CH) peaks 
at ~5.35 ppm.
The individual PUFAs that were resolved from the rest and were quantified 
were: 
a. linoleic acid (18:2n-6) (LA) with its specific methylene protons  
CH=CHCH2CH=CH gave a triplet at 2.75 ppm for the first study.
b. docosahexaenoic acid (22:6n-3) with its specific α- and β-methylene protons 
(-CH=CHCH2CH2COO) gave multiplet at 2.36 ppm.
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c. arachidonic acid (20:4n-6) (AA) and eicosapentaenoic acid (20:5n-3), their 
characteristic β-methylene group, CH=CHCH2CH2 CH2COO, gave a multiplet at 
1.65 ppm.
d. total n-3 PUFA, their n-CH3 peaks gave a triplet at ~0.96 ppm.
Unsaturation index: Total fatty acid chain content was represented by the area 
of the n-CH3 at 0.80-0.96 ppm. The area of the olefinic protons (~5.35 ppm), 
after subtraction of the contribution from the cholesterol C-6 proton, was divided 
by the fatty acid chain to give an average degree of unsaturation in the fatty 
acid chains (the unsaturation index).
Appendix II shows a typical 1H-NMR spectrum showing the diagnostic peaks 
used for lipid analysis. Appendix III shows the calculations used to estimate the 
% mole lipids in a biological sample. Appendicies IV (A) and IV (B) show typical 
1H-NMR spectra of brain and liver tissues.
2.6 Fatty acid analysis
2.6.1 Fatty acid standards
The commercially available mixed standard fatty acid methyl esters (100 mg) 
and the individually purchased fatty acid methyl ester standards C22:5n-3 (10 
mg), C22:4n-6 (25 mg), and C18:1n-7 (100 mg) were individually dissolved in 1 
ml dichloromethane each to give 10 mg/ml, 25 mg/ml and 100 mg/ml solutions 
respectively. The different solutions were aliquoted into 10 aliquots of 100 µl 
each in 1.5 ml vials, sealed and stored in –20 °C for up to 3 weeks. 
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10 mg of the internal standard C21:0 was dissolved in 10 ml methanol-
chloroform (1:2, v/v) containing the antioxidant BHT (0.01 % w/v) and stored in 
the –20 °C for up to 3 weeks.
2.6.2 Fatty acid esterification
Lipid extracts (stored at –80 °C) were left to stand at room temperature for a few 
min to reach room temperature. 200 µl of lipid extract was then removed from 
the storage glass vial and transferred to a clean derivatization tube (DT1). The 
solvent was removed by drying the extract under a gentle stream of nitrogen. 
Following this, the internal standard (45 µl of 1 mg/ml C21:0 ) was added to the 
lipid extract and solvent was also removed under a gentle stream of nitrogen. 
250 µl of toluene: methanol (50:50 v/v) and 250 µl of 14 % BF3-methanol 
solution were then added to the dried lipid extract. DT1 was flushed gently with 
nitrogen, sealed with a teflon cap and gently vortexed for 30 s. It was then 
placed into the tube insert of the preheated heating module set to a temperature 
of 100 °C. The solutions were heated at 100 °C for 90 min to complete the 
esterification reaction. 
After this, the tubes (DT1) were removed and placed in ice to cool for about 10 
min. 10 % (w/v) potassium carbonate solution (1.5 ml) was then added to each 
tube. This was followed by the addition of 2 ml trimethylpentane (isoctane) and 
the tube was resealed. The mixture was then vortexed and centrifuged at 4 °C 
for 5 min at 1000 g (3000 rpm). The upper layer that contained the fatty acid 
methyl esters (FAME) was removed and transferred to a second clean 
derivatization tube (DT2) whilst the lower aqueous layer was discarded. The 
solvent contained in DT2 was then dried gently under nitrogen. This was done 
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with care and not left for too long as highly volatile short-chained FAME (under 
C16) may evaporate. The resulting residue was then reconstituted in 50 µl 
dichloromethane. This gave a final internal standard concentration of 900 ng/µl. 
DT2 was tightly sealed with a clean teflon cap, vortexed gently and the solution 
transferred to a clean 100 µl conical shaped insert vial using a glass syringe, 
placed on the autosampler and analysed immediately by GC-FID. 
2.6.3 Preparation of internal standard and other fatty acid methyl esters
In order to confirm the retention time of the internal standard, 900 µl of 1 mg/ml 
C21:0 in methanol-chloroform (1:2, v/v) containing the antioxidant BHT (0.01 % 
w/v) was transferred into a clean derivatisation tube and the solvent was 
removed under a stream of nitrogen. 250 µl of toluene: methanol (50:50 v/v) 
and 250 µl of 14 % BF3-methanol solution were then added to the dried internal 
standard. The sample was then processed as described above (see section 
2.6.2). The final sample of internal standard methyl ester was re-dissolved in 
1000 µl of dichloromethane. This gave a final concentration of 900 ng/µl internal 
standard methyl ester. A 100 µl aliquot of this solution was transferred to a 
clean 250 µl insert vial and analysed by GC-FID. The remaining esterified 
internal standard was stored at –20 °C for a maximum of 1 week.
A similar process was followed for the esterification of other fatty acid standards 
when required. These fatty acids were C22:5n-3 (10 mg), C22:4n-6 (25 mg) and 
C18:1n-7 (100 mg). 
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2.6.4 Gas chromatographic analysis of fatty acid methyl esters
Fatty acid methyl esters were separated by capillary gas chromatography using 
a BPX-70 forte GC capillary column (Phenomenex, serial no. 9934A05, 60 m x 
0.25 mm i.d. x 0.25 μm film) with GC-FID. Helium was used as the carrier gas at 
a flow rate of 21 cm/s. A mixture of hydrogen and air was used as the detector 
gas. The injector and flame ionisation detector were maintained at 220 ºC and 
250 ºC respectively. The injection volume was 1µl. The initial oven temperature 
was set at 70 ºC for 2 min after which it was increased to 150 ºC at a rate of 20 
ºC per min, and held at 150 ºC for 5 min. Then increased from 150 ºC to 218 ºC 
at a rate of 2.50 ºC per min, and from 218 ºC it was increased to 225 ºC at a 
rate of 0.60 ºC per min, and held at this temperature for 10 min. Finally, the 
temperature increased from 225 ºC to 230 ºC at a rate of 2.50 ºC per min and 
held for 3 min. The analysis was performed in a split mode using a ratio of 30:1. 
To ensure that there was no carry over in between injections, a blank injection 
of dichloromethane was performed between sample or standard injections.
2.6.4 Fatty acid methyl ester identification and quantitation
2.6.4.1 Reference standards
In order to establish the exact conditions of the GC analysis, and the retention 
times of individual fatty acids, commercially available FAME standad mixture 
was supplemented with internal standard (C21:0). The following solution was 
prepared: 20 µl FAME (100 mg/ml) and 100 µl C21:0 (900 µg/µl), and analysed. 
Furthermore the retention times of the following fatty acid methyl esters were 
established: C22:5n-3 methyl ester, C22:4n-6 methyl ester and C18:1n-7 methyl 
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ester. A mixed cocktail of the commercially available FAME standard, internal 
standard, C22:5n-3 methyl ester, C22:4n-6 methyl ester and C18:1n-7 methyl 
ester was also analysed to confirm that there were no co-eluting peaks. 
Appendix V (A) shows the composition of the fatty acid methyl ester standard 
used in this study. Appendix V (B) shows the corresponding GC-FID spectrum. 
Appendicies VI (A) and VI (B) show typical GC-FID chromatograms of rat brain 
lipids with and without the internal standard respectively. Appendicies VI (C) 
and VI (D) show typical GC-FID chromatograms of rat liver lipids, with and 
without the internal standard respectively.
2.6.4.2 Quantitation
All biological samples were analysed in duplicate. Identification of fatty acids 
was based on comparison of the retention times of FAME in the biological 
samples to those of the mixed FAME standard. The FAME peaks were 
integrated, and the peak area normalised using the peak area of the internal 
standard. Data was expressed as % weight of total fatty acids. The sum of the 
weight of all fatty acids was taken to be the total fatty acid content (100 %) of 
the rat brain or liver tissue. Sample calculations are shown in Appendix VII. 
2.7 Analysis of atorvastatin
2.7.1 Brain tissue slice sample preparation 
The brain tissue slices were stored in a DMSO-containing solution. To remove 
the DMSO, the slices were washed in PBS as described in section 2.4.1. The 
washed slices were then processed as described in section 2.4.3. 
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2.7.2 Solid tissue homogenisation and extraction
The solid tissue samples (brain or liver) were placed into clean 5 ml glass 
extraction vials (EV1) kept cool in ice and then homogenised with a Ystral® D-
79282 blade homogeniser (Ballrechten-Dottingen) for 10 pulses, five times, in 
1ml ice-cold water. 50 µl of the brain homogenate was thereafter transferred 
into an eppendorf vial and stored at –20 ○C for protein content analysis. To 
ensure that the analytes were protonated prior to extraction 20 µl ortho-
phosphoric acid (10%, v/v) was then added to the homogenate. The internal 
standard prepared by dissolving 1 mg methaqualone (internal standard) in 1 ml 
methanol to give a 1 mg/ml solution. This was further diluted to give a 1 ng/ml 
solution. Thereafter, 20 µl of this solution was added to the homogenate to give 
a final concentration of 20 pg/ml methaqualone in the homogenate. The 
homogenate was then vortexed for 30 s. A mixture of diethyl ether: 
dichloromethane (7:3, v/v) (5 ml) was added and the resulting mixture was 
vortexed five times, for 4 min at 1 min intervals. The homogenate was then 
centrifuged at 1000 g (3000 rpm) for 5 min at 4 ○C to separate the aqueous and 
organic layers. The supernatant (organic layer) was transferred into a clean 
extraction vial EV2. A further 5 ml diethyl ether-dichloromethane (7:3, v/v) was 
added to the aqueous lower layer, and interface between the two layers 
containing denatured proteins (as remained in EV1). This mixture was then 
vortexed five times for 4 min at 1 min intervals and centrifuged at 1000 g (3000 
rpm) for 5 min at 4 ○C to separate aqueous and organic layers. The resulting 
supernatant (organic layer) was removed and combined with the first 
supernatant in EV2. The solvent was then removed under a stream of nitrogen. 
The resulting residue was re-dissolved in 60 µl methanol and stored at –20 ○C 
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until analysis (within 48 hours). On the day of analysis, the samples were 
centrifuged at 83.85 g (500 rpm) for 2 min at 4 ○C to ensure all the solvent was 
gathered at the bottom of the vial. The solution was then transferred to an insert 
vial (100 µl) and placed in the autosampler for analysis by LC/ESI-MS/MS.
2.7.3 Extraction of plasma samples
1 ml plasma was transferred into clean 5 ml glass extraction vials (EV1) and 
kept cool in ice; 50 µl of this was transferred into an eppendorf vial and stored at 
–20 ○C for protein content analysis. To ensure that the analytes were 
protonated prior to extraction 20 µl ortho-phosphoric acid (10%, v/v) was then 
added to the homogenate. As described in section 2.7.3 for solid tissue 
homogenates, 20 µl of a 1 ng/ml methaqualone solution was added to to the 
mixture to give a final concentration of 20 pg/ml methaqualone in plasma. The 
mixture was then extracted with diethyl ether: dichloromethane (7:3, v/v) as 
described for solid tissue homogenates in section 2.7.3.
2.7.4 ESI-MS/MS settings
To optimise both the MS and MS/MS conditions required for the most efficient 
ionisation of atorvastatin, ortho-hydroxy-atorvastatin, para-hydroxy-atorvastatin 
and methaqualone (IS) standards, analysis were carried out using ESI-MS/MS. 
The mass spectrometer was operated in the positive ion mode (ES+) and full 
scan spectra acquired over the mass range of m/z of 50-650. Individual 
compounds at a concentration of 10 ng/ml were analysed by direct infusion 
through a syringe pump (flow rate 10 µl/min) into the HPLC solvent (flow rate 
0.2 ml/min). The sensitivity of the method was optimised by altering the capillary 
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voltage, cone voltage, collision energy, source and desolvation temperatures of 
the ESI source. A detailed description of the steps taken for method 
development is described in Chapter 3.
2.7.5 LC/ESI-MS/MS
For analysis of atorvastatin, ortho-hydroxyatorvastatin, para-hydroxyatorvastatin 
and methaqualone (IS), the instrument was operated in the positive ionisation 
mode (ES+) using capillary voltage of 3.50 kV, cone voltage 40 V, desolvation 
temperature of 360 ○C and source temperature of 120 ○C. For optimisation of 
product ions, the collision energy (CE) was varied to obtain optimum sensitivity 
using argon as collision gas. Dwell times were 0.2 s, the interscan time was 0.1 
s and the interchannel delay was 0.02 s for all experiments. Table 2.1 shows 
the multiple reaction monitoring (MRM) transitions and CE settings that were 
used. A detailed description of the steps taken for method development is 
shown in Chapter 3.
LC analysis was performed on a C18 column (Gemini, 5 μ, 150 x 2 mm). 
Compounds were eluted by an isocratic phase system consisting of two 
solvents mixed 50:50 (v/v). Solvent A was made up of acetonitrile: water, 10: 90 
v/v with 0.01 % formic acid and solvent B was made up of acetonitrile: water, 
90: 10 v/v with 0.01 % formic acid. The injection volume was 10 µl and flow rate 
0.2 ml/min. The duration of the run was 18 min. The autosampler chamber was 
maintained at 8 ○C.
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Compound m/z CE (eV) MRM (m/z)
Atorvastatin 559 20 559 > 440
ortho-hydroxyatorvastatin 575 15 575 > 466
para-hydroxyatorvastatin 575 20 575 > 440
Methaqualone (Internal standard) 251 25 251 > 132
2.7.6 Preparation of atorvastatin, ortho-hydroxyatorvastatin, para-
hydroxyatorvastatin standards and methaqualone (IS)
Atorvastatin calcium salt (1.7 mg), ortho-hydroxyatorvastatin dihydrate 
monosodium salt (1mg) and para-hydroxyatorvastatin disodium salt (1mg) were 
dissolved in methanol to give stock solutions of 1 mg/ml. These were stored at –
20 ○C. 10µl of each solution was transferred into a clear glass vial and 990 µl of 
methanol was added to dilute the solutions to a final concentration of 1 µg/ml. 
Volume (μl) Final analyte 
concentration
Composite stock 
solution
(100 ng/ml)
Methaqualone
(1 ng/ml)
Methanol ng/ml
20 20 20 33
10 20 30 17
5 20 35 8
3 20 37 4
1 20 39 0.8
Table 2.1 Multiple reaction monitoring (MRM) transitions and collision energy 
settings for the LC/ESI-MS/MS analysis of atorvastatin and its metabolites.
Table 2.2 Composite stock solutions and final analyte concentrations used for 
the construction of calibration lines 
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A composite stock solution was prepared by adding 100 µl of each of the 1 
µg/ml solutions to 700 µl methanol to give a 100 ng/ml mixed standard solution. 
20, 10, 5, 3 and 1 µl aliquots of this solution was then mixed with 20 µl of 
methaqualone (1 ng/ml) and varied volumes of methanol, to give final analyte 
concentrations as presented in Table 2.2. All working standard solutions were 
freshly prepared prior to LC/ESI-MS/MS analysis.
2.7.7 Calibration lines and quantitation
The peak-area ratio of every compound to the internal standard (methaqualone) 
were calculated and plotted against the concentration of the calibration 
standards (33-0.8 ng/ml). Calibration lines were calculated by the least-squares 
linear regression method. To calculate the concentration of any given analyte 
the peak-area ratio to methaqualone was calculated and read off the 
corresponding calibration line. All results are expressed as amount of analyte 
per mg protein.
2.7.8 Limits of detection and quantitation
The limit of detection was calculated by using a signal-to-noise (S/N) ratio of 3. 
The limit of quantitation (LoQ) was determined by using a S/N ratio of 5. Peak 
integrations and S/N calculations were performed using the MassLynx TM V4.0 
software (Waters, Elstree, UK).
2.8 Protein content determination
Protein content determination of samples was performed using the BioRad kit 
following the manufacturer’s instructions. Briefly BSA (1.5 mg) was dissolved in 
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1 ml milli-Q water to give a stock solution of 1.5 mg/ml. This solution was 
divided as 500 µl aliquots in eppendorff vials and kept at -20°C. Standard 
solutions for calibration lines were prepared by diluting the 1.5 mg/ml BSA 
standard with 0.5 N NaOH to give final concentrations of 0.25 mg/ml, 0.5 mg/ml, 
0.75 mg/ml and 1.0 mg/ml. The dilutions made are presented in Table 2.3. 5 µl 
of each standard solution was then transferred into a 96-well plate and 25 µl of 
a mixture of reagent S (20 µl) and reagent A (1ml) from the BioRad kit, was 
added to each standard followed by the addition of 200 µl of solution B. The 
plate was left to stand for 15 min at room temperature in the dark. The 
absorbance was estimated at 650 nm using a plate reader.
Final concentration 
(mg/ml)
Stock (Hermann et al.)
(μl)
0.5 M NaOH (μl)
0 0 150
0.25 25 125
0.50 50 100
0.75 75 75
1.00 100 50
1.50 150 0
This analysis was done in triplicate and the mean absorbance calculated. 
Calibration lines were constructed by plotting the absorbance versus 
concentration; the lines were calculated using the least-squares linear 
regression method. Example of analyte calibration line is shown in Figure 2.1. 
Biological samples (50 µl) were mixed with 0.5 M NaOH and a further three 
dilutions were made from this solution using 0.5 M NaOH. The analysis was 
Table 2.3 Composite stock solutions and final analyte concentrations used for 
the construction of BSA calibration lines 
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performed as described for the BSA standards. The concentration of samples 
was then determined from the standard curve of absorbance versus protein 
(mg/ml) taking the dilution factors into consideration.
Figure 2.1 Bovin serum albumin calibration line 
2.9 Statistics
All statistical analysis performed with the SPSS 15.0 software. Results were 
tested with the Kolomogorov-Smirnov test to determine whether data were 
parametric or non-parametric. When established to be parametric, the 
independent samples two-tailed unpaired Student’s t-test was used to compare 
data. ANOVA with Bonferroni’s post hoc adjustment was used for multiple 
comparisons. A significant result was considered when p < 0.05.
y = 0.1384x + 0.0023
R2 = 0.9934
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3.0 ANALYSIS OF ATORVASTATIN BY LC/ESI-MS/MS 
3.1 Introduction
Atorvastatin is an HMG-CoA reductase inhibitor (statin). This class of medicines 
are administered for their cholesterol lowering effects and are also known to 
have pleitropic effects (Liao, 2002). These pleitropic effects have been shown to 
counteract inflammatory responses in mammalian cells such as astrocytes, 
microglia, macrophages and monocytes and therefore may be beneficial in 
neuroinflammation (Pahan et al., 1997, Vaughan and Delanty, 1999, Wagner et 
al., 2002, Wang et al., 2007). The molecular mechanism of this anti-
inflammatory action is of interest. Therefore the effects of atorvastatin on 
lipopolysaccharide- and age-induced alterations in the brain and liver lipid 
profiles of adult and aged animals were investigated in order to understand its 
anti-inflammatory mechanism of action in the brain. 
The main site of action of statins has been reported to be the liver where they 
inhibit cholesterol synthesis from mevalonate by the action of HMG-CoA 
reductase (Germershausen et al., 1989, Koga et al., 1992, Parker et al., 1990). 
Atorvastatin is administered in its active hydroxy acid calcium salt (Figure 1.12) 
and is reported to be primarily metabolised in the liver by the action of the 
CYP450 mixed oxidase enzyme system (Black et al., 1999, Jacobsen et al., 
2000, Lau et al., 2006). Specifically, it was reported that the action of CYP3A4 
and CYP3A5 on atorvastatin in the liver produces two major active hydroxy 
metabolites namely ortho-hydroxyatorvastatin and para-hydroxyatorvastatin, 
and two inactive lactone forms namely ortho-hydroxyatorvastatin lactone and 
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para-hydroxyatorvastatin lactone (Black et al., 1999, Jacobsen et al., 2000). 
The lactone forms are interconverted by CYP3A4 to the active hydroxy forms 
(Jacobsen et al., 2000). Minor metabolites produced include β-oxidized 
atorvastatin derivatives and glucuronide conjugated ortho-hydroxyatorvastatin 
(Black et al., 1999, Black et al., 1998, Prueksaritanont et al., 2002). A schematic 
representation of the atorvastatin metabolic pathway is shown in Figure 1.12 
(Chapter 1). Atorvastatin and its metabolites are predominantly eliminated via 
the liver, although other sites of elimination include the gut wall and kidney (Lau
et al., 2006).
About 70 % of the lipid lowering effect of atorvastatin has been attributed to the 
action of the active hydroxy metabolites (Kantola et al., 1998). In addition these 
metabolites have lipid independent effects. Studies have demonstrated that 
ortho-hydroxyatorvastatin and para-hydroxyatorvastatin inhibit low density 
lipoprotein oxidation, a key process in atherosclerosis (Berliner et al., 1995), 
probably by a free radical scavenging action (Aviram et al., 1998). Ortho-
hydroxyatorvastatin has also been shown to inhibit oxidative stress by reducing 
isoprostane levels in a model cell membrane (Mason et al., 2006).
The ability of atorvastatin to reach the central nervous system is still debatable. 
Some reports propose that atorvastatin is relatively lipophilic and thus has 
limited ability to cross the blood brain barrier (Joshi et al., 1999, Mason et al., 
2004, Pedersen and Gaw, 2001) while others argue that it is hydrophilic and 
cannot cross the blood brain barrier (Sparks et al., 2002). The active hydroxy 
metabolites are reported to be less lipophilic than the parent hydroxy acid, 
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whilst the lactone forms are reported to be more lipophilic than the parent 
hydroxy acid form (Ishigami et al., 2001). 
Various analytical techniques for the determination of statins and their 
metabolites have been proposed. Gas chromatography-mass spectrometry 
(GC-MS) has been applied for statins in plasma (Funke et al., 1989, Morris et 
al., 1993). Although GC-MS is highly selective and sensitive, it requires a 
complicated derivatisation step. High performance liquid chromatography 
(HPLC) with ultraviolet and fluorescent detection with and without derivatisation 
steps have also been employed, however the chromatographic run time is long 
(Erturk et al., 2003, Lanchote et al., 2001, Ochiai et al., 1997, Otter and Mignat, 
1998). LC-MS/MS appears to be the method of choice for the analysis of statins 
in biological tissues. It is sensitive, selective and simple, does not require 
derivatisation and LC/ESI-MS/MS has been mostly used for the simultaneous 
determination and quantitation of atorvastatin and its metabolites in serum and 
plasma (Bullen et al., 1999, Hermann et al., 2005, Jemal et al., 1999, Nirogi et 
al., 2006). Thus in relation to the present study, we aimed to develop a LC/ESI-
MS/MS method with high sensitivity and selectivity that would allow for the 
simultaneous detection and quantitation of atorvastatin and its active hydroxy 
metabolites in rat brain, liver and plasma. 
The method development for optimising the LC/ESI-MS/MS analysis of 
atorvastatin and its active metabolites was carried out on a triple quadrupole 
instrument using commercially available standards. Methaqualone was used as 
an internal standard, calibration curves were constructed and linearity 
established within a range of six concentrations of the commercially available 
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atorvastatin, ortho-hydroxyatorvastatin and para-hydroxyatorvastatin. Limits of 
detection and quantitation were also determined.
3.2 Materials and methods
The materials used in this study are listed in section 2.1.3. The equipment used 
are described in section 2.2. The final assay protocol for the LC/ESI-MS/MS 
assay is presented in section 2.7.
3.3 Results
3.3.1 LC/ESI-MS/MS
The development of the LC/ESI-MS/MS was performed in two steps as follows:
1. Optimisation of MS and MS/MS conditions for the analysis of 
atorvastatin, ortho-hydroxyartovastatin, para-hydroxyatorvastatin and 
methaqualone.
2. Optimisation of the LC/ESI-MS/MS method.
3.3.1.1 MS and MS/MS
Initially the ionisation of atorvastatin, ortho-hydroxyartovastatin, para-
hydroxyatorvastatin and methaqualone standards was assessed by 
electrospray ionisation mass spectrometry (ESI-MS) to determine whether the 
positive or negative mode was optimal for the formation of the molecular ion. 
This optimisation was carried out by directly infusing each compound at a 
concentration of 1 ng/ml. The optimal mode for detecting all compounds was 
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found to be the positive mode (ES+) and this was in agreement with earlier 
investigations (Hermann et al., 2005, Jemal et al., 1999, Nirogi et al., 2007, 
Nirogi et al., 2006). 
Here instrument parameters such as the cone voltage and capillary voltage 
were altered in the range of 40-69 V and 3.50-3.47 kV respectively. Optimal 
ionisation was achieved for all standards when the cone voltage and capillary 
voltage were 40 V and 3.5 kV respectively. These conditions enabled the 
achievement of the highest relative abundance for each precursor ion. 
Following this, ionisation and fragmentation patterns of the analytes were 
studied by ESI-MS/MS. For this purpose solutions of the analytes were directly 
infused into the HPLC flow through a syringe pump to ensure that the ionisation 
was compatible to the conditions of the assay. The collision energy can greatly 
influence the generation and intensity of product ions. The collision energy was 
varied from 2-26 eV until optimal collision energy was achieved for each 
compound. This experiment was imperative in order to identify characteristic 
and stable product ions that can be used to set up multiple reaction monitoring 
(MRM) assays that can be used for the development of an LC/ESI-MS/MS 
assay.
3.3.1.1.1 Optimisation of MS and MS/MS conditions for atorvastatin
Figure 3.1A shows the full scan ESI-MS spectrum of atorvastatin in the positive 
mode. The molecular ion [M+H]+ occurs at m/z 559. Figure 3.1B shows the 
fragmentation pattern of atorvastatin obtained at optimum collision energy of 20 
eV. The fragment ions occurred at m/z 292, m/z 422, m/z 440 and m/z 466. The
most intense fragment ion was that at m/z 440 and is formed by the neutral loss
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Figure 3.1 ESI-MS (A) and ESI-MS/MS (B) spectra of atorvastatin
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Figure 3.2 ESI-MS (A) and ESI-MS/MS (B) spectra of ortho-hydroxyatorvastatin
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Figure 3.3 ESI-MS (A) and ESI-MS/MS (B) spectra of para-hydroxyatorvastatin
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Figure 3.4 ESI (A) and ESI-MS/MS (B) spectra of methaqualone (internal 
standard)
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of the phenylaminocarbonyl group. The transition m/z 559 > 440 was therefore 
chosen for the MRM assay. These findings are in agreement with the literature 
(Nirogi et al., 2006). 
3.3.1.1.2 Optimisation of MS and MS/MS conditions for ortho-
hydroxyatorvastatin
Figure 3.2A shows the full scan ESI-MS spectrum of ortho-hydroxyatorvastatin 
in the positive mode. The molecular ion [M+H]+ occurs at m/z 575. Figure 3.2B 
shows the fragmentation pattern of ortho-hydroxy-atorvastatin obtained at 
optimum collision energy of 15 eV. The fragment ions occurred at m/z 440 and 
m/z 466. The most intense fragment ion was that at m/z 466 and is formed by 
the neutral loss of the phenylamino group which is thought to be due to the 
intramolecular hydrogen bonding with the NH group in the ortho position (Nirogi
et al., 2006). The transition m/z 575 > 466 was therefore chosen for the MRM 
assay and is in agreement with the literature (Nirogi et al., 2006).
3.3.1.1.3 Optimisation of MS and MS/MS conditions for para-
hydroxyatorvastatin
Figure 3.3A shows the full scan ESI-MS spectrum of para-hydroxyatorvastatin 
in the positive mode. The molecular ion [M+H]+ occurs at m/z 575. Figure 3.3B 
shows the fragmentation pattern of para-hydroxyatorvastatin obtained at 
optimum collision energy of 20 eV. The fragment ions occurred at m/z 440 and 
m/z 466. The most intense fragment ion was that at m/z 440, which is also 
found for atorvastatin, and is formed by the neutral loss of the 
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phenylaminocarbonyl group. The transition m/z 575 > 440 was therefore chosen 
for the MRM assay and is in agreement with the literature (Nirogi et al., 2006).
3.3.1.1.4 Optimisation of MS and MS/MS conditions for methaqualone (IS)
Figure 3.4A shows the full scan ESI-MS spectrum of methaqualone in the 
positive mode. This compound was used as the internal standard (IS) due to its 
structural similarity to atorvastatin. The molecular ion [M+H]+ occurs at m/z 251. 
Figure 3.4B shows the fragmentation pattern of methaqualone obtained at 
optimum collision energy of 25 eV. The fragment ions occurred at m/z 91, m/z
117, m/z 120, m/z 132 and m/z 161. The most intense fragment ion was that at 
m/z 132. The transition m/z 251 > 132 was therefore chosen for the MRM 
assay. These findings are in agreement with the literature (Hermann et al., 
2005).
3.3.1.2 LC/ESI-MS/MS
To separate the analytes we followed a modification of the method suggested 
previously (Nirogi et al., 2006). This was an isocratic system consisting of 50 % 
solvent A (acetonitrile : water, 10 : 90 v/v with 0.1 % formic acid) and 50 % of 
solvent B (acetonitrile : water, 90 : 10 v/v with 0.1 % formic acid). The 
compounds eluted at different retention times and were detected using 
structure-specific MRM transitions. The retention times were as follows: para-
hydroxyatorvastatin: 4.44 min, methaqualone: 5.31 min, ortho-
hydroxyatorvastatin: 10.58 min and atorvastatin: 12.69 min. The total run time 
was 18 min and included a washout period of 8 min before the next injection.
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Figure 3.5 LC/ESI-MS/MS chromatogram of ortho-hydroxyatorvastatin, para-hydroxyatorvastatin, atorvastatin and methaqualone 
(internal standard). An isocratic system consisting of 50 % solvent A (acetonitrile : water, 10 :90 v/v with 0.1 % formic acid) and 50 
% of solvent B (acetonitrile : water, 90 : 10 v/v with 0.1 % formic acid) was used for the LC separation.
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Figure 3.5 shows a multiple reaction monitoring (MRM) transition for four mass 
pairs m/z 251 >132, m/z 559 > 440, m/z 575 > 440 and m/z 575 > 466 for 
methaqualone, atorvastatin, para-hydroxyatorvastatin and ortho-
hydroxyatorvastatin respectively.
3.3.2 Linearity, limits of detection and quantitation
Standard calibration curves were constructed for each compound over the 
range of 0.8 to 33 ng/ml. The results confirmed that the assay was linear over 
this range of concentrations where the determined response was directly 
proportional to the analyte concentration. Sample calibration lines are shown in 
Figure 3.6.
Figure 3.6 Sample calibration lines for (A) atorvastatin, (B) ortho-
hydroxyatorvastatin and (C) para-hydroxyatorvastatin (LC/ESI-MS/MS assay).
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The limits of detection were found to be 3 ng/ml and the limits of quantitation 
were found to be in the range of 2-8 ng/ml depending on the analyte (Table 
3.1). 
Compound
Limit of detection
(ng/ml)
Limit of quantitation 
(ng/ml)
Atorvastatin 3 2
ortho-hydroxyatorvastatin 3 8
para-hydroxyatorvastatin 3 8
3.4 Discussion
We aimed to develop a sensitive and selective LC/ESI-MS/MS assay that would 
permit the simultaneous detection and quantitation of atorvastatin, ortho-
hydroxyatorvastatin and para-hydroxyatorvastatin in rat brain, liver and serum. 
This was considered important in order to determine whether atorvastatin is 
able to cross the blood brain barrier and gain access to the brain. This 
determination was necessary in our investigation of the molecular mechanism 
of action of atorvastatin in neuroinflammation. 
A simple extraction step was employed for sample preparation. This did not 
require derivatization steps like the GC-MS and some HPLC methods that have 
been reported (Morris et al., 1993, Ochiai et al., 1997). Moreover the GC-MS 
method is not suitable for the hydroxylated metabolites as the derivatization 
step destroys them (Bullen et al., 1999). The detection limit for each compound 
was 3 ng/ml and the limits of quantitation ranged from 2-8 ng/ml. These values 
Table 3.1 Limit of detection and limit of quantitation of the LC/ESI-MS/MS 
assay for atorvastatin, ortho-hydroxyatorvastatin and para-hydroxyatorvastatin. 
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were comparable to those described for plasma in the literature (Bullen et al., 
1999).
Indeed the lipophilicity of atorvastatin and its ability to cross the blood brain 
barrier is still debatable (Knopp, 1999, Serajuddin et al., 1991). Thus, apart from 
providing information about the levels of atorvastatin and its metabolites in the 
tissues investigated, this assay may be useful in providing information about the 
extent of penetration of the blood brain barrier by atorvastatin and its active 
hydroxy metabolites. The extent of penetration into the blood brain barrier is 
crucial for therapeutic approaches, especially if atorvastatin is able to directly 
affect brain cholesterol biosynthesis. Since statins are designed to target the 
liver (Endo and Endo, 2004), it is not clear whether it is also beneficial to reduce 
brain cholesterol, especially in diseases like Alzheimer’s disease where brain 
cholesterol homeostasis is already compromised (Sparks et al., 2002). 
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4.0 THE EFFECT OF ATORVASTATIN ON AGE-
INDUCED CHANGES IN BRAIN LIPIDS
4.1 Introduction
Brain tissue has a high lipid content. The lipid composition of the brain is altered 
as the animal ages (Calderini et al., 1983, Lopez et al., 1995). Since most brain 
lipids have structural functions including neuronal membrane integrity and 
fluidity, their modifications have been reported to affect enzyme activities such 
as CYP450 mixed function enzyme system and PLA2 activities (Andre et al., 
2006, Wauthier et al., 2006). They also influence neurotransmission by affecting 
neurotransmitter receptor binding and activities (Allen et al., 1983, Cunha et al., 
2001, Delion et al., 1997). These in turn may result in reduced learning ability, 
cognitive impairment and memory decline (Kessler and Yehuda, 1985). 
Neuroinflammation is regarded as an intrinsic feature of the aging brain 
(Godbout et al., 2005). Increased inflammation in the aged brain has also been 
correlated to increased risk of brain disorders such as senile dementia, 
Alzheimer’s disease and Parkinson’s disease (Pratico et al., 1998, Pratico et al., 
2004, Whitton, 2007). 
In the liver also, age alters lipid composition, however reports have varied in the 
type of changes that occur. For instance, some investigators have reported no 
effects on AA and total n-6 PUFA (Tamburini et al., 2004) while some have 
reported decreases in AA (Youdim and Deans, 1999). Similarly, various effects 
have been reported for saturated, monounsaturated fatty acids and n-3 PUFA. 
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Specifically, total saturated fatty acids have been shown to remain unchanged 
with age (Tamburini et al., 2004, Youdim and Deans, 1999), whilst DHA and 
total n-3 PUFA have been reported to increase in the liver with age. Other 
reports have shown decreases (Youdim and Deans, 1999) or no effects 
(Tamburini et al., 2004) on n-9 monounsaturated fatty acids. 
Although aged related alterations have been reported for fatty acid metabolism, 
it has been shown that cholesterol homeostasis may be maintained in the aged 
rat liver (Marino et al., 2002). However, it was shown that there were moderate 
elevations in the cholesterol content in the aged rat liver while in the human liver 
no changes were observed (Kalen et al., 1989). Reports on the effects of age 
on liver phosholipids have also varied. Some have reported no effects in the 
phospholipid content of both human and rat liver and rat liver microsomes 
(Kalen et al., 1989, Wood et al., 1986), while a decrease in PC has been 
reported in 18 month old rats (Miyazawa et al., 1993).
In addition to their cholesterol lowering action, statins have been shown to 
influence fatty acid synthesis in cells and have anti-inflammatory activities 
(Lindberg et al., 2005, Rise et al., 2003, Rise et al., 2005). The anti-
inflammatory activities have been shown to offer neuroprotection (Endres et al., 
1998). It has also been proposed that essential fatty acids and their metabolites 
may have similar actions as statins, which may make them function as 
endogenous second messengers of statins (Das, 2001). For instance, dietary n-
3 PUFA inhibit HMG-CoA reductase activity in the liver and intestine of rabbits 
(Field et al., 1987). Docosanoids derived from DHA are reported to have 
neuroprotective effects (Marcheselli et al., 2003). Furthermore, DHA mediated 
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accumulation of PS has been demonstrated to prevent apoptosis (Kim et al., 
2000). In addition, DHGLA and EPA generated eicosanoids antagonise the 
inflammatory effects of eicosanoids from the AA cascade (Hung et al., 2000, 
Weiss et al., 2002). 
On the basis of available evidence, we hypothesize that statins may be able to 
modulate the age related alterations in lipid metabolism and therefore affect 
lipid composition in brain and liver. We have therefore evaluated these changes 
and assessed the effect of atorvastatin, a widely used statin with a view to 
further understand its molecular mechanism of action. 
4.2 Study design
In this study, 12 aged (22-24 months) and 12 adult (3-4 months) male Wistar 
rats served as subjects. Aged and adult rats were randomly divided into control 
and atorvastatin treatment groups. Each group consisted of 6 animals. The 
control group received normal laboratory chow and the atorvastatin treatment 
group received the experimental diet that consisted of atorvastatin (5 
mg/kg/day) in sunflower oil mixed with laboratory chow (5 ml/150g chow). 
Treatment lasted for 8 weeks after which animals were sacrificed by 
decapitation.
All materials and methods used in this study are described in Chapter 2 
(sections 2.1, 2.2, 2.3.1, 2.4, 2.5, 2.6, 2.7, 2.8 and 2.9).
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4.3 Results
4.3.1 Atorvastatin and brain lipids
1H-NMR analysis of the total lipid extract allowed profiling of the major classes 
of lipids in cortical tissue: phospholipids, sphingolipids, cholesterol and ether 
lipids, the predominant PUFA (DHA and AA), and estimation of the unsaturation 
index defined as a measure of the total number of double bonds per fatty acid 
chain. 1H-NMR analysis of lipids did not however permit detailed analysis of 
fatty acids and these were analysed using GC-FID. 
4.3.1.1 Age induced changes in the rat brain lipid profile
The results of the effect of age on the lipid profile of rat brain are expressed as 
% mole of lipid classes and % mole of total fatty acid chain including the 
unsaturation index (mean ± SD). These results are summarised in Table 4.1.
Age induced changes in fatty acids include a statistically significant reduction in 
DHA (p = 0.005) and a statistically significant increase in unsaturated fatty acid 
chains (p = 0.042).
Age induced changes on the lipid classes include statistically significant 
reductions in the relative amount of, phosphatidylcholine (p < 0.0005), total 
choline phospholipids (p = 0.002), total ethanolamine (p = 0.004) and total 
diacylglycerophospholipids (p < 0.0005). Conversely, there were statistically 
significant increases in the levels of total sphingolipids (p = 0.043) and 
cholesterol (p = 0.009). 
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% mole
Adult Adult + ATV Aged Aged + ATV
(A) Fatty acid chain
n-3 PUFA 8.87 ± 0.41 8.56 ± 0.66 8.31 ± 0.33 8.06 ± 0.54
Linoleic acid (C18:2n-6)* 1.20 ± 0.07 1.25 ± 0.05 1.30 ± 0.06 1.24 ± 0.06
Docosahexaenoic acid (C22:6n-3) 8.72 ± 1.07 8.73 ± 0.75 6.71 ± 0.68a 6.50 ± 0.63aa
Arachidonic acid (C20:4n-6) 8.89 ± 0.53 8.93 ± 0.37 9.41 ± 0.57 8.93 ± 0.42
Unsaturated fatty acid chains 51.6 ± 1.41 54.8 ± 0.51 55.5 ± 1.72a 54.2 ± 2.26
Saturated fatty acid chains 47.6 ± 1.94 44.9 ± 0.84 44.5 ± 1.72 45.8 ± 2.26
Unsaturation index 0.99 ± 0.06 0.99 ± 0.04 0.91 ± 0.07 0.87 ± 0.04a
(B) Lipids
Total choline phospholipids 22.9 ± 1.05 22.2 ± 0.54 20.5 ± 0.61aa 20.4 ± 1.1aa
Phosphatidylcholine 20.1 ± 1.02 19.4 ± 0.54 17.2 ± 0.81aaa 17.1 ± 0.62aaa
Sphingomyelin 2.86 ± 0.10 2.81 ± 0.08 3.29 ± 0.30 3.33 ± 0.90
Total ethanolamine phospholipids 21.4 ± 0.73 20.9 ± 0.28 19.7 ± 0.42aa 19.9 ± 0.89aa
Total sphingolipids 14.6 ± 1.53 15.2 ± 0.98 16.6 ± 0.54a 16.8 ± 1.08a
Cholesterol 37.9 ± 0.82 38.2 ± 0.46 40.0 ± 0.85aa 40.5 ± 1.08aa
Plasmalogens 10.7 ± 0.44 10.5 ± 0.28 11.0 ± 0.26 11.0 ± 0.43
Total ether lipids 11.2 ± 0.22 11.2 ± 0.29 11.5 ± 0.32 11.4 ± 0.42
Total diacylglycerophospholipids 36.3 ± 1.62 35.3 ± 1.35 31.9 ± 1.07aaa 31.4 ± 1.09aaa
Table 4.1 The effect of atorvastatin (5 mg/kg/day) on (A) fatty acid and (B) lipid composition of adult and aged rat brains. Results are 
expressed as % mole of total fatty acid chain including the unsaturation index and % mole of lipid classes (mean ± SD); n = 6 animals 
per group. a p < 0.05, aa p < 0.01, aaa p < 0.001 comparing data to adult.
* The level of linoleic acid was close to the limit of detection of the method therefore no statistical anaylsis was performed. ATV: atorvastatin, 
Adult+ATV: adult rats treated with atorvastatin, Aged+ATV: aged rats treated with atorvastatin, Adult: adult controls, Aged: aged controls.
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4.3.1.2 Effect of atorvastatin treatment on the adult rat brain lipid profile
The results of the effect of atorvastatin on the lipid profile of adult rat brain are 
expressed as % mole of lipid classes and % mole of total fatty acid chain 
including the unsaturation index (mean ± SD). These results are summarised in 
Table 4.1
From our results, atorvastatin did not modify the relative amounts of fatty acids, 
the degree of unsaturation of the fatty acid chains nor the different lipid classes 
in the adult rat brain. 
4.3.1.3 Effect of atorvastatin treatment on the aged rat brain lipid profile
The results of the effect of atorvastatin on the aged rat brain lipid profile are 
expressed as % mole of total lipid classes and % mole of total fatty acid chain 
including the unsaturation index (mean ± SD). These results are summarised in 
Table 4.1.
Our results show that although atorvastatin did not modify the age induced 
reduction in DHA (p = 0.002), it caused a reduction of the age-induced increase 
in unsaturated fatty acid chains to levels similar to controls (p = 0.324). 
Furthermore, atorvastatin caused a statistically significant reduction in the 
unsaturation index (p = 0.018) of the aged rat brain compared to the adult rat 
brain. 
Additionally, atorvastatin did not modify the age-induced changes in other lipid 
classes in the brain. Phosphatidylcholine (p < 0.0005), total choline
phospholipids (p = 0.001), total ethanolamine phospholipids (p = 0.009) and 
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total diacylglycerophospholipids (p < 0.0005) were all still significantly reduced 
in the brain of the aged animals that received atorvastatin treatment. 
Furthermore, the age induced increases in total sphingolipids and cholesterol 
were not modified by atorvastatin, as the concentrations of total sphingolipids (p
= 0.031) and cholesterol (p = 0.001) remained significantly increased in the 
brain of the aged animals that received atorvastatin. Thus suggesting that 
atorvastatin did not have direct effects on the biosynthesis of cholesterol in the 
brain. 
4.3.1.4 Effect of age on rat brain fatty acid profile
Detailed fatty acid profiles of adult and aged rat brain were obtained by GC-FID. 
This allowed the profiling of saturated and monounsaturated fatty acids and 
PUFA (n-6 and n-3). The results, expressed as % weight of total fatty acids 
(mean ± SD) are summarised in Table 4.2.
Findings from fatty acid analysis showed that the concentration of palmitic acid 
(C16:0) and stearic acid (C18:0) were the most abundant in the brain of the 
adult and aged animals. In addition, C16:0 (p = 0.001) and C18:0 (p = 0.007) 
where significantly reduced in the aged animals when compared to adult. 
Heptadecanoic acid (C17:0) and tricosanoic acid (C23:0) were not detected in 
the adult rat brain but were detected in the aged rat brain. Total saturated fatty 
acid concentrations, which were also significantly different (p = 0.013) within the 
two age groups.
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% weight
Adult Adult + ATV  Aged Age + ATV
FATTY ACID
C16:0 21.0 ± 0.80 20.6 ±0.63 19.0 ± 0.67aa 19.2 ± 0.38aa
C17:0 ND ND 0.25 ± 0.01 0.29 ± 0.03
C18:0 23.3 ± 1.08 23.0 ± 0.41 21.4 ± 0.60aa 21.6 ± 0.82a
C23:0 ND ND 0.50 ± 0.08 0.51 ± 0.05
C24:0 0.79 ± 0.15 0.73 ± 0.06 1.33 ± 0.30 1.14 ± 0.31
Σ SFA 44.5 ± 1.30 44.2 ± 81 42.4 ± 0.68a 42.6 ± 0.71a
C16:1 0.33 ± 0.02 0.33 ± 0.01 0.39 ± 0.03a 0.42 ± 0.03aa
C17:1 1.94 ± 0.30  2.33 ± 0.08a 2.52 ± 0.21aa 2.55 ± 0.15aa
C18:1n-9 18.6 ± 1.45 20.1 ± 0.57 21.1 ± 0.66aa 21.1 ± 0.77aa
C18:1n-7 3.50 ± 0.30 3.68 ± 0.15 3.50 ± 0.14 3.55 ± 0.15
C20:1n-9 0.74 ± 0.36 0.52 ± 0.20 0.48 ± 0.06 0.50 ± 0.06
C24:1 1.13 ± 0.40 1.10 ± 0.11 2.01 ± 0.61 1.82 ± 0.44
Σ MUFA 25.6 ± 2.28 27.8 ± 0.56 30.0 ± 0.99aa 30.0 ± 1.06aa
C18:2n-6 0.63 ± 0.07 0.56 ±0.02 0.61 ± 0.05 0.65 ± 0.06a
C20:3n-6 0.06 ± 0.14 ND 0.31 ± 0.01 ND
C20:4n-6 10.4 ± 0.23 10.2 ± 0.46 10.5 ± 0.16 10.2 ± 0.26
C22:4n-6 3.17 ± 0.13 3.32 ± 0.13 3.32 ± 0.13 3.23 ± 0.13
Σ n-6 14.2 ± 0.45 14.2 ± 0.58 14.6 ± 0.24 14.1 ± 0.28
C18:3n-3 0.38 ± 0.05 0.37 ± 0.03 0.62 ± 0.11 0.59 ± 0.11
C20:3n-3 0.58 ± 0.19 0.51 ± 0.06 0.75 ± 0.13 0.76 ± 0.14
C22:6n-3 13.8 ± 0.86 13.1 ± 0.37 11.5 ± 0.68aaa 11.7 ± 0.77aa
Σ n-3 14.4 ± 0.86 13.8 ± 0.29 12.9 ± 0.50aa 13.1 ± 0.57b
Σ PUFA 28.5 ± 1.15 27.8 ± 0.56 27.5 ± 0.54 27.2 ± 0.73
Σ UFA 55.3 ± 1.03 55.8 ± 0.77 57.5 ± 0.59aa 56.8 ± 0.41
Table 4.2 The effect of atorvastatin (5 mg/kg/day) on total fatty acid composition of 
aged rat brain. Results are expressed as % weight of total fatty acid (mean ± SD); 
n=5 animals per group. а p < 0.05, аа p < 0.01, ааa p < 0.001 comparing data to 
adult, b p < 0.05 comparing data to aged. 
ATV: atorvastatin, Adult+ATV: adult rats treated with atorvastatin, Aged+ATV: aged rats 
treated with atorvastatin, Adult: adult controls, Aged: aged controls, Σ SFA: total saturated 
fatty acid, Σ MUFA: total monounsaturated fatty acid, Σ n-6: total omega 6 PUFA, Σ n-3: 
total omega 3 PUFA, Σ PUFA: total polyunsaturated fatty acid, Σ UFA: total unsaturated 
fatty acids, ND: not detected.
134
The monounsaturated fatty acid including palmitoleic (C16:1), heptadecenoic 
(C17:1), vaccenic (C18:1n-7), oleic (C18:1n-9), eicosenoic (C20:1n-9) and 
nervonic (C24:1) acids were detected in both adult and aged rat brain. C18:1n-9 
was the most abundant monounsaturated fatty acid, followed by C18:1n-7 in 
both adult and aged rat brain. C16:1 (p = 0.037), C17:1 (p = 0.001) and C18:1n-
9 (p = 0.003), were significantly increased in the aged brain with a concomitant 
significant increase (p = 0.001) in total monounsaturated fatty acids. 
The n-6 PUFA detected in the adult and aged rat brains included C18:2n-6, 
DHGLA, AA and C22:4n-6. AA was the most abundant n-6 PUFA and this was 
followed by C22:4n-6. No age-induced changes were observed for these fatty 
acids and so the total n-6 PUFA in the adult and aged rat brain were not 
significantly different (p = 0.492). This result was in agreement with the 1H-NMR 
results for AA (Table 4.1). Table 4.2 also gave information on the effect of age 
on linoleic acid. This could not be concluded in the 1H-NMR analysis because 
linoleic acid concentration was below the limit of detection of the 1H-NMR 
method. 
The n-3 PUFA detected in the adult and aged rat brains included, C18:3n-3, 
eicosatrienoic acid (C20:3n-3) and DHA. DHA was the most abundant n-3 
PUFA detected in the brain of both adult and aged animals. The concentration 
of DHA was significantly reduced (p < 0.000) in the aged rat brain (Table 4.2). 
This reduction in DHA levels was in agreement with the results obtained in the 
1H-NMR analyses (Table 4.1) indicating that these methods are 
complementary. Furthermore, total n-3 PUFA was significantly reduced (p < 
0.0005) in the aged animals compared to the corresponding adult controls. It is 
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possible that these reductions may be due to the reduced DHA since no other 
n-3 PUFA detected was affected by age. 
Despite the changes in n-3 PUFA, total PUFA concentrations were not 
significantly different (p = 0.294) between the adult and aged rat brains. 
However the total unsaturated fatty acids were significantly increased (p = 
0.028) suggesting that the increase in total monounsaturated fatty acids may 
have caused a major modification of the total unsaturated fatty acid composition 
in the aged rat brain. This increase in total unsaturated fatty acids was in 
agreement with 1H-NMR results, which showed a significant increase (p = 
0.042) in unsaturated fatty acid chains (Table 4.1).
4.3.1.5 Effect of atorvastatin treatment on the adult rat brain fatty acid 
profile
The results of the effect of atorvastatin on the adult rat brain fatty acid profile 
expressed as % weight of total fatty acids (mean ± SD) are summarised in 
Table 4.2. 
Our findings showed that in the adult rat brain, atorvastatin significantly 
increased the concentration of C17:1 (p = 0.037). Also, DHGLA, which was 
detected in the brain of adult animals that did not receive atorvastatin treatment, 
was not detected in the brain of adult animals that received atorvastatin 
treatment (controls). These effects did not cause any changes in the total 
composition of monounsaturated fatty acids (p = 0.151), n-6 PUFA (p = 1.000), 
total PUFA (p = 1.000) and total unsaturated fatty acid composition (p = 0.811) 
in the adult rat brain that received atorvastatin, when compared to the 
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corresponding animals that did not receive atorvastatin. These results suggest 
that in this age group the fatty acid composition was not easily modified by 
atorvastatin treatment.
4.3.1.6 Effect of atorvastatin treatment on the aged rat brain fatty acid 
profile
The results of the effect of atorvastatin on the aged rat brain fatty acid profile 
expressed as % weight of total fatty acids (mean ± SD) are summarised in 
Table 4.2. 
Table 4.2 shows that atorvastatin did not have any effects on the age induced 
reduction in saturated fatty acids. However, in the n-6 PUFA group, DHGLA 
was not detected in the atorvastatin treated aged rat brain but it was detected in 
the brain of aged rats that did not receive atorvastatin as was found in the adult 
group. In addition, although atorvastatin treatment did not affect the age-
induced reduction in DHA concentration, it modified the age-induced reduction 
in total n-3 PUFA (Table 4.2). Atorvastatin significantly increased (p = 0.016) 
the total n-3 PUFA concentration in the aged rat brain. This increased 
concentration of n-3 PUFA was similar to adult animal levels (p = 1.000). It was 
also noted that atorvastatin treatment did not modify the age-induced changes 
in the concentrations of C16:0 and C18:0, and did not alter the total saturated 
fatty acid concentration either. This was in agreement with the 1H-NMR findings. 
In addition, atorvastatin treatment did not modify the age induced increases in 
C18:1n-9 (p = 0.002) and total monounsaturated fatty acids (p = 0.001). 
However, atorvastatin reduced the age-induced increase in total unsaturated 
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fatty acid composition and brought it to levels similar to adult animals (p = 
0.110). This result was also consistent with 1H-NMR results (Table 4.1).
4.3.2 Atorvastatin and liver lipids
1H-NMR analysis of the total lipid extract allowed profiling of the major classes 
of lipids in the liver: phospholipids, sphingolipids, cholesterol and ether lipids, 
the predominant PUFA (DHA and AA), and estimation of the unsaturation index 
defined as a measure of the total number of double bonds per fatty acid chain. 
1H-NMR analysis of lipids did not however permit detailed analysis of fatty acids 
and these were analysed using GC-FID. 
4.3.2.1 Age induced changes in the rat liver lipid profile
The results of the effect of age on the lipid profile of adult rat liver are expressed 
as % mole of lipid classes and % mole of total fatty acid chain including the 
unsaturation index (mean ± SD). These results are summarised in Table 4.3.
When the aged rat liver lipid composition was compared to the adult rat liver 
lipid composition, there were statistically significant increases in the relative 
amounts of n-3 PUFA (p= 0.004), AA (p = 0.008) and unsaturated fatty acid 
chains (p = 0.002) in the aged rat liver. In contrast to this, there was a 
significant reduction in the saturated fatty acid chain (p = 0.002) in the aged rat 
liver compared to the adult rat liver.
In the lipid classes, age caused a significant reduction in the relative amount of 
sphingomyelin (p < 0.0005) but did not modify the relative amounts of the other 
lipid classes analysed by 1H-NMR.
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% mole
Adult Adult + ATV Age Age + ATV
(A) Fatty acid chain
n-3 PUFA 3.84 ± 0.76 3.61 ± 0.77 5.30 ± 0.42aa 5.09 ± 0.67a
Linoleic acid (C18:2n-6) 16.7 ± 2.64 16.4 ± 1.90 17.4 ± 1.36 17.3 ± 2.33
Docosahexaenoic acid (C22:6n-3) 3.68 ± 0.94 3.28 ± 0.67 4.39 ± 0.69 4.14 ± 0.97
Arachidonic acid (C20:4n-6) 15.7 ± 2.38 16.8 ± 1.56 22.3 ± 1.71aa 21.3 ± 1.52a
Unsaturated fatty acid chains 59.7 ± 5.84 57.5 ± 2.96 71.2 ± 3.92aa 66.9 ± 1.03
Saturated fatty acid chains 40.3 ± 5.84 42.5 ± 2.96 28.8 ± 3.92aa 33.1 ± 1.03
Unsaturation index 1.17 ± 0.28 1.12 ± 0.20 1.45 ± 0.08 1.26 ± 0.17
(B) Lipids
Total choline phospholipids 53.8 ± 0.80 53.0 ± 2.77 52.1 ± 3.20 50.0 ± 2.87
             Phosphatidylcholine 48.9 ± 2.24 47.8 ± 2.62 48.3 ± 2.86 46.3 ± 2.81
             Sphingomyelin 5.57 ± 0.68 5.21 ± 0.32 3.72 ± 0.62aaa 3.63 ± 0.44aaa
Total ethanolamine phospholipids 19.1 ± 0.63 19.1 ± 1.87 18.1 ± 2.79 18.1 ± 2.84
Total sphingolipids 5.02 ± 0.72 5.15 ± 0.96 4.74 ± 0.98 4.60 ± 1.13
Cholesterol 13.9 ± 1.15 14.2 ± 1.11 13.9 ± 0.84 14.9 ± 1.62
Plasmalogens 1.06 ± 0.13 1.07 ± 0.26 1.12 ± 0.22 1.09 ± 1.82
Total ether lipids 1.02 ± 0.29 0.85 ± 0.23 1.02 ± 0.18 1.36 ± 0.20
Total diacylglycerophospholipids 80.0 ± 1.78 79.8 ± 1.80 80.3 ± 1.50 78.1 ± 3.22
Table 4.3 The effect of atorvastatin (5 mg/kg/day) on (A) fatty acid and (B) lipid composition of aged rat liver. Results are expressed 
as % mole of total fatty acid chain including the unsaturation index and % mole of lipid classes (mean ± SD); n = 6 animals per group. 
a p < 0.05, aa p < 0.01, aaa p < 0.001 comparing data to adult.
ATV: atorvastatin, Adult+ATV: adult rats treated with atorvastatin, Aged+ATV: aged rats treated with atorvastatin, Adult: adult controls, Aged: 
aged controls.
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4.3.2.2 Effect of atorvastatin treatment on the adult rat liver lipid profile
The results of the effect of atorvastatin on the lipid profile of adult rat liver are 
expressed as % mole of lipid classes and % mole of total fatty acid chain 
including the unsaturation index (mean ± SD). These results are summarised in 
Table 4.3.
Atorvastatin treatment did not affect the lipid composition of the adult rat liver. 
There was no significant difference (p = 1.000) between the relative amounts of 
cholesterol in the adult rat liver that did not receive atorvastatin and the animals 
that received atorvastatin treatment.
4.3.2.3 Effect of atorvastatin treatment on the aged rat liver lipid profile
The results of the effect of atorvastatin on the lipid profile of aged rat liver are 
expressed as % mole of lipid classes and % mole of total fatty acid chain 
including the unsaturation index (mean ± SD). These results are summarised in 
Table 4.3.
In the aged rat liver, it was noted that atorvastatin did not modify the age-
induced increase in AA. However, atorvastatin counteracted the age-induced 
changes in unsaturated and saturated fatty acid chains respectively by bringing 
their concentrations to levels similar to those of adult animals. This was 
concluded because there were no statistically significant differences between 
the unsaturated (p = 0.214) and saturated (p = 0.214) fatty acid chains in the 
liver of the adult animals and the liver of the aged atorvastatin treated animals 
(Table 4.3). Also, atorvasatin did not modify the age-induced decrease in 
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sphingomyelin, as this was still significantly lower (p < 0.0005) than the relative 
amount of sphingomyelin in the liver of adult animals that did not receive 
atorvastatin. Finally, atorvastatin did not affect cholesterol levels in the aged rat 
liver, suggesting it had no direct effects on the synthesis of cholesterol in rat 
liver.
4.3.2.4 Effect of age on rat liver fatty acid profile
Detailed fatty acid profiles of adult and aged rat liver were obtained by GC-FID. 
This allowed the profiling of saturated and monounsaturated fatty acids and 
PUFA (n-6 and n-3). The results, expressed as % weight of total fatty acids 
(mean ± SD) are summarised in Table 4.4.
The saturated fatty acids detected in both adult and aged rat livers were myristic 
acid (C14:0), pentadecanoic acid (C15:0), C16:0, C17:0, C18:0, and lignoceric 
acid (C24:0). C16:0 and C18:0 were the most abundant saturated fatty acids 
detected in both age groups. They represented 20.9 ± 2.6 and 20.8 ± 2.0 % 
weight of total fatty acids respectively in the adult rat liver and 22.9 ± 1.2 and 
14.6 ± 1.6 % weight of total fatty acids respectively in the aged rat liver. In the 
adult rat liver C16:0 and C18:0 were each 49 % of total saturated fatty acids, 
and in the aged rat liver these were 59% and 36 % of total saturated fatty acids 
respectively. Age caused a significant increase in C14:0 (p = 0.006) and a 
significant decrease in C18:0 (p < 0.0005). These modifications however did not
affect the total saturated fatty acid concentration in the aged liver. Although 
there was an increase in the concentration of C16:0, this increase failed to 
reach statistical significance (p = 0.543).
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% weight
Adult Adult + ATV Aged Age + ATV
FATTY ACID
C14:0 0.24 ± 0.09 0.33 ± 0.07 0.49 ± 0.14aa 0.49 ± 0.12aa
C15:0 0.23 ± 0.04 0.23 ± 0.03 0.23 ± 0.04 0.21 ± 0.03
C16:0 20.9 ± 2.57 22.0 ± 2.71 22.0± 0.80 24.3 ± 0.45a
C17:0 0.68 ± 0.06 0.67 ± 0.07 0.57 ± 0.09 0.52 ± 0.11a
C18:0 20.8 ± 1.98 21.7 ± 2.17 14.6 ± 1.82aaa 15.6 ± 0.51aa
C24:0 0.44 ± 0.17 0.43 ± 0.05 0.33 ± 0.05 ND
Σ SFA 42.6 ± 4.25 43.5 ± 2.38 39.0 ± 1.97 42.2 ± 2.57
C16:1 0.30 ± 0.10 0.44 ± 0.21 1.45 ± 0.65aa 1.56 ± 0.59aa
C17:1 0.26 ± 0.01 0.27 ± 0.04 0.29 ± 0.05 0.30 ± 0.01
C18:1n-9 11.0 ± 1.46 12.1 ± 0.74 12.0 ± 1.58 10.8 ± 1.35
C18:1n-7 3.49 ± 0.26 3.08 ± 0.24 4.01 ± 0.33aa 3.63 ± 0.17
C20:1n-9 0.27 ± 0.13 0.38 ± 0.06 0.19 ± 0.02 ND
Σ MUFA 15.7 ± 1.34 15.9 ± 0.95 18.8 ± 1.01a 15.7 ±1.31
C18:2n-6 15.7 ± 0.94 15.5 ± 1.01 15.8 ± 3.27 15.3 ± 0.37
C20:2 0.70 ± 0.10 0.58 ± 0.06 0.40 ± 0.07aaa 0.42 ± 0.11aaa
C20:3n-6 0.74 ± 0.15 0.70 ± 0.15 0.74 ± 0.15 0.87 ± 0.36
C20:4n-6 19.3 ± 3.81 18.9 ± 1.65 19.1 ± 0.79 18.1 ± 0.94
C22:4n-6 0.48 ± 0.08 ND 0.34 ± 0.05 ND
Σ n-6 36.9 ± 4.27 35.4 ± 2.53 36.8 ± 2.03 35.0 ± 1.45
C18:3n-3 0.27 ± 0.08 0.32 ± 0.08 0.51 ± 0.18aa 0.34 ± 0.03
C20:3n-3 0.34 ± 0.04 ND 0.31 ± 0.14 0.47 ± 0.24
C20:5n-3 0.24 ± 0.05 ND 0.42 ± 0.02a 0.34 ± 0.05
C22:5n-3 0.87 ± 0.23 0.74 ± 0.15 0.94 ± 0.18 0.87 ± 0.16
C22:6n-3 3.82 ± 1.33 3.81 ± 0.31 5.72 ± 1.18a 5.62 ± 0.96a
Σ n-3 5.60 ± 1.30 4.70 ± 0.56 7.61 ± 0.85a 7.45 ± 0.89a
Σ PUFA 44.7 ± 1.24 41.6 ± 2.42 44.4 ± 1.11 41.3 ± 1.89
Σ UFA 59.4 ±1.56 56.4 ± 2.75 61.0 ± 2.86a 57.4 ± 2.63
Table 4.4. The effect of atorvastatin (5 mg/kg/day) on total fatty acid composition of 
aged rat liver. Results are expressed as % weight of total fatty acid (mean ± SD); 
n=6 animals per group. а p < 0.05, аа p < 0.01, ааa p < 0.001 comparing data to 
adult. 
ATV: atorvastatin, Adult: adult rats, Adult+ATV: controls treated with atorvastatin, Aged: 
aged rats, Aged+ATV: aged rats treated with atorvastatin, Σ SFA: total saturated fatty acid, 
Σ MUFA: total monounsaturated fatty acid, Σ n-6: total omega 6 PUFA, Σ n-3: total omega 3 
PUFA, Σ PUFA: total polyunsaturated fatty acid, Σ UFA: total unsaturated fatty acids, ND: 
not detected.
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Age also modified the monounsaturated fatty acid composition. There were 
significant age induced increases in the concentration of C16:1 (p = 0.003) and 
C18:1n-7 (p = 0.008). This resulted in the significant increase (p = 0.013) in the 
total monounsaturated fatty acid concentration in the aged rat liver. 
Age induced a significant decrease (p < 0.0005) in the concentration of 
eicosadienoic acid (C20:2). No other effects were observed for n-6 PUFA. 
In the n-3 PUFA group, age induced a significant increase in the concentrations 
of C18:3n-3 (p = 0.007), EPA (p = 0.034) and DHA (p = 0.018). These 
increases may have contributed to the significant increase in total n-3 PUFA (p
= 0.021). In addition, the presence of EPA is in agreement with the 1H-NMR 
analysis, indicating that the increase in the relative amount of AA as noted in 
the 1H-NMR experiment can be attributed to the presence of EPA. Finally, age 
did not cause any significant effects on the total PUFA (p = 1.000) and total 
unsaturated fatty acid (p = 1.000) in the rat liver.
4.3.2.5 Effect of atorvastatin treatment on adult rat liver fatty acid profile
The results of the effect of atorvastatin on adult rat liver fatty acid profile are 
expressed as % weight of total fatty acids (mean ± SD), and are summarised in 
Table 4.4. 
C22:4n-6, C20:3n-3 and EPA were not detected in the liver of adult rats that 
were treated with atorvastatin. However, these changes did not affect total n-6 
PUFA, total n-3 PUFA, and total unsaturated fatty acid concentrations as they 
remained similar to those of the corresponding controls. 
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4.3.2.6 Effect of atorvastatin treatment on aged rat liver fatty acid profile
The results of the effect of atorvastatin on aged rat liver fatty acid profile 
expressed as % weight of total fatty acids (mean ± SD) are summarised in 
Table 4.4. 
Lignoceric acid (C24:0) was detected in the atorvastatin treated aged rat liver. 
Atorvastatin further increased the concentration of C16:0 (p = 0.014) when 
compared with adult animals. Additionally, total saturated fatty acid 
concentration was not affected by the atorvastatin treatment. 
In monounsaturated fatty acids, atorvastatin did not affect the age-induced 
increase in C16:1 but it was found to counteract the increase in C18:1n-7 and 
the total concentration of monounsaturated fatty acids. This effect brought the 
concentration of C18:1n-7 and total monounsaturated fatty acid concentration to 
levels similar to those of adult animals. In addition, C20:1n-9 was not detected 
in the liver of aged animals that received atorvastatin treatment. This may also 
have contributed to bringing the total concentration of monounsaturated fatty 
acids in the aged rat liver to levels similar to those of adult animals that were not 
treated with atorvastatin. 
In the n-6 PUFA, C18:2n-6, DHGLA and AA were not affected by the 
atorvastatin treatment in the aged rat liver. Although C22:4n-6 was not detected 
in the atorvastatin treated livers, and the age induced decrease in C20:2 was 
not modified by the atorvastatin treatment, the total concentration of n-6 PUFA 
was not affected. 
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The effects of atorvastatin observed in the n-3 PUFA include a reduction of 
C18:3n-3 (p = 1.000) and EPA (p = 0.195) concentrations to levels similar to 
those found in adult animals. However, atorvastatin had no effects on the age-
induced increase in DHA and total n-3 PUFA concentrations since these were 
still significantly increased (p = 0.025 and p = 0.042 respectively). 
Finally, total PUFA and unsaturated fatty acid concentrations in the atorvastatin 
treated aged rat livers were not significantly different from their corresponding 
controls and from those of the adult animals. 
4.3.3 Atorvastatin levels in brain, liver and serum of adult and aged rats
Tissue samples from brain, liver and serum of adult and aged rats that were 
treated with atorvastatin supplementation were analysed for atorvastatin and its 
metabolites. The LC/ES-MS/MS assay developed in this study (Chapter 3) was 
used for this purpose. The results obtained are shown in Table 4.5. The results 
are expressed as mean (ng metabolite / mg protein) ± SD. The amounts of 
atorvastatin, ortho-hydroxyatorvastatin and para-hydroxyatorvastatin were close 
to the limits of quantitation of the method so no statistical analysis were 
performed for levels in the different tissues of the animal groups.
In the adult rat brains atorvastatin, ortho-hydroxyatorvastatin and para-
hydroxyatorvastatin were not detected. However, in the aged brains, 
atorvastatin was detected, but the metabolites, ortho-hydroxyatorvastatin and 
para-hydroxyatorvastatin were not detected. 
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(ng metabolite / mg protein)
Adult rats Aged rats
Tissue ATV o-ATV p-ATV ATV o-ATV p-ATV
Brain ND ND ND 0.04 ± 0.01 ND ND
Liver 0.26 ± 0.12 0.06 ± 0.04 0.05 ± 0.03 0.20 ± 0.11 0.04 ± 0.02 0.04 ± 0.03
Serum 0.01 ± 0.01 0.02 ± 0.00 ND ND ND ND
Table 4.5 Concentration of atorvastatin (ATV), ortho-hydroxyatorvastatin (o-ATV), para-hydroxyatorvastatin (p-ATV) in brain, 
liver and serum of adult and aged rats. Results are expressed as mean (ng metabolite / mg protein) ± SD, n = 6 animals per 
group. 
ND: Not detected
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In the adult and aged rat livers, atorvastatin, ortho-hydroxyatorvastatin and 
para-hydroxyatorvastatin were detected. Higher concentrations of atorvastatin, 
ortho-hydroxyatorvastatin and para-hydroxyatorvastatin were detected in the 
liver than in the brain and serum of both adult and aged animals. 
In the adult rat serum small amounts of atorvastatin and ortho-
hydroxyatorvastatin were detected but para-hydroxyatorvastatin was not 
detected. In the aged rat serum, atorvastatin, ortho-hydroxyatorvastatin and 
para-hydroxyatorvastatin were not detected.
4.4 Discussion
Age induces structural and biochemical changes in the brain that have been 
associated with alterations in neuronal cell membrane lipid composition. These 
effects have been linked to brain dysfunction such as memory decline, cognitive 
dysfunction and reduction in learning abilities (Bourre, 2004, Kessler and 
Yehuda, 1985). The liver plays a crucial role in the metabolism of lipids in the 
whole body and contributes appreciably to the composition of brain lipids. Age
related changes in lipid composition especially fatty acid composition, have also 
been reported to occur in the liver (Tamburini et al., 2004, Youdim and Deans, 
1999).
Atorvastatin is a potent statin whose target tissue is the liver, and has been 
reported to have neuroprotective effects beyond its cholesterol lowering effects 
in mammals such as mice, rats and humans (Bosel et al., 2005, Laufs et al., 
2000, Lu et al., 2004). In addition, it has been shown to affect fatty acid 
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metabolism in vitro at a concentration lower than that needed to inhibit 
cholesterol biosynthesis (Rise et al., 2005). 
Thus the present study evaluated the age-induced changes in the lipid 
composition of the rat brain and liver and investigated the effects of atorvastatin 
on the individual lipid classes. We aimed that this investigation will enhance our 
understanding of the molecular mechanism of atorvastatin neuroprotective 
action.
The findings from this study clearly show that ageing affected the brain lipid 
profile (Tables 4.1 and 4.2). These effects included significant reductions in the 
relative amounts of PC, total choline phospholipids, total ethanolamine 
phospholipids and total diacylglyecrophospholipids, with a concomitant increase 
in the relative amounts of total sphingolipids and cholesterol. Furthermore, it 
was noted that ageing reduced DHA and total unsaturated fatty acid chains. 
These effects are in agreement with previous findings and are considered to 
contribute to membrane rigidity, an effect implicated in neurodegeneration and 
behavioural deficiencies (Joseph et al., 1997, Levant et al., 2004, Yehuda et al., 
2002). 
It has previously been shown that ageing reduces C16:0 and C18:0 in the rat 
brain (Ulmann et al., 2001). Our results were in agreement with this finding. 
Further to this, despite the detection of more saturated fatty acids, such as 
C17:0 and C23:0 in the aged brain, the reduction in C16:0 and C18:0 total 
saturated fatty acid concentration was reduced in the age rat brain. This further 
shows that C16:0 and C18:0 are the major saturated fatty acids in the rat brain.
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There was also an age induced increase in total monounsaturated fatty acids 
which was contributed to by C18:1n-9 and C17:1. It is suggested that C18:1n-9 
stimulates the biosynthesis of cholesterol in the liver (Goh and Heimberg, 
1973). This process may also occur in the brain since the brain is capable of 
synthesizing cholesterol and fatty acids like the liver (Bjorkhem et al., 1998, 
Cook, 1978). In the ageing brain, cholesterol content is increased and the 
present findings support this. Furthermore, it has been reported that in the aged 
rat brain, increased cholesterol enhances Δ9 desaturase activity and inhibits Δ6 
desaturase and Δ5 desaturase activities (Cook and Spence, 1973). This may 
lead to reduced metabolism of C18:2n-6 and C18:3n-3 and subsequent deficits 
in n-6 and n-3 PUFA such as AA and DHA as have been reported for the
ageing brain (Lopez et al., 1995). In addition, the decrease in C18:0 from our 
findings, may reflect an enhanced metabolism to C18:1n-9. The increase in 
monounsaturated fatty acid may also explain the increase in total unsaturated 
fatty acids seen in the aged rat brain.
Treatment with atorvastatin was found to have no effect on age-induced 
alterations in phospholipids, sphingolipids and cholesterol but it significantly 
reduced the unsaturation index and reduced unsaturated fatty acid chains to 
levels similar to those of adult animals (Table 4.1). The effect of atorvastatin in 
the brain is still unclear because the extent of its blood brain barrier penetration 
is not well established unlike that of simvastatin and lovastatin, which are known 
to be highly lipophilic (Christians et al., 1998). Moreover, the lipophilicity of 
atorvastatin is still debatable (Serajuddin et al., 1991, Sparks et al., 2002). 
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Detailed fatty acid analysis showed that atorvastatin treatment significantly 
increased C18:2n-6 concentration in the aged rat brain. In addition, DHGLA was 
not detected in the aged rat brain but was detected in the atorvastatin treated 
aged rat brain (Table 4.2). This effect could mean that atorvastatin enhanced 
the complete conversion of DHGLA to AA in the n-6 pathway. This suggestion 
may be supported by the finding that atorvastatin enhances the conversion of 
C18:2n-6 to AA (Rise et al., 2003). 
It has been shown that oral administration of atorvastatin in experimental 
traumatic brain injury, reduces neurological functional deficits, increases 
neuronal survival, synaptogenesis and angiogenesis in the rat hippocampus (Lu
et al., 2004). n-3 PUFA are thought to have anti-inflammatory effects, improve 
neuronal loss in nerve injury and in aged animals and are important for neuronal 
membrane structure and function (King et al., 2006, Little et al., 2007, Lukiw et 
al., 2005). Our findings showed that atorvastatin counteracted the age-induced 
reduction in total n-3 PUFA by restoring its concentration to levels similar to 
those of adult animals (Table 4.2). This suggests that atorvastatin may act by 
enhancing n-3 PUFA metabolism that is compromised in the ageing brain.
Findings from liver lipid analysis (Table 4.3) showed that age caused a 
significant increase in the relative amounts of n-3 PUFA, AA, unsaturated and 
saturated fatty acid chains. It also caused a significant reduction in the relative 
amount of sphingomyelin. However, age did not affect the other classes of lipids 
including phospholipids, cholesterol, total sphingolipids and ether lipids. Also, 
age did not affect PC concentration and this is contrary to a previous finding in 
the 18 month rat liver where PC concentration was reduced (Miyazawa et al., 
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1993). In the mouse liver, age was shown not to affect phospholipid and 
cholesterol content and it was shown that in the aged rat liver, cholesterol levels 
are stable and may not alter with age (Marino et al., 2002, Wood et al., 1986). 
This may also be an indication that cholesterol is differentially metabolised in rat 
brain and liver. This ability of the liver to maintain stable cholesterol content may 
stem from its crucial role in maintaining cholesterol homeostasis in the whole 
body (Dietschy et al., 1993, Yao et al., 2007). It has also been suggested that in 
the aged rat, the liver may be able to maintain its cholesterol homeostasis by 
balancing increased cholesterol synthesis with an increase in release into the 
blood (Marino et al., 2002). 
Detailed fatty acid analysis in the liver showed that ageing affected the 
concentration of individual fatty acids without affecting the total amount of 
individual fatty acid classes except for total monounsaturated fatty acids (Table 
4.4). It has previously been reported that age may cause a decrease in 
monounsaturated fatty acids (Tamburini et al., 2004). However, our finding that 
age induced a significant increase in DHA supports previous studies, which 
showed age-induced increases in DHA and n-3 PUFA in the aged liver 
(Tamburini et al., 2004, Youdim and Deans, 1999). The increase in DHA and n-
3 PUFA may be a compensatory feedback response of the liver as a 
consequence of the decrease of the content of DHA and n-3 PUFA in the aged 
brain. Reports show that in addition to supply from de novo metabolism and 
diet, the brain also gets it supply of PUFA including DHA (C22:6n-3) from the 
liver (Rapoport et al., 2007, Scott and Bazan, 1989, Sheaff et al., 1995). 
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Despite these age-induced alterations in individual fatty acids observed in this 
study, the liver was able to maintain its total composition of PUFA, but total 
unsaturated fatty acid concentration was increased. 
In both adult and aged rat liver, atorvastatin did not alter the concentration of 
cholesterol. It has previously been shown that atorvastatin reduces plasma 
triacylglycerol and not plasma cholesterol levels in rats because rats secrete 
more VLDL than LDL (Krause and Newton, 1995). Moreover previous findings 
show that statins do not have a hypocholesterolemic effect on normolipidemic 
mice and rats (Endo et al., 1979) and that statins do not reduce cholesterol 
concentration in normolipidemic rodent livers (Fujioka and Tsujita, 1997). This 
effect is attributed to the feedback compensatory upregulation of HMG-CoA 
reductase activity and a reduction of cholesterol-7α-hydroxylase activity 
resulting from inhibition of cholesterol synthesis in the liver (Bergstrom et al., 
1998, Fujioka and Tsujita, 1997). 
Additionally, detailed fatty acid analysis in the adult liver showed that 
atorvastatin treatment may have affected PUFA metabolism without affecting 
total PUFA concentration (Table 4.4). A previous study demonstrated that 
statins are able to enhance the conversion of C18:2n-6 and EPA to their long 
chain PUFA derivatives in cells (Rise et al., 1997). Thus our findings in the adult 
rat brain may indicate that atorvastatin enhanced the conversion of C20:3n-3 
and EPA to their longer chained derivatives docosapentaenoic acid (C22:5n-3) 
and DHA, since these two precursors were not detected in the adult rat liver of 
animals that were treated with atorvastatin.
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In the aged liver, atorvastatin reduced the age-induced increase in C18:1n-7 to 
levels similar to those found in the adult rat liver and C20:1n-9 was not detected 
(Table 4.4). These findings may have resulted in the reduction of the age-
induced increase in total monounsaturated fatty acids in the aged rat liver to 
levels similar to those of adult rats. Furthermore, C22:4n-6 was not detected in 
the aged rat liver indicating that atorvastatin may have enhanced its β-oxidation 
to AA. As in the aged brain, atorvastatin did not affect AA concentrations in the 
liver. However, it has been shown that atorvastatin stimulates AA release in rat 
liver cells (Levine, 2003). It may be possible that atorvastatin is capable of 
balancing this release with increased synthesis and incorporation back into 
phospolipids since reports have also shown that statins enhance C18:2n-6 
metabolism to its longer chained PUFA (Rise et al., 1997, Rise et al., 2003). 
Furthermore, it may be possible that atorvastatin may have enhanced n-3 PUFA 
pathway in the liver for supply to the brain without affecting the n-6 PUFA 
pathway since age did not induce any deficits in the AA in the brain.
We also detected small amounts of atorvastatin in the aged rat brain but not the 
adult rat brain (Table 4.5). This suggests that atorvastatin penetrated the blood 
brain barrier and entered the brain. This penetration may have occurred by 
passive diffusion into the brain or by a possible age induced impairment of the 
blood brain barrier. Indeed reports have shown that age compromises the blood 
brain barrier (Pelegri et al., 2007). Further to this, inflammation has been shown 
to down regulate CYP450 mixed function enzymes in the brain (Nicholson and 
Renton, 1999) and atorvastatin is a substrate for CYP450 metabolism. Although 
statin metabolism in the brain is not clear (Johnson-Anuna et al., 2005), the 
effect of age induced neuroinflammation may also affect its metabolism in the 
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brain. This may result in a reduction in the metabolism of atorvastatin to its 
hydroxy metabolites and may also explain why atorvastatin alone was detected 
in the aged brain. 
Atorvastatin and its metabolites, ortho-hydroxyatorvastatin and para-
hydroxyatorvastatin were detected in the adult and aged rat liver. The amount of 
atorvastatin detected in the liver was higher than the amounts found in the brain 
and plasma. Also ortho-hydroxyatorvastatin and para-hydroxyatorvastatin were 
not detected in the brain and serum. This may not be entirely surprising since 
the liver is the major site of atorvastatin metabolism and reports have also 
shown that atorvastatin has a higher distribution in the liver than in the brain and 
plasma (Black et al., 1999, Chen et al., 2007).
It is well established that first pass metabolism in the liver and transporter 
mediated process often limit the bioavailability of orally administered drugs (Lau
et al., 2006). Atorvastatin undergoes extensive gut and liver metabolism by 
CYP3A (the most abundant CYP450 enzyme expressed in both gut and liver), 
which results in low plasma concentrations in dogs, rats and human (Black et 
al., 1999, Hermann et al., 2005). Concentrations reported in human plasma 
include 12.5 ng/ml for atorvastatin, and 0.5 ng/ml and 0.4 ng/ml for ortho-
hydroxyatorvastatin and para-hydroxyatorvastatin respectively (Hermann et al., 
2005). Para-hydroxyatorvastatin was not detected in adult rat serum while very 
small amounts of atorvastatin and ortho-hydroxyatorvastatin were detected in 
adult rat serum (Table 4.5). In a previous finding, considerably low levels of 
para-hydroxyatorvastatin was found in rat plasma compared to atorvastatin and 
ortho-hydroxyatorvastatin (Black et al., 1999). However, it is also possible that 
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the para-hydroxyatorvastatin concentration in the adult rat serum was too low to 
be detected by the LC/ESI-MS/MS assay developed in this project. 
Furthermore, CYP3A inhibitors such as erythromycin, have been shown to 
increase plasma concentrations of atorvastatin by inhibition of first-pass 
conversion of atorvastatin to inactive metabolites and by inhibition of p-
glycoprotein-mediated intestinal or biliary secretion (Siedlik et al., 1999).
Overall, findings from this study collaborate evidence that age induces 
alterations in lipid composition in the rat brain and liver. Atorvastatin modulated 
some of these effects without affecting cholesterol content thus further 
establishing the cholesterol independent effects of atorvastatin. Additionally, the 
findings in this study further highlight the effects of statins in the lipid 
biochemistry of normolipidemic rats.
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5.0 THE EFFECT OF ATORVASTATIN ON 
LIPOPOLYSACCHARIDE-INDUCED INFLAMMATION
5.1 Introduction
Lipopolysacchride (LPS) is a conjugate of a hydroxyl fatty acid attached to an 
oligosaccharide and is the principal cell wall component of the Gram-negative 
bacteria. When administered peripherally it induces inflammatory and 
immunological responses such as fever, injury and neurological cell death 
(Nolan et al., 2003, Singh and Jiang, 2004). LPS binds to Toll-like receptors 
(TLR), a group of transmembrane proteins that play critical roles in immune 
responses. The mammalian TLR (TLR4) are mainly expressed on cells such as 
macrophages and dendritic cells (Hoshino et al., 1999). When LPS binds to 
TLR, it activates immune cells such as macrophages to stimulate 
proinflammatory cytokines, trigger the innate immunity as well as establish 
adaptative immunity (Deiters et al., 2003). 
Inflammatory changes characterised by an increase in the concentration of 
proinflammatory cytokines such as interleukin 1β (IL-1β) have been observed in 
rats (Barry et al., 2005) and mice (Godbout et al., 2005) treated with LPS. 
Cytokines are known to cause altered brain neurotransmitter release that 
results in behavioural responses typical of neurological disorders such as 
depression and schizophrenia (Garcia-Bueno et al., 2008, Schiepers et al., 
2005). Based on this evidence, LPS-induced brain inflammation has been used 
as a model system to study the possible mechanisms involved in these 
disorders including depression, Alzheimer’s disease and Parkinson’s disease 
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(Bluthe et al., 1999, Castanon et al., 2001, Godbout et al., 2005, Hernandez-
Romero et al., 2008, Watanabe et al., 2004).
Evidence suggests that the response to infection and inflammation induced by 
LPS may have substantial effects on the regulation of lipid metabolism in 
different tissues (Khovidhunkit et al., 2004). In the brain, it was reported that 
LPS increased free C18:2n-6 and AA but did not affect C16:0, C18:0, C18:1n-9 
and DHA (Rosenberger et al., 2004). Furthermore, administration of LPS has 
been shown to induce COX-2 in the central nervous system and in rat microglia 
(Minghetti and Levi, 1995, Schiltz and Sawchenko, 2002). COX-2 mediates the 
biosynthesis of potent inflammatory lipid mediators such as prostaglandins from 
AA (Akundi et al., 2005, Jackson et al., 2000, Minghetti and Levi, 1995, Mitchell
et al., 1993). 
In general, excessive amounts of n-6 PUFA and a very high n-6/n-3 PUFA ratio 
is considered to promote the pathogenesis of many diseases including those 
characterised by inflammatory disorders (Kang, 2003). In addition, studies 
demonstrate that LPS administration may not affect the profiles of brain 
cholesterol, sphingolipids and phospholipids (Kheir-Eldin et al., 2001, Memon et 
al., 2001, Rosenberger et al., 2004) In the liver, it is reported that LPS 
specifically upregulates hepatic HMG-CoA reductase activity and not the 
activities of HMG-CoA synthase, farnesyl pyrophosphate and squalene 
synthase (Feingold et al., 1995, Memon et al., 2001, Memon et al., 1997). LPS 
also downregulates hepatic cholesterol 7α-hydroxylase and cholesterol 27-
hydroxylase that both catalyse cholesterol catabolism (Memon et al., 2001). 
Evidence also shows that the de novo sphingomyelin and fatty acid synthesis 
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may be stimulated by LPS treatment in the liver (Feingold and Grunfeld, 1987, 
Feingold et al., 1991, Memon et al., 1998). 
Based on the anti-inflammatory and immunomodulatory effects reported for 
atorvastatin (Bustos et al., 1998), the present study tried to evaluate the effects 
of atorvastatin on changes in the brain and liver lipid composition, which may be 
induced by LPS, with a view to gain more insight into its molecular mechanism 
of action. 
5.2 Study design
In this study, 24 2-3 month old adult male Wistar rats were used. The animals 
were divided into two groups of 12 rats. One group served as the control group 
and received normal chow while the other group received an exprimental diet of 
atorvastatin (5 mg/kg/day) for 3 weeks. At the end of the 3 weeks treatment 
period, the control and atorvastatin treated animal groups were subdivided into 
those that received saline (0.9 % w/v) intraperitoneally and those that received 
lipopolysaccharide (100 µg/kg in sterile 0.9 % w/v saline). Saline was the 
vehicle used to administer LPS to adult rats and controls were administered 
saline only. Animals were sacrificed by decapitation three hours after 
intraperitoneal injection of saline and LPS. 
All materials and method used in this study are described in Chapter 2 (sections 
2.1, 2.2, 2.3.1, 2.4, 2.5, 2.6, 2.7, 2.8 and 2.9).
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5.3 Results
5.3.1 Effect of LPS and atorvastatin treatment on rat brain lipid profiles
1H-NMR analysis was performed on the total lipid extract obtained from adult 
control (saline-administered) and LPS-treated rat cortical tissue. This was also 
followed by GC-FID analysis for detailed fatty acid profiling. 
5.3.1.1 Effect of LPS on the lipid profile of adult rat brain
The results of the effect of LPS on the lipid profile of adult rat brain are 
expressed as % mole of lipid classes and % mole of total fatty acid chain 
including the unsaturation index (mean ± SD). These results are summarised in 
Table 5.1. 
The brain lipid profile of adult control (saline-treated) rats was similar to that of 
the adult rats used in the previous study (Table 4.1, Chapter 4). The brain lipid 
profile of adult control rats was compared to the brain lipid profile of LPS-treated 
rats. There were no significant differences between the brain lipid profiles of the 
two animal groups. 
5.3.1.2 Effect of atorvastatin on adult LPS-treated rat brain lipid profile
The results of the effects of atorvastatin on the lipid profile of adult LPS-treated 
rat brain are summarised in Table 5.1. The results are expressed as % mole of 
total lipid classes and % mole of total fatty acid chain including the unsaturation 
index (mean ± SD).
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% mole
Saline Saline + ATV LPS LPS + ATV
(A) Fatty acid chain
n-3 fatty acids 9.40 ± 0.63 8.61 ± 0.73 8.54 ± 0.26 8.42± 0.64
Linoleic acid (C18:2n-6)* 3.35 ± 0.46 2.68 ± 0.18 3.39 ± 0.16 2.03 ± 0.21
Docosahexaenoic acid (C22:6n-3) 10.8 ± 1.35 9.59 ± 1.19 9.52 ± 0.33 10.0 ± 0.96
Arachidonic acid (C20:4n-6) 10.4 ± 0.87 9.36 ± 0.21 9.80 ± 0.26 9.23 ± 0.50a
Unsaturated fatty acid chains 53.5± 1.99 54.0 ± 3.02 54.3 ± 1.23 53.7 ± 1.94
Saturated fatty acid chains 46.5 ± 1.99 46.0 ± 3.02 45.7 ± 1.23 46.3 ± 1.94
Unsaturation index 1.15 ± 0.08 1.06 ± 0.08 1.02 ± 0.02 1.09 ± 0.06
(B) Lipids
Total choline phospholipids 25.5 ± 3.08 22.9 ± 1.35 22.8 ± 0.91 22.9 ± 0.69
         Phosphatidylcholine 22.0 ± 2.46 20.0 ± 1.23 19.8 ± 0.82 20.0 ± 0.66
         Sphingomyelin 3.51 ± 0.63 2.94 ± 0.22 2.95 ± 0.11 2.90 ± 0.26
Total ethanolamine phospholipids 22.9 ± 1.46 21.7 ± 0.87 22.0 ± 0.92 21.6 ± 0.45
Total sphingolipids 12.0 ± 2.50 14.3 ± 0.63 14.1 ± 1.18 13.8 ± 0.26
Cholesterol 37.2 ± 0.73 37.2 ± 0.41 36.4 ± 1.35 36.6 ± 1.03
Plasmalogens 11.1 ± 0.25 10.8 ± 0.36 10.6 ± 0.38 10.8 ± 0.42
Total ether lipids 11.3 ± 0.49 11.9 ± 0.22 12.0 ± 1.12 11.5 ± 0.45
Total diacylglycerophospholipids 39.6 ± 3.63 36.7 ± 0.73 37.5 ± 1.25 38.2 ± 1.33
Table 5.1 The effect of atorvastatin (5 mg/kg/day) on (A) fatty acid and (B) lipid composition of LPS-treated adult rat brain. Results are 
expressed as % mole of total fatty acid chain including the unsaturation index and % mole of lipid classes (mean ± SD); n = 6 animals 
per group. a p < 0.05 comparing data to saline.
* The level of linoleic acid was close to the limit of detection of the method therefore no statistical anaylsis was performed. Saline: controls 
administered saline, Saline+ATV: controls administered saline and atorvastatin, LPS: lipopolysaccharide-treated rats, LPS+ATV: 
lipopolysaccharide-treated rats administered atorvastatin.
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The atorvastatin treatment did not alter cholesterol concentration and did not 
have any effects on the other major lipid classes analysed in this group. 
Atorvastatin further decreased the concentration of AA in the LPS-treated rat 
brain (p = 0.031). This indicates that atorvastatin may have direct effects on the 
metabolism of AA in the brain.
5.3.1.3 Effect of LPS treatment on rat brain fatty acid profile.
Detailed fatty acid profiles were obtained by GC-FID. The results of the effect of 
LPS-treatment on rat brain fatty acid profile are expressed as % weight of total 
fatty acids (mean ± SD) and are summarised in Table 5.2. 
Similar to findings in the previous chapter, the main saturated fatty acids 
detected were C16:0 and C18:0 and their concentrations were not affected by 
the LPS treatment (p = 0.550 and 1.000 respectively). 
The monounsaturated fatty acids detected in the LPS-treated rat brains were 
C16:1, C17:1, C18:1n-9, C18:1n-7, C20:1n-9 and C24:1. C24:1 was not 
detected in the control rat brain. Furthermore, C18:1n-9 was significantly 
increased (p = 0.020) in the LPS-treated rat brain compared to the control rat 
brain. There was also a statistically significant increase (p = 0.013) in the total 
monounsaturated fatty acid concentration in the LPS-treated rat brain compared 
to the control rat brain.
The n-6 PUFA detected in the LPS-treated rat brains were C18:2n-6, AA and 
C22:4n-6. The concentrations of these fatty acids were not significantly different 
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% weight
Saline Saline + ATV LPS LPS + ATV
FATTY ACID
C16:0 22.0 ± 1.14 19.5 ± 1.11aaa 22.0 ± 0.63 20.1 ± 0.38aaa, b
C18:0 22.4 ± 0.76 22.0 ± 0.61 22.8 ± 1.93 22.2 ± 0.43
C20:0 ND 1.15 ± 0.30 ND 0.94 ± 0.27
C22:0 ND 0.46 ± 0.11 ND 0.37 ± 0.07
C24:0 ND 0.54 ± 0.09 ND 0.45 ± 0.18
Σ SFA 45.4 ± 1.56 44.8 ± 0.73 44.5 ± 1.40 44.1 ± 0.68
C16:1 0.35 ± 0.03 0.28 ± 0.10 0.40 ± 0.09 0.35 ± 0.01
C17:1 1.86 ± 0.14 1.77 ± 0.46 2.10 ± 0.47 1.97 ± 0.08
C18:1n-9 17.7 ± 0.91 17.6 ± 0.81 19.9 ± 1.18a 17.8 ± 0.40b
C18:1n-7 3.39 ± 0.24 3.51 ± 0.19 3.75 ± 0.36 3.49 ± 0.08
C20:1n-9 0.81 ± 0.35 1.35 ± 0.12aa 1.14 ± 1.09 1.33 ± 0.09aa, bb
C22:1n-9 ND 1.18 ± 0.40 ND 1.05 ± 0.33
C24:1 ND 1.50 ± 0.20 1.09 ± 0.81 1.39 ± 0.42
Σ MUFA 22.1 ± 1.14 25.2 ± 0.94a 26.1 ± 2.95a 25.0 ± 0.87a
C18:2n-6 0.54 ± 0.07 0.63 ± 0.04 0.61 ± 0.11 0.66 ± 0.04aa
C20:4n-6 12.0 ±0.79 10.2 ± 0.76aa 11.3 ± 0.75 10.4 ± 0.25aa
C22:4n-6 3.39 ± 0.28 3.28 ± 0.27 3.37 ± 0.23 3.09 ± 0.62
Σ n-6 16.0 ± 0.67 14.1 ± 1.05a 15.1 ± 0.70 14.4 ± 0.34a
C20:3n-3 ND ND 0.44 ± 0.16 0.53 ± 0.06
C22:6n-3 13.7 ± 1.02 13.4 ± 0.96 13.7 ± 2.63 14.2 ± 1.03
Σ n-3 13.7 ± 1.02 13.4 ± 0.96 13.9 ± 2.77 14.6 ± 0.86
Σ PUFA 29.4 ± 1.64 27.5 ± 1.99 27.5 ± 1.53 28.8 ± 1.11
Σ UFA 50.7 ± 1.83 52.7 ± 2.79 51.8 ± 2.71 53.8 ± 0.44
Table 5.2 The effect of atorvastatin (5 mg/kg/day) on total fatty acid composition of 
LPS-treated adult rat brain. Results are expressed as % weight of total fatty acid 
chain or lipid (mean ± SD): n = 6 animals per group. а p < 0.05, аа p < 0.01, ааa p < 
0.001 comparing data to saline, b p < 0.05, bb p < 0.01 comparing data to LPS. 
Saline: controls administered saline, Saline+ATV: controls administered atorvastatin, LPS: 
lipopolysaccharide-treated rats, LPS+ATV: lipopolysaccharide-treated rats administered 
atorvastatin, Σ SFA: total saturated fatty acid, Σ MUFA: total monounsaturated fatty acid, Σ n-6: 
total omega 6 PUFA, Σ n-3: total omega 3 PUFA, Σ PUFA: total polyunsaturated fatty acid, Σ 
UFA: total unsaturated fatty acids, ND: not detected.
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(p = 1.000, 0.412 and 1.000 respectively) from those of adult controls. This 
information also helped to conclude the effect of LPS on C18:2n-6 in the brain 
because it was not possible to do so in the 1H-NMR analysis as C18:2n-6 was 
below the limit of detection of that method. Overall, the total n-6 PUFA 
concentrations of the LPS-treated rat brain compared to the control rat brain 
were not statistically different (p = 1.000).
In the LPS-treated rat brain, the n-3 PUFA detected were C20:3n-3 and DHA 
but only DHA was detected in the corresponding controls. However, the total 
concentration of n-3 PUFA in the two groups was not significantly different (p = 
1.000).
Generally, LPS did not influence the total concentration of PUFA and 
unsaturated fatty acids in the control rat brain (p = 1.000 and 0.684 
respectively). This suggests that although LPS treatment altered the 
concentrations of monounsaturated fatty acids, it did not alter the general 
distribution of unsaturated fatty acids in the brain. These results are also 
comparable to those obtained from 1H-NMR analysis.
5.3.1.4 Effect of atorvastatin treatment on the adult rat brain fatty acid 
profile
The effect of atorvastatin (administered to animals for 3 weeks) on the adult rat 
brain fatty acid profile are summarised in Table 5.2. The results are expressed 
as % weight of total fatty acids (mean ± SD).
Some differences in the effect of atorvastatin on the adult rat brain fatty acid 
profile were observed in this study compared to the previous study (Table 4.2). 
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Atorvastatin treatment caused a statistically significant reduction (p < 0.000) in 
the concentration of C16:0 in this study, but it had no effects on this fatty acid in 
the aged study. In addition, arachidic acid (C20:0) and behenic acid (C22:0) 
were not detected in the controls in the aged and LPS studies but were 
detected in the corresponding atorvastatin treated rat brains in the LPS study. 
In the aged study, atorvastatin affected the concentration of C17:1 and did not 
affect the concentration of C20:1n-9. Conversely, in the LPS study, atorvastatin 
was found to have no affect on the concentration of C17:1, it significantly 
increased the concentration of C20:1n-9 (p = 0.005), C22:1n-9 and C24:1 were 
detected and total monounsaturated fatty acids was increased (p = 0.040). 
Furthermore, atorvastatin did not influence AA and total n-6 PUFA in the aged 
study but significantly reduced AA (p = 0.002) and total n-6 PUFA (p = 0.017) in 
the LPS study. 
5.3.1.5 Effect of atorvastatin on LPS-treated rat brain fatty acid profile
The results of the effects of atorvastatin on the fatty acid profile of adult LPS-
treated rat brain are summarised in Table 5.2. The results are expressed as % 
weight of total fatty acids (mean ± SD).
LPS did not affect the concentration of C16:0 in the adult rat brain but 
atorvastatin significantly reduced (p = 0.029) its concentration. Small amounts 
of C20:0, C22:0 and C24:0 were also detected with atorvastatin treatment. 
However, atorvastatin did not influence the total saturated fatty acid 
concentration in the LPS-treated rat brain (p = 1.000). 
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LPS increased C18:1n-9 and this effect was reversed by atorvastatin (p = 
0.014). This reversal resulted in similar levels of C18:1n-9 in both control and
LPS-treated rats (p = 1.000). LPS did not have any effects on C20:1n-9 but 
atorvastatin enhanced (p = 0.001) C20:1n-9 concentration in the LPS-treated 
rat brain. This increase was also significantly higher (p = 0.008) than the 
concentration of controls. C22:1n-9 was not detected in the LPS-treated rat 
brain but was detected in the corresponding atorvastatin treated animals. LPS 
treatment increased total monounsaturated fatty acid concentration in the rat 
brain and this effect was not altered by atorvastatin (p = 1.000), thus the 
monounsaturated fatty acid concentration after atorvastatin treatment was also 
significantly higher than levels in controls (p = 0.05).
LPS treatment caused an increase in C18:2n-6 concentration which did not 
reach significant levels, but this effect was enhanced by atorvastatin resulting in 
a significant increase (p = 0.009) in C18:2n-6 levels compared to those of 
controls. Atorvastatin further reduced (p = 0.005) the AA concentration of LPS-
treated rat brain. A similar trend was noted for the concentration of total n-6 
PUFA in the LPS-treated rat brain (p = 0.017). No significant effects of 
atorvastatin were observed for the n-3 PUFA, total PUFA and total unsaturated 
fatty acids in animals that were treated with LPS. 
5.3.2 Effect of LPS and atorvastatin treatment on rat liver lipid profiles
1H-NMR analysis was performed on the total lipid extract obtained from adult 
control and LPS-treated rat liver. This was also followed by GC-FID analysis for 
detailed fatty acid profiling. 
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5.3.2.1 Effect of LPS on the lipid profile of adult rat liver
The results of the effect of LPS on the lipid profile of adult rat liver are 
expressed as % mole of lipid classes and % mole of total fatty acid chain 
including the unsaturation index (mean ± SD). These results are summarised in 
Table 5.3.
The liver lipid profile of adult control rats was compared to the liver lipid profile 
of LPS-treated rats. There were no significant differences between the liver lipid 
profiles of these two animal groups.
5.3.2.2 Effect of atorvastatin on adult rat liver lipid profile
The effect of atorvastatin (administered to animals for 3 weeks) on the adult rat 
liver fatty acid profile are summarised in Table 5.3. The results are expressed 
as % mole of lipid classes and % mole of total fatty acid chain including the 
unsaturation index (mean ± SD). 
The aged study showed that atorvastatin caused some increase in the relative 
amount of cholesterol in the adult liver that did not reach significant levels 
(Table 4.3). In the present study, this effect by atorvastatin on cholesterol 
concentration was more profound, as was observed in the statistically 
significant increase (p < 0.0005) in the relative amount of cholesterol in control 
rat liver. Additionally, the relative amounts of total choline phospholipids and PC 
were significantly reduced (p < 0.0005 for both), while the relative amount of 
ethanolamine phospholipids was significantly increased (p = 0.005) in the adult
166
Table 5.3 The effect of atorvastatin (5 mg/kg/day) on (A) fatty acid and (B) lipid composition of LPS treated adult rat liver. Results are 
expressed as % mole of total fatty acid chain and % mole of total lipid classes (mean ± SD); n = 6 animals per group. a p < 0.05, aa p < 
0.01, aaa p < 0.001 comparing data to saline, b p < 0.05, bbb p < 0.001 comparing data to LPS.
% mole
Saline Saline + ATV LPS LPS + ATV
(A) Fatty acid chain
n-3 fatty acids 4.32 ± 0.53 3.92 ± 0.54 4.20 ± 0.52 4.25 ± 0.46
Linoleic acid (C18:2n-6) 18.3 ± 0.95 18.1 ± 1.22 18.0 ± 1.46 19.0 ± 0.44
Docosahexaenoic acid (C22:6n-3) 4.24 ± 0.67 3.12 ± 0.74 3.86 ± 0.76 4.04 ± 0.46
Arachidonic acid (C20:4n-6) 20.7 ± 2.37 20.5 ± 3.88 20.7 ± 3.54 20.0 ± 2.30
Unsaturated fatty acid chains 62.6 ± 2.61 61.6 ± 4.17 63.2 ± 3.50 63.2 ± 2.09
Saturated fatty acid chains 37.4 ± 2.61 38.4 ± 4.17 36.8 ± 3.50 36.7 ± 2.09
Unsaturation index 1.49 ± 0.11 1.36 ± 0.17 1.40 ± 0.24 1.53 ± 0.05
(B) Lipids
Total choline phospholipids 53.4 ± 1.15 45.1 ± 2.17aaa 52.5 ± 0.88 44.1 ± 3.18aaa, bbb
          Phosphatidylcholine 48.5 ± 0.94 39.5 ± 2.09aaa 47.8 ± 0.80 39.1 ± 2.99aaa, bbb
          Sphingomyelin 4.91 ± 0.33 5.54 ± 0.52 4.67 ± 0.51 4.96 ± 0.38
Total ethanolamine phospholipids 21.1 ± 1.49 25.6± 1.32aa 20.4 ± 1.86 24.0 ± 2.50b
Total sphingolipids 4.66 ± 0.42 6.07 ± 0.67a 5.37 ± 1.22 5.09 ± 0.90
Cholesterol 13.3 ± 0.47 17.1 ± 1.65aaa 13.2 ± 0.93 15.7 ± 0.66a, b
Plasmalogens 0.98 ± 0.17 1.15 ± 0.06 1.29 ± 0.34 1.09 ± 0.09
Total ether lipids 0.82 ± 0.16 0.97 ± 0.40 1.12 ± 0.15 1.31 ± 0.57
Total diacylglycerophospholipids 81.3 ± 0.96 75.8 ± 2.07aaa 80.3 ± 1.88 78.5 ± 1.49
Saline: controls administered saline, Saline+ATV: controls treated with atorvastatin, LPS: lipopolysacharride-treated rats, LPS+ATV: 
lipopolysaccharide-treated rats administered atorvastatin.
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rat liver. Total sphingolipids and total diacylglycerophospholipids were also 
significantly increased (p = 0.042) and reduced (p < 0.0005) respectively by 
atorvastatin in the control rat liver. However, in the previous study, atorvastatin 
had no effects on these lipid classes in the adult rat liver. 
5.3.2.3 Effect of atorvastatin on adult LPS-treated rat liver lipid profile
The results of the effects of atorvastatin on the lipid profile of adult LPS-treated 
rat brain are summarised in Table 5.3. The results are expressed as % mole of 
lipid classes and % mole of total fatty acid chain including the unsaturation 
index (mean ± SD).
Results showed that atorvastatin treatment did not cause any statistically 
significant changes in the total fatty acid chain including the unsaturation index 
of LPS-treated adult rat liver. 
Conversely, atorvastatin modified the lipid profile of LPS-treated adult rat liver. 
Atorvastatin significantly reduced the relative amounts of total choline 
phospholipids (p < 0.0005) and phosphatidylcholine (p < 0.0005) in LPS-treated 
rat livers. When these reduced levels were compared to control levels, they 
were also significantly reduced (p < 0.0005 respectively). Additionally, 
atorvastatin caused a statistically significant increase (p = 0.020) in the relative 
amounts of total ethanolamine phospholipids in LPS-treated rat liver. However, 
this increase in total ethanolamine phospholipids did not reach significant levels 
(p = 0.112) when compared with the level found in adult controls. LPS treatment 
did not alter cholesterol levels. However, atorvastatin significantly increased the 
relative amounts of cholesterol in LPS-treated adult rat liver (p = 0.012), and 
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this increase was also significantly higher (p = 0.021) than the amount of 
cholesterol in the control rat liver.
5.3.2.4 Effect of LPS treatment on rat liver fatty acid profile
Detailed fatty acid profiles were obtained by GC-FID. The results of the effect of 
LPS-treatment on rat liver fatty acid profile are expressed as % weight of total 
fatty acids (mean ± SD) and are summarised in Table 5.4 
The saturated fatty acids detected in the LPS-treated rat liver were C14:0, 
C15:0, C16:0, C17:0 and C24:0. However, C24:0 was not detected in the 
corresponding controls. 
The monounsaturated fatty acids detected in the LPS-treated rat liver were 
C16:1, C18:1n-9, C18:1n-7, C20:1n-9. Additionally, C22:1n-9 and C24:1 were 
not detected in the LPS treated rat liver but were detected in the corresponding 
controls. Other fatty acid classes were not affected by LPS treatment in the 
adult rat liver. 
Atorvastatin did not influence n-6 PUFA, n-3 PUFA, total PUFA and total 
unsaturated fatty acids of the LPS-treated rat liver.
5.3.2.5 Effect of atorvastatin treatment on adult rat liver fatty acid profile
The effect of atorvastatin (administered to animals for 3 weeks) on the adult rat 
liver fatty acid profile are summarised in Table 5.4. The results are expressed 
as % weight of total fatty acids (mean ± SD).
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% weight
Saline Saline + ATV LPS LPS + ATV
FATTY ACID
C14:0 0.20 ± 0.04 0.22 ± 0.07 0.29 ± 0.08 0.20 ± 0.10
C15:0 0.18 ± 0.02 0.19 ± 0.02 0.22 ± 0.05 0.19 ± 0.05
C16:0 19.3 ± 1.19 19.4 ± 1.50 20.7 ± 2.05 19.3 ± 1.14
C17:0 0.56 ± 0.03 0.57 ± 0.07 0.63 ± 0.06 0.56 ± 0.07
C18:0 20.1 ± 0.96 20.1 ± 2.62 20.4 ± 1.39 20.8 ± 1.35
C24:0 0.35 ± 0.02 0.38 ± 0.14 ND 0.27 ± 0.08
Σ SFA 40.7 ± 0.77 40.8 ± 3.04 41.3 ± 1.40 41.2 ± 0.55
C16:1 0.35 ± 0.04 0.42 ± 0.18 0.49 ± 0.33 0.35 ± 0.10
C18:1n-9 8.38 ± 1.43 8.88± 1.25 7.17± 0.59 6.41 ± 0.49a
C18:1n-7 2.52 ± 0.10 2.57 ± 0.25 2.68 ± 0.23 2.21 ± 0.14bb
C20:1n-9 0.25 ± 0.01 0.23 ± 0.08 0.20 ± 0.10 0.16 ± 0.02
C22:1n-9 0.24 ± 0.04 ND ND ND
C24:1 0.21 ± 0.02 ND ND ND
Σ MUFA 11.9 ± 1.42 12.1 ± 1.65 10.6 ± 0.91 9.17 ± 0.62a
C18:2n-6 15.3 ± 0.87 17.8 ± 0.94aa 15.8 ± 1.34 15.9± 1.07
C20:2 0.57 ± 0.03 0.54 ± 0.13 0.58 ± 0.09 0.48 ± 0.09
C20:3n-6 0.98 ± 0.07 0.86 ± 0.14 1.01 ± 0.11 0.82 ± 0.14
C20:4n-6 24.0 ± 1.59 22.3 ± 2.74a 24.3 ± 1.19 24.3 ± 1.76
C22:4n-6 0.54 ± 0.17 0.59 ± 0.19 0.59 ± 0.04 0.63 ± 0.08
Σ n-6 41.2 ± 0.82 41.3 ± 2.02 41.6 ± 1.30 42.6 ± 0.69
C18:3n-3 0.27 ± 0.05 0.46 ± 0.22 0.25 ± 0.11 0.28 ± 0.13
C20:5n-3 0.28 ± 0.09 0.28 ± 0.03 0.23 ± 0.08 0.20 ± 0.04
C22:5n-3 1.02 ± 0.13 1.05 ± 0.15 1.02 ± 0.07 1.06 ± 0.05
C22:6n-3 5.03 ± 0.91 4.66 ± 0.99 4.88 ± 0.55 5.13 ± 0.26
Σ n-3 6.60 ± 0.88 6.15 ± 0.94 6.36 ± 0.47 6.77 ± 0.36
Σ PUFA 47.4 ± 2.05 46.0 ± 2.67 48.0 ± 1.27 49.3 ± 0.82
Σ UFA 59.3 ± 0.71 58.6 ± 3.35 58.6 ± 1.38 58.5 ± 0.49
Table 5.4 The effect of atorvastatin (5 mg/kg/day) on total fatty acid composition of LPS-
treated adult rat liver. Results are expressed as % weight of total fatty acid chain or lipid 
(mean ± SD): n = 6 animals per group. а p < 0.05, аа p < 0.01, comparing data to saline, bb p
< 0.01 comparing data to LPS.
Saline: controls administered saline, Saline+ATV: controls treated with atorvastatin, LPS: 
lipopolysaccharide-treated rats, LPS+ATV: lipopolysaccharide-treated rats administered atorvastatin,
ΣSFA: total saturated fatty acid, Σ MUFA: total monounsaturated fatty acid, Σ n-6: total omega 6 
PUFA, Σ n-3: total omega 3 PUFA, Σ PUFA: total polyunsaturated fatty acid, Σ UFA: total unsaturated 
fatty acids, ND: not detected.
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The aged study (Table 4.4) showed that atorvastatin treatment did not affect the 
different fatty acid classes in the adult rat liver. However, in the present study 
atorvastatin increased (p = 0.008) the concentration of C18:2n-6 and decreased 
(p = 0.022) the concentration of AA in adult rat liver. Despite these changes, 
there was no effect on total n-6 PUFA concentration in the adult rat liver. 
5.3.2.6 Effect of atorvastatin on LPS-treated rat liver fatty acid profile
The results of the effects of atorvastatin on the fatty acid profile of adult LPS-
treated rat liver are summarised in Table 5.4. The results are expressed as % 
weight of total fatty acids (mean ± SD).
It was noted that LPS caused a reduction in the concentration of C18:1n-9 
which did not reach significant levels (p = 1.000) when compared to controls. 
However, atorvastatin enhanced this reduction in the concentration of C18:1n-9 
as the reduction was significantly lower (p = 0.030) than the concentration of 
C18:1n-9 in control rat liver. It was also observed that atorvastatin significantly 
reduced the concentration of C18:1n-7 (p = 0.003) in the LPS-treated rat liver. 
This reduction in C18:1n-7 concentration was not significantly different (p = 
0.101) from the concentration of C18:1n-7 in the control rat liver. Also, 
atorvastatin further reduced the total monounsaturated fatty acids in LPS 
treated rat liver (p = 0.011).
5.3.3 Atorvastatin levels in brain, liver and serum of LPS-treated rats
The LC/ESI-MS/MS assay developed in this study (Chapter 3) was used to 
determine the concentration of atorvastatin, ortho-hydroxyatorvastatin and para-
hydroxyatorvastatin in the rat brain, liver and serum of both control and LPS
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ng metabolite / mg protein
Saline LPS
Tissue ATV o-ATV p-ATV ATV o-ATV p-ATV
Brain 0.05 ± 0.02 ND ND 0.09 ± 0.12 ND ND
Liver 0.12 ± 0.10 0.04 ± 0.02 0.02 ± 0.01 0.04 ± 0.06 ND 0.01 ± 0.01
Serum ND ND ND ND ND ND
Table 5.5 Concentration of atorvastatin (ATV), ortho-hydroxyatorvastatin (o-ATV), para-hydroxyatorvastatin (p-ATV) in 
brain, liver and serum of adult control (saline-administered) and LPS-treated rats. Results are expressed as mean (ng 
metabolite/mg protein) ± S.D., n = 6 animals per group. 
Saline: control rats administered saline, LPS: lipopolysaccharide-treated rats, ND: not detected
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treated animals that were treated with atorvastatin. The results are shown in 
Table 5.5. Data are expressed as mean (ng metabolite / mg protein) ± SD. The 
amounts of atorvastatin, ortho-hydroxyatorvastatin and para-
hydroxyatorvastatin were close to the limits of detection of the method so no 
statistical analysis was performed for levels in the different tissues of the animal 
groups.
Atorvastatin, ortho-hydroxyatorvastatin and para-hydroxyatorvastatin were not 
detected in the plasma of either control or LPS-treated samples. In the brain a 
small amount of atorvastatin was detected in both control and LPS-treated 
animals. The liver was found to have the highest levels of atorvastatin, ortho-
hydroxyatorvastatin and para-hydroxyatorvastatin. 
5.4 Discussion
Atorvastatin has been shown to counteract LPS-induced neuroinflammation and 
brain functional deficits that results from neuroinflammation (Clarke et al., 2008, 
Clarke et al., 2007). The molecular mechanism of this action is still of particular 
interest. The present study used LPS-treated rat brain as a model of the 
changes occurring in the brain in the acute phase response of 
neuroinflammation. Previous studies have shown that LPS alters lipid 
metabolism in different tissues including the brain and liver (Feingold et al., 
1995, Khovidhunkit et al., 2004, Rosenberger et al., 2004). Atorvastatin has 
been shown to modulate lipid metabolism in rabbit liver, rat liver cells and in 
human monocytic cell lines (Alegret et al., 1998, Levine, 2003, Rise et al., 
2003). Based on this evidence, we therefore investigated the effect of 
173
atorvastatin on brain and liver lipid profiles of adult and LPS-treated adult rats 
with a view to gain more insight into its molecular mechanism of action.
In agreement with literature (Khovidhunkit et al., 2004, Rosenberger et al., 
2004), our results showed that LPS treatment did not have any effects on the 
major brain lipid classes including cholesterol, phospholipids, sphingolipids and 
ether lipids (Tables 5.1). In addition, findings in the brain showed that total n-6 
and total n-3 PUFA were not affected by LPS treatment (Table 5.2). There were 
no significant changes in C18:2n-6, AA and DHA concentrations in LPS-treated 
rat brain. However, other studies have shown that AA is increased in the rat 
brain, as well as cultured rat brain cells such as microglia after LPS treatment 
(Lee et al., 2004, Minghetti and Levi, 1995, Rosenberger et al., 2004). 
It was previously shown that after 6 days of intracerebral ventricular LPS 
infusion, the level of C18:1n-9 was not altered in the rat brain (Rosenberger et 
al., 2004), but our results showed LPS increased the level of C18:1n-9 after 3 h 
(Table 5.2). These differences in findings may indicate that an acute systemic 
administration of LPS could elicit different responses from a prolonged local 
intracerebral LPS administration. In addition, this may explain why C18:2n-6, 
AA and DHA concentrations were not affected by LPS treatment in the present 
study. This suggestion is based on the fact that in previous studies where 
C18:2n-6 and AA were affected by LPS treatment, LPS was administered 
intracerebrally for a longer period (6 days) (Lee et al., 2004). Moreover, these 
changes observed in previous studies were temporary as the effects were 
reversed after 28 days (Lee et al., 2004).
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Dissimilarities in the effects of atorvastatin were noted for adult rat brain and 
liver in the LPS study compared to the effects in the aged study (Chapter 4). For 
instance in the LPS study, atorvastatin significantly reduced the concentration of 
C16:0 and AA in the adult rat brain when compared to controls (Table 5.2). 
Atorvastatin also significantly increased the concentration of C20:1n-9 and total 
monounsaturated fatty acids when compared to controls (Table 5.2). 
Additionally, atorvastatin treatment caused a significant increase and reduction 
in C18:2n-6 and AA respectively in the adult rat liver in the LPS study (Table 
5.4). These effects were not observed in the aged study (Table 4.2 and Table 
4.4). Furthermore, in the LPS study, the atorvastatin induced increase in the 
concentration of cholesterol in the adult liver was more profound than in the 
aged study (Table 5.3 and Table 4.3). There was also a concomitant reduction 
in the concentration of PC, total choline phospholipids and total 
diacylglycerophospholipids, and increase in total ethanolamine phospholipids in 
the LPS study (Table 5.3).
It is important to point out that in the LPS study, animals were treated with 
atorvastatin for 3 weeks and in the aged study, animals were treated for 8 
weeks. It is possible that there may be long- and short-term effects of 
atorvastatin on rat brain and liver lipid metabolism. Moreover it has been 
previously reported that duration of statin treatment may induce different effects 
on the concentration of cholesterol in rat liver and hepatocytes (Isusi et al., 
2000, Ness et al., 1998). It was reported that atorvastatin lowered liver 
cholesterol in rats that were fed atorvastatin in the diet for 3 days (Ness et al., 
1998). In addition it was shown that in rat liver hepatocytes, atorvastatin, 
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simvastatin and lovastatin caused a decrease in cholesterol concentration after 
2 h which were normalised after 4 h (Isusi et al., 2000). 
LPS treatment did not have any major influence on the concentration of 
cholesterol and phospholipids in the rat liver (Table 5.3). This may explain why 
atorvastatin caused an increase in the concentration of cholesterol and a 
concomitant decrease in PC and increase in PE in both control rat liver and 
LPS-treated rat liver. In addition to enhancing HMG-CoA reductase activity in 
the rat liver, it has been shown that atorvastatin and simvastatin alter 
phospholipid synthesis and reduce total phospholipid content in rat liver, and 
this effect has been linked to their ability to lower plasma triacylglycerol levels in 
rats (Roglans et al., 2002). Phospholipids and cholesterol are found on the 
outer surface of VLDL and triacylglycerols are present in the core. These lipids 
are required for VLDL synthesis and secretion in the liver. Simvastatin and 
atorvastatin induce decreases in rat and rabbit liver phospholipids that result in 
a decrease in VLDL secretion (Roglans et al., 2002, Verd et al., 1999). It is 
necessary to re-iterate that in humans, statins inhibit liver cholesterol synthesis 
and as a result, human plasma cholesterol levels are reduced (Krause and 
Newton, 1995, Mabuchi et al., 1983). Thus, the findings from this study may 
further highlight that differences exist between the effects of statins in rat and 
human lipid metabolism, which should be a point of concern when developing 
treatments for humans based on findings from experimental models (especially 
rodents).
The reduction in phospholipid concentration in the rat liver results in a 
compensatory increase in the activity of cytidine triphosphate (CTP) : 
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phosphocholine cytidyl transferase (Roglans et al., 2002). It has also been 
reported that the activity of cytidine triphosphate (CTP) : phosphocholine cytidyl 
transferase, the rate limiting enzyme in PC synthesis via the cytidyine 
diphosphocholine (CDP-choline) pathway is increased when there is an 
increase in cholesterol (Ridgway et al., 1999). This is thought to be a 
compensatory mechanism to counteract membrane rigidity that may occur as a 
result of cholesterol increase (Ridgway et al., 1999). PC is also generated in the
liver through methylation of PE by phosphatidylethanolamine N-
methyltransferase (Walkey et al., 1997). Therefore, it may also be possible that 
the reduction in PC observed in the present study could have resulted in an 
upregulation of PE synthesis as a compensatory response to enhance 
production of PC (Table 5.3).
In the LPS study, a small amount of atorvastatin was detected in the control rat 
brain and LPS-treated rat brain. It is still unclear how atorvastatin reached the 
brain. Since its lipophilicity is still debatable (Christians et al., 1998, Sparks et 
al., 2002), passive diffusion may or may not be the route of transport. However, 
it is possible that a disruption of the blood brain barrier could have occurred as 
a result of LPS treatment as previous findings have shown (Descamps et al., 
2003). This disruption could therefore have allowed a passive diffusion of 
atorvastatin into the LPS-treated rat brain. However it has been shown that 
various statin transporters exist in the blood brain barrier (Decleves et al., 2000, 
Hsiang et al., 1999, Kikuchi et al., 2004). Organic anion transporters and 
monocarboxylic acid transporters transport statins into cells and are expressed 
in the brain including rat brain (Kusuhara et al., 1999). P-glycoprotein is another 
statin transporter, which is expressed in the brain (Decleves et al., 2000). These 
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transporters facilitate the transport of statins across the intact blood brain barrier 
and could explain why atorvastatin was detected in the brain of adult rat 
controls.
A previous study suggested that statins do not accumulate in the brain but in 
those cases that they reach the brain, they are transported out of the brain 
possibly by active transport (Johnson-Anuna et al., 2005). This was 
demonstrated by a 21-day, and 1-day treatment of adult (2 month old) mice with 
simvastatin, lovastatin and pravastatin. After the first 24 h of the 21-day 
treatment, less than 50 pmol/g brain of simvastatin and lovastatin were detected 
but pravastatin was not detected in the cerebral cortex. After 1h, 3h and 6h of 
the 1-day treatment, the maximum average concentrations of simvastatin, 
lovastatin and pravastatin in the cerebral cortex were 600, 300, and 100 pmol/g 
brain respectively. These levels however declined with time (Johnson-Anuna et 
al., 2005). P-glycoprotein and organic anion transporters are also involved in 
the excretion of statins out of cells (Kikuchi et al., 2004). Active transport out of 
the brain may therefore explain why atorvastatin was detected in the adult brain 
in the LPS study (3 weeks treatment) and not in the aged study (8 weeks 
treatment) (Tables 4.5 and 5.5). This suggestion is also supported by the claim 
that statin levels decline in the brain with time (Johnson-Anuna et al., 2005). 
Atorvastatin, ortho-hydroxyatorvastatin and para-hydroxyatorvastatin were 
detected at higher levels in the liver compared to the brain and plasma (Table 
5.5). This was also observed with the adult rat liver in the aged study (Table 
4.5). Although statistical analysis was not carried out for the distribution of 
atorvastatin and its metabolites in control and LPS-treated animals (as the 
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concentrations were close to the limit of quantitation of the method), it seemed 
that these compounds were detected more in the liver of control rats than in the 
liver of LPS-treated rats (Table 5.5). Studies have shown that the CYP3A 
activity (Sewer and Morgan, 1998) as well as the entire CYP450 enzyme 
system activity is downregulated in the brain and liver in LPS induced 
neuroinflammation (Renton and Nicholson, 2000). This is thought to be due to 
the overexpression of inflammatory cytokines and/or nitric oxide (Renton and 
Nicholson, 2000, Sewer and Morgan, 1998). Based on these findings, it may be 
suggested that the lower levels of atorvastatin metabolites in the LPS-treated 
rat liver could indicate a reduction in the activity of CYP3A and thus, reduced 
metabolism of atorvastatin.
Atorvastatin, ortho-hydroxyatorvastatin and para-hydroxyatorvastatin were not 
detected in serum in this study. This was not the case with the adult rat serum 
in the aged study (Table 4.5), where atorvastatin and ortho-hydroxyatorvastatin 
were detected in serum although in very low concentrations. As was discussed 
in Chapter 4 (section 4.4), the extensive first pass metabolism of atorvastatin in 
the liver results in very low levels of atorvastatin in plasma and may have also 
influenced the results in the LPS study.
It is important to remember that atorvastatin and its hydroxy metabolites are 
unstable and undergo interconversion in tissues including liver, brain and 
plasma (Chen et al., 2007, Siedlik et al., 1999). Acidic conditions favour the 
interconversion of atorvastatin from acid to lactone form (Hermann et al., 2005). 
The LC/ESI-MS/MS analysis of atorvastatin in this study was performed under 
acidic conditions and may have resulted in the interconversion of atorvastatin 
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and its hydroxy metabolites to the lactone forms. As lactone forms of 
atorvastatin, ortho-hydroxyatorvastatin and para-hydroxyatorvastatin standards 
were not analysed in this project, any interconversion that may have occurred in 
tissue samples would not be observed. Nevertheless, it is possible that this may 
have influenced some of the findings in both the LPS and aged study.
Overall, findings from this study suggest that LPS alters lipid metabolism in both 
brain and liver and that atorvastatin modulated some of these effects. 
Furthermore, LPS may have an effect on the metabolism and uptake of 
atorvastatin in the liver. Finally, the differences in the responses to atorvastatin 
treatment in the adult rat brain and liver in this study compared to that of the 
aged study (Chapter 4) may be due to the shorter duration of atorvastatin 
treatment (3 weeks treatment) in this study. These findings may also add 
information to the molecular mechanism of action of atorvastatin in the rat.
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6.0 PROFILING OF BRAIN LIPIDS AND FATTY ACIDS IN 
THE FLINDERS SENSITIVE LINE RAT
6.1 Introduction
Depression is a mood disorder with complex behavioural deficits, that is 
characterised by symptoms such as cognitive decline, memory impairment, 
reduced motivation, weight loss and insomnia (Nestler et al., 2002). Depression 
has no definite cause and studies have suggested that the immune, endocrine 
and central nervous systems play critical roles in its pathology (Dunn and 
Swiergiel, 2008, Merali et al., 1997, Piccirillo et al., 1994). These systems have 
been shown to have several routes of communication. For instance, it was 
shown that the systemic administration of IL-1β in male Sprague Dawley rats 
stimulated an increase in norepinephrine, dopamine and serotonin 
neurotransmission in the nucleus accumbens, prefrontal cortex and 
hippocampus (Merali et al., 1997). Levels of these neurotransmitters are altered 
in depression. Additionally, it is thought that the increased level of cortisol in the 
plasma of depressed patients may be related to the dysregulation of the 
hypothalamic-pituitary-adrenal (HPA) axis (Piccirillo et al., 1994). IL-1β also 
induces alterations in HPA and this effect may be enhanced by norepinephrine 
in depression [reviewed in (Anisman and Merali, 2003)]. 
Focusing on the central nervous system, it is has been suggested that various 
brain regions such as the hypothalamus, striatum, prefrontal cortex and nucleus 
accumbens may mediate the diverse symptoms of depression (Drevets, 2000, 
Mayberg et al., 1999). Human brain imaging studies and post-mortem studies 
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have demonstrated that blood flow and structural irregularities in some brain 
regions such as the prefrontal cortex occur in depression (Drevets, 2000, 
Drevets et al., 2008, Mayberg et al., 1999). Under normal conditions, these 
brain regions have specific functions, for instance the striatum is important in 
memory functions while the nucleus accumbens and hypothalamus are 
important for motivation (Nestler et al., 2002). 
Furthermore, it has been suggested that excitatory amino acid transmission 
could constitute an important target in depression (Michael-Titus et al., 2000). It 
is believed that the alterations in monoamine neurotransmission also may 
modulate glutamic acid neurotransmission (Maura et al., 1998). Furthermore, 
the N-methyl-D-aspartate (NMDA) receptors of glutamic acid have been 
particularly targeted by antidepressants (Michael-Titus et al., 2000, Nowak et 
al., 1996, Paul et al., 1993), and studies have shown that the binding 
characteristics of these receptors are changed by antidepressants whilst these 
changes occur only in the cortex (Paul et al., 1993). Overall, these changes in 
glutamic acid receptors are thought to be a compensatory mechanism for an 
alteration in mononaminergic neurotransmission (Michael-Titus et al., 2000).
Blood tissue examinations in epidemiological and clinical studies have shown
that in depression there is an imbalance between n-3 and n-6 PUFA and this is 
usually through a decrease in the level of n-3 PUFA (Cyranowski et al., 2007, 
Edwards et al., 1998, Maes et al., 1996). These low blood levels of n-3 PUFA 
particularly EPA and DHA and high concentrations of n-6 PUFA especially AA 
have been attributed to the consumption of diets inadequate in n-3 PUFA and 
high in saturated and n-6 PUFA (Hibbeln and Salem, 1995). Additionally dietary 
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supplementations with n-3 PUFA in clinical studies (Peet, 2003, Su et al., 2003)
as well as animal studies (Zimmer et al., 2000) have been carried out to further 
establish the implication of the n-3 and n-6 PUFA imbalance in depression.
Lipids are constituents of cell membranes. Their distribution within the neural 
membrane is very organised and contributes to the structural and functional 
integrity of the brain that promote appropriate interactions with integral 
membrane proteins. Reports have shown that alterations in the composition and 
distribution of lipids in brain cell membranes may cause neurochemical and 
physiological changes that result in behavioural deficits (Nakashima et al., 
1993). 
Many studies have focused on the neurochemical basis of depression (Antoniou
et al., 2008, Ballard et al., 2002, Michael-Titus et al., 2000, Zangen et al., 1999). 
Although a lot of work has shown the involvement of lipids in depression 
(Hibbeln and Salem, 1995, Horrobin, 2001, Horrobin and Bennett, 1999, Maes
et al., 1999, Maes et al., 1996), most of these studies are focused on n-3 PUFA 
deficiency in the serum of depressive patients and more recently in the brain of 
experimental animals and post mortem studies (Fedorova and Salem, 2006, 
McNamara et al., 2007). 
The FSL rat is a unique and well studied animal model for depression 
(Overstreet et al., 2005, Overstreet et al., 1992, Yadid et al., 2000). This model 
has shown alterations in neurotransmitter levels and functions that are 
characteristic of depressive disorders (Yadid et al., 2000). Moreover it has been 
shown to exhibit behavioural features such as reduced locomotion (Overstreet, 
1986), an increased amount of rapid eye movement sleep (Benca et al., 1996), 
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reduction in onset of rapid eye movement sleep, cognitive difficulties and 
reduced body weight (Overstreet et al., 2005). In addition, the FSL rats have 
shown sensitivity to chronic but not acute treatment to anti-depressants 
(Overstreet et al., 2005, Zangen et al., 1997, Zangen et al., 1999). 
We have therefore investigated the total lipid profile of brain regions of the FSL 
rats. These brain regions include the hypothalamus, prefrontal cortex, nucleus 
accumbens and striatum. Earlier reports have demonstrated that modifications 
in the specific fatty acid composition in the nucleus accumbens (Zimmer et al., 
2000, Zimmer et al., 2002), prefrontal cortex and striatum (Delion et al., 1994)
as a result of chronic dietary C18:3n-3 deficiency may result in alteration in 
neurotransmission in rats. The findings from this study were compared to 
Sprague-Dawley control animals with a view to determine if there are any 
alterations in the normal lipid profile as a result of depression. 
6.2 Study design
Flinders Sensitive Line and Sprague-Dawley (control) rats (230-250 g) were 
maintained under conditions of constant temperature (22 ○C) and humidity (50 
%) on a 12 h light – 12 h dark cycle (lights off at 07:00). Both groups were fed 
an identical diet: food and water available ad libitum.
All materials and methods applied in this study are described in Chapter 2 
(sections 2.1.1, 2.1.2, 2.1.5, 2.2, 2.3.2, 2.4.3, 2.4.4, 2.5, 2.6 and 2.9).
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6.3 Results
6.3.1 1H-NMR spectroscopy lipid profiles of brain regions
Similar to the two previous chapters, 1H-NMR analysis of the total lipid extract 
on the FSL and Sprague-Dawley rat brain regions were performed. This allowed 
profiling of the major classes of lipids in the brain regions: phospholipids, 
sphingolipids, cholesterol and ether lipids, the predominant PUFA (DHA and 
AA), and estimation of the unsaturation index. This was also followed by GC-
FID analysis for detailed fatty acid profiling.
6.3.1.1 Lipid profiling in hypothalamus
The results of the total lipid extracts from the Sprague-Dawley control 
hypothalamus and FSL rat hypothalamus are summarised in Table 6.1. The 
results are expressed as % mole of total lipid classes and % mole of total fatty 
acid chain including the unsaturation index (mean ± SD).
Total n-3 PUFA and DHA were significantly lower in the FSL group compared to 
the control group (p = 0.042 and p = 0.011 respectively). The relative amount of 
AA was high in the FSL animals. However this amount did not reach significant 
levels when compared to the amount of AA in the Sprague-Dawley controls (p = 
0.568). In addition, the amounts of unsaturated and saturated fatty acid chains 
were relatively lower and higher in the FSL rats respectively. These levels 
however did not reach statistical significance when compared to the Sprague-
Dawley controls (p = 0.313). The unsaturation index was similar in both animal 
groups. Total sphingolipids and cholesterol levels were significantly increased 
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% mole
HYPOTHALAMUS PREFRONTAL CORTEX NUCLEUS ACCUMBENS STRIATUM
CONTROL FSL CONTROL FSL CONTROL FSL CONTROL FSL
(A) Fatty acid chain
n-3 fatty acids 8.76 ± 1.47 6.58 ± 1.03* 5.40 ± 1.06 6.80 ± 1.37 6.22 ± 0.22 6.84 ± 0.40 7.94 ± 0.81 7.19 ± 0.81
Linoleic acid (C18:2n-6)a 0.86 ± 0.26 1.03 ± 0.15 ND ND ND ND ND ND
Docosahexaenoic acid (C22:6n-3) 5.39 ± 0.86 3.72 ± 0.49* 4.68 ± 1.22 4.57 ± 0.89 5.61 ± 0.77 5.69 ± 1.41 4.84 ± 0.51 5.13 ± 0.97
Arachidonic acid (C20:4n-6) 8.29 ± 0.94 8.69 ± 0.84 4.29 ± 1.50 7.75 ± 0.84** 5.56 ± 0.60 7.80 ± 1.18* 6.52 ± 0.61 8.63 ± 0.79**
Unsaturated fatty acid chains 48.9 ± 3.64 46.4 ± 2.97 18.7 ± 3.62 19.5 ± 2.83 32.9 ± 4.60 30.0 ± 2.24 29.0 ± 4.30 30.9 ± 4.51
Saturated fatty acid chains 51.1 ± 3.64 53.6 ± 2.97 81.2 ± 3.62 80.5 ± 2.83 67.1 ± 4.60 70.0 ± 2.24 71.0 ± 4.30 69.1 ± 4.51
Unsaturated index 0.80 ± 0.09 0.71 ± 0.06 0.35 ± 0.13 0.40 ± 0.13 0.64 ± 0.09 0.59 ± 0.13 0.71 ± 0.06 0.61 ± 0.10
(B) Lipids
Total choline phospholipids 21.6 ± 1.80 20.6 ± 1.55 25.7 ± 3.73 24.9 ± 2.86 23.1 ± 1.41 23.4 ± 1.96 18.7 ± 2.40 17.3 ± 2.31
Phosphatidylcholine 17.7 ± 1.84 16.9 ± 1.38 23.4 ± 4.07 21.2 ± 2.47 19.6 ±1.21 19.8 ±1.57 15.9 ± 2.02 14.5 ± 1.95
           Sphingomyelin 3.87 ± 0.25 3.71 ± 0.17 4.10 ± 0.81 3.75 ± 0.42 3.43 ± 0.19 3.56 ± 0.49 2.73 ± 0.40 2.76 ± 0.37
Total ethanolamine phospholipids 19.6 ± 1.20 20.4 ± 1.88 16.0 ± 2.30 15.0 ± 3.33 17.2 ± 1.51 16.7 ± 3.30 17.4 ± 1.36 17.3 ± 1.24
Total sphingolipids 16.0 ± 1.78 20.2 ± 1.46** 9.94 ± 1.76 11.5 ± 1.97 16.5 ± 1.22 15.1 ± 3.24 19.1 ± 3.70 20.8 ± 1.81
Cholesterol 37.2 ± 1.86 39.9 ± 0.58* 39.1 ± 3.35 40.6 ± 2.28 39.3 ± 1.77 38.8 ± 1.63 40.2 ± 0.49 39.6 ± 1.44
Plasmalogens 11.1 ± 1.04 11.3 ± 0.54 3.69 ± 2.31 4.77 ± 0.36 8.93 ± 0.95 9.76 ± 2.37 9.43 ± 3.20 8.94 ± 1.75
Total ether lipids 15.0 ± 1.79 12.5 ± 1.20* 8.07 ± 3.99 9.92 ± 1.59 10.2 ± 0.99 11.5 ± 2.22 12.8 ± 0.87 11.3 ± 1.45
Total diacylglycerophospholipids 31.8 ± 2.43 27.3 ± 2.06* 42.9 ± 1.38 38.0 ± 1.84** 34.0 ± 1.76 34.6 ±3.25 27.8 ± 3.86 28.3 ± 1.16
Table 6.1: Lipid profiles from different areas of Sprague-Dawley (CONTROL) and Flinders Sensitive Line (FSL) rats using ¹H-NMR. Results are expressed as % 
mole of total fatty acid chain including the unsaturation index and % mole of total lipid classes (mean ± SD); n=5 animals per group. * p < 0.05, ** p < 0.01 
comparing FSL to CONTROL.
a The level of linoleic acid was close to the limit of detection of the method therefore no statistical anaylsis was performed.
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(p = 0.028 and p = 0.006 respectively) while total ether lipids and total 
diacylglycerophospholipids were significantly decreased (p = 0.044 and p = 
0.020 respectively) in the FSL animals compared to corresponding controls.
6.3.1.2 Lipid profiling in prefrontal cortex
The results of the total lipid extracts from the Sprague-Dawley control prefrontal 
cortex and FSL rat prefrontal cortex are summarised in Table 6.1. The results 
are expressed as % mole of total lipid classes and % mole of total fatty acid 
chain including the unsaturation index (mean ± SD).
In the prefrontal cortex the relative amounts of total n-3 PUFA, DHA, 
unsaturated chains, saturated chains and unsaturated index were not 
significantly different. There was a significant increase in the relative 
concentration of AA of the FSL rats compared to that of controls (p = 0.003). 
There was also a statistically significant reduction in total 
diacylglycerophospholipids in the FSL animals compared to corresponding 
controls (p = 0.003).
6.3.1.3 Lipid profiling in nucleus accumbens
The results of the total lipid extracts from the Sprague-Dawley control nucleus 
accumbens and FSL rat nucleus accumbens are summarised in Table 6.1. The 
results are expressed as % mole of total lipid classes and % mole of total fatty 
acid chain including the unsaturation index (mean ± SD).
There was a statistically significant increase in the amount of AA (p = 0.021) of 
the FSL rat nucleus accumbens when compared to the Sprague-Dawley control 
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animals. Total n-3 PUFA and DHA were similar in both animal groups. No 
significant changes were observed for unsaturated and saturated fatty acid 
chains as well as any of the lipid classes in this brain region of the FSL rats 
compared to the controls.
6.3.1.4 Lipid profiling in striatum
The results of the total lipid extracts from the Sprague-Dawley control striatum 
and FSL rat striatum are summarised in Table 6.1. The results are expressed 
as % mole of total lipid classes and % mole of total fatty acid chain including the 
unsaturation index (mean ± SD).
In this brain region, similar levels of total n-3 PUFA, DHA, unsaturated chains, 
saturated chains and unsaturated index were observed. AA was significantly 
higher in the FSL rats than the controls (p = 0.001). All other lipid classes were 
not significantly different.
6.3.2 Fatty Acid Analysis by Gas Chromatography 
Detailed fatty acid profiles were obtained by analysis using GC-FID as 
previously shown in Chapters 4 and 5.
6.3.2.1 Fatty acid profile in hypothalamus
The results of the fatty acid profile from the Sprague-Dawley control 
hypothalamus and FSL rat hypothalamus are summarised in Table 6.2. The 
results are expressed as % weight of total fatty acids (mean ± SD).
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Σ MUFA: total monounsaturateds fatty acids, Σ PUFA: total polyunsaturated fatty acids, Σ SFA: total saturated fatty acids, Σ UFA: total unsaturated fatty acids, ND: not 
detected.
% weight
HYPOTHALAMUS PREFRONTAL CORTEX NUCLEUS ACCUMBENS STRIATUM
FATTY 
ACIDS
CONTROL FSL CONTROL FSL CONTROL FSL CONTROL FSL
16:0 21.2  1.32 20.9  0.55 34.1  1.43 32.7  1.99 28.0  1.56 25.8  1.78 26.3  2.45 25.6  1.25
18:0 24.4  0.52 27.3  0.78 ** 38.9  0.28 37.5  1.52 35.1  1.78 31.2  2.91* 30.6  2.65 30.9  1.87
24:0 3.43  0.35 3.09  0.27 ND ND ND ND ND ND
 SFA 49.1  1.93 51.9  0.85 72.9  1.69 70.2  3.26 63.0  3.26 57.0  4.54 56.9  5.06 56.5  2.81
17:1 1.98  0.43 1.96  0.26 ND ND ND ND ND ND
18:1n-9 19.9  1.07 18.6  0.96 9.05  1.31 9.07  0.71 12.8  1.07 12.6  0.91 16.7  1.56 14.2  0.88*
18:1n-7 3.97  0.17 3.84  0.21 ND ND 2.63  0.09 2.87  0.06* 3.34  0.49 3.28  0.30
20:1n-9 1.94  0.49 2.29  0.27 ND ND ND 0.67  1.35* ND 0.83  1.30
22:1n-9 3.88  0.90 4.48  1.41 ND ND 5.37  1.00 3.30  0.98* ND 0.41  0.92
 MUFA 31.7  2.63 31.2  1.05 9.05  1.31 9.07  0.71 20.3  1.47 18.7 1.67 20.1  2.01 18.8  1.94
20:4n-6 8.76  0.45 10.3  0.58** 8.32  0.44 11.1  1.56* 8.34  0.79 11.3  2.22* 9.80  0.75 12.2  0.64**
22:4n-6 ND ND ND ND ND 3.14  0.42 2.60  0.16 1.97  1.01
22:6n-3 9.69  1.38 7.17  0.76** 9.69  0.84 9.01  1.63 8.32  1.63 9.41  3.17 11.3  1.31 10.1  0.61
 PUFA 18.4 ± 1.67 17.5  1.18 18.1  0.76 18.3  1.68 24.5  1.56 24.2  1.70 18.0  0.43 20.1  2.06
 UFA 50.1 ± 1.10 48.7  0.85 39.2  0.21 36.7  1.10 45.4  2.54 43.0  2.04 27.1  1.70 29.8  3.26
Table 6.2 Fatty acid composition of different brain areas from Sprague-Dawley (CONTROL) and Flinders Sensitive Line (FSL) rats using GC-FID (n=5 animals 
per group). Results are expressed as % weight (mean ± SD) SFA, MUFA, PUFA and UFA. * p < 0.05, ** p < 0.01 comparing FSL to CONTROL
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In the hypothalamus, C16:0, C18:0 and C24:0 were the prevalent saturated 
fatty acids. A statistically significant increase was seen in the amount of C18:0 
of FSL animals compared to controls (p = 0.001). However this increase did not 
cause any significant effects to total saturated fatty acids in the FSL animals 
and so the levels were the same as in the controls. The monounsaturated fatty 
acids detected were C17:1, C18:1n-9, C18:1n-7, C20:1n-9 and C22:1n-9. Each 
of these was not significantly different between the two animal groups (p = 
0.961, 0.102, 0.343, 0.248, and 0.460 respectively) and so total 
monounsaturated fatty acid concentration was similar in both animal groups (p
= 0.752). AA and DHA concentrations were significantly increased (p = 0.003) 
and reduced (p = 0.014) respectively in the FSL animals compared to the 
Sprague-Dawley controls. However total PUFA and total unsaturated fatty acids 
were not affected.
6.3.2.2 Fatty acid profile in prefrontal cortex
The results of the fatty acid profile from the Sprague-Dawley control prefrontal 
cortex and FSL rat prefrontal cortex are summarised in Table 6.2. The results 
are expressed as % weight of total fatty acids (mean ± SD).
In the prefrontal cortex, C16:0 and C18:0 were the main saturated fatty acids 
detected. These were not significantly different between Sprague Dawley 
control and FSL animals (p = 0.499 and 0.399 respectively). C18:1n-9 was the 
only monounsaturated fatty acids detected in Sprague-Dawley control and FSL 
animals. This was not significantly different between both groups (p = 0.587).
AA and DHA were the only PUFA detected. AA was significantly higher (p = 
0.035) in the FSL animals compared to Sprague-Dawley controls. However, no 
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significant differences were observed for DHA. Neither total PUFA nor 
unsaturated fatty acids were significantly different in this region despite the 
higher levels of AA when compared to Sprague-Dawley controls.
6.3.2.3 Fatty acid profile in nucleus accumbens 
The results of the fatty acid profile from the Sprague-Dawley control nucleus 
accumbens and FSL rat nucleus accumbens are summarised in Table 6.2. The 
results are expressed as % weight of total fatty acids (mean ± SD).
In this region, C16:0 and C18:0 were the saturated fatty acids detected in both 
Sprague-Dawley control and FSL animals. The concentration of C18:0 was 
significantly lower (p = 0.041) in the FSL animals compared to the Sprague-
Dawley controls. In the monounsaturated fatty acids, C18:1n-7 was significantly 
increased (p = 0.010) in the FSL animals compared to the Sprague-Dawley 
controls. In contrast there was a significant reduction (p = 0.017) in the 
concentration of C22:1n-9 in the FSL rats compared to controls. Despite these 
changes, there was no concomitant alteration in the total monounsaturated fatty 
acid concentration. Here also, AA, C22:4n-6 and DHA contributed to total PUFA 
detected. AA was significantly higher in the FSL rats (p = 0.026) and total n-6 
PUFA concentration was also significantly higher (p = 0.036) in the FSL rats in 
comparison to Sprague-Dawley controls. There was no significant difference (p
= 0.563) in the concentration of DHA in the two animal groups. Total PUFA and 
unsaturated fatty acid concentrations were also not significantly different (p = 
0.090 and 0.191 respectively) between the FSL rats and Sprague-Dawley 
controls. 
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6.3.2.4 Fatty acid profile in striatum
The results of the fatty acid profile from the Sprague-Dawley control striatum 
and FSL rat striatum are summarised in Table 6.2. The results are expressed 
as % weight of total fatty acids (mean ± SD).
The prevalent saturated fatty acids in this region were C16:0 and C18:0 and 
these were not significantly different in either animal groups. Although traces of 
C20:1n-9 and C22:1n-9 were detected in two animals in the FSL group, C18:1n-
9 and C18:1n-7 were the main monounsaturated fatty acids detected in both 
groups in this region. There were no significant differences between the levels 
of these fatty acids when comparing animal groups. The n-6 PUFA detected 
included AA and C22:4n-6 in both control and FSL animals. AA was significantly 
higher (p = 0.001) in the FSL animals than in the controls. Total n-6 PUFA 
concentration was also significantly higher (p = 0.050) in the FSL rats compared 
to controls. DHA was the main PUFA detected for n-3 PUFA and its levels as 
well as total PUFA and unsaturated fatty acids were not significantly different (p
= 0.360, 0.236 and 0.967 respectively) in both animal groups. 
6.4 Discussion
Depression is a neuropsychiatric disease that does not have a single cause but 
amongst others is associated with alteration in lipid composition and 
metabolism (Maes et al., 1996, McNamara et al., 2007). The experiments 
presented in this chapter were carried out on the FSL rat model of depression to 
profile the lipid composition of brain regions that are reported to be involved with 
functions that may be affected in depression (Nestler et al., 2002). The findings 
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were compared to Sprague-Dawley controls in order to investigate if alterations 
in the normal lipid profile have any relationship with the pathogenesis of 
depression. The Sprague-Dawley rats served as controls because the FSL rats 
were developed by selective breeding of this strain of rats for increased 
sensitivity to the hypothermic effect of the anticholinesterase agent diisopropyl 
fluorophosphate (Overstreet et al., 1979).
In this study we showed the lipid profiles of the hypothalamus, prefrontal cortex, 
nucleus accumbens and striatum of the regions of the Sprague-Dawley control 
and the FSL rats. Findings from this study are in line with literature where it has 
been shown that different brain areas have different proportions of fatty acids 
and lipid classes (Delion et al., 1994, Zhang et al., 1996). In the regions 
investigated, some lipids, like cholesterol and ether plasmalogens occur in 
similar amounts in all regions, whilst others like phospholipids and sphingolipids 
vary. Also the fatty acid composition showed variations depending on the brain 
region. 
The results obtained demonstrated that there were modifications in the fatty 
acid composition of the FSL rat brain. The major findings were in the significant 
increases in AA concentrations in all brain regions as was reported in an earlier 
study (Green et al., 2005), and a significant increase in total n-6 PUFA in 
prefrontal cortex and striatum. This increase in total n-6 PUFA also paralleled 
the findings in a previous study where it was reported total n-6 PUFA increased 
in the hypothalamus, striatum, prefrontal cortex and nucleus accumbens (Green
et al., 2005). It may be assumed that this increase in AA and n-6 PUFA may be 
as a result of increased intake of n-6 PUFA from the diet. Fatty acids are 
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transported to the brain from the liver through the blood (Connor et al., 1990, 
Scott and Bazan, 1989) and it has been suggested that the fatty acid 
composition of the blood may reflect the composition in the central nervous 
system (Carlson et al., 1986). However, dietary causes are ruled out since both 
animal groups in this study were fed the same diet (section 2.3.2.1). This 
therefore points to abnormal PUFA metabolism as a possible cause of the 
increases in AA and total n-6 PUFA in the FSL rat brain regions. Abnormal 
PUFA composition has been reported in different brain regions in 
neuropsychiatry diseases such as Alzheimers disease (Skinner et al., 1993)
where a significant increase was reported in C22:4n-6 concentration.
An abnormality in metabolism suggests possible differences in metabolic 
enzymes. For instance, impairment in PLA2 activity in depression was one of the 
subjects of a previous report (Horrobin, 2001). PLA2 catalyzes the release of AA 
from the sn-2 position of phospholipids. Once AA is available, it is acted upon 
by COX-2 to produce various eicosanoids such as PGE2 in the AA cascade that 
have inflammatory effects. Previous findings have shown that in depressive 
patients, the concentrations of the 2 series prostaglandins and TXAs are 
elevated in blood, saliva and cerebrospinal fluid (Lieb et al., 1983, Piccirillo et 
al., 1994). Furthermore, neuropsychiatry drugs such as carbamazepine and 
valproic acid are known to downregulate cytosolic PLA2 and COX-2 activities 
and reduce the production of PGE2 (Bazinet et al., 2006, Rapoport and Bosetti, 
2002). Indeed there is a phospholipid hypothesis of neuropsychiatric diseases 
(Horrobin, 1998, Horrobin, 2001, Horrobin and Bennett, 1999) and 
neuroinflammation is accepted to be a characteristic of depression (Anisman 
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and Merali, 2003) and other neuropsychiatry disorders like Alzheimer’s disease 
(Liang et al., 2005). 
Another possible reason for the observed difference in AA in the control and 
FSL rats may be the process through which the FSL rat strains were developed. 
The FSL rats were genetically developed to be sensitive to the 
anticholinesterase agent diisopropyl fluorophosphate. This anticholinesterase is 
believed to phosphorylate neuropathy target esterase (Johnson, 1969) that has 
an important role in normal brain development and the homeostasis of 
membrane PC (Glynn, 2005). Neuropathy target esterase in turn possesses 
phospholipase B (PLB) activity therefore it can deacylate PC to yield 
glycerophosphocholine and free fatty acids (Glynn, 2006). It is therefore 
possible that diisopropyl fluorophosphates may have caused a disturbance of 
the activity of neuropathy target esterase consequently resulting in abnormal 
PC remodelling. In addition, there may be an accumulation of PC containing AA 
molecular species in the FSL rat brain. Thus detailed phospholipid analysis is a 
subject of further research for the FSL rat brain.
Other findings from this study showed a significant decrease in the 
concentration of DHA and total n-3 PUFA only in the hypothalamus of the FSL 
rats. This decrease seemed to have been compensated for by the increase in 
AA since total PUFA concentration was not altered in the FSL rats. In diet 
studies, it is reported that n-6 PUFA synthesis, specifically docosapentaenoic 
acid (22:5n-6) is elevated in DHA deficiency (Delion et al., 1994, Levant et al., 
2004) and C22:5n-6 is retroconverted to AA in the n-6 biosynthetic pathway 
(Sprecher et al., 1995). Since in this study dietary influence is ruled out, there 
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may be an abnormal preferential accumulation of precursors for n-6 PUFA 
metabolism at the expense of n-3 PUFA. n-6 and n-3 PUFA compete for the 
same metabolic enzymes, thus increased substrate availability in one family 
channels enzymatic activity towards that particular family thus increasing their 
metabolic products (Rahm and Holman, 1964). Furthermore, it has been 
demonstrated that reduced n-3 PUFA especially DHA may induce depression in 
pregnant rats and may affect brain development and induce behavioural deficits 
in the new born (Levant et al., 2007, Levant et al., 2004). In line with disturbed 
metabolism, it is also possible that the activity of the specific PLA2 for DHA 
release from phospholipids (Strokin et al., 2003) may be increased in the FSL 
rat brain. Thereby making DHA available for both enzymatic and non-enzymatic 
degradation. This hypothesis is also a subject for further investigation. It is also 
crucial to point out that the degree of unsaturation in both animal groups as was 
observed in the unsaturation index, was the same despite modifications in fatty 
acid concentrations. This suggests possible compensatory changes in the 
metabolism and distribution of unsaturated fatty acids in the FSL rat brain that 
may contribute to changes in brain structure and function.
In the nucleus accumbens and striatum there were significant alterations in 
individual monounsaturated fatty acids. These alterations included increased 
C18:1n-7 and reduced C18:1n-9 and erucic acid C22:1n-9 which did not affect 
the total levels of monounsaturated fatty acids as was previously reported 
(Green et al., 2005). Previous findings have also shown that PUFA including AA 
are more potent than their precursor essential fatty acids in inhibiting the 
synthesis of monounsaturated fatty acids of the n-9 series via desaturation by 
Δ9 desaturase (Clarke and Jump, 1996). Thus suggesting a re-distribution of 
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monounsaturated fatty acids in the FSL rat brain instead of absolute alteration 
in total concentrations. This redistribution instead of absolute reduction may 
support an important role monounsaturated fatty acids play in membrane fluidity 
and function (Ntambi, 1999). 
In the hypothalamus the concentrations of cholesterol and sphingomyelin were 
increased and the concentrations of total diacylglycerophospholipids and ether 
lipids were reduced. A similar trend was observed for total 
diacylglycerophospholipids in the prefrontal cortex. This negative correlation 
between cholesterol and sphingolipids with phospholipids has been reported in 
various lipidomics studies of brain degeneration and disorders such as age 
(Little et al., 2007) and Alzheimer’s disease (Nitsch et al., 1992). Cholesterol, 
phospholipids and sphingolipids are constituents of brain cell membranes. They 
are not randomly organised but asymmetrically organised in the brain cell 
membrane (Ikeda et al., 2006). Phospholipids and sphingolipids contribute to 
the lipid asymmetry, and cholesterol and sphingolipids form lipid rafts (Ramstedt 
and Slotte, 2006, Rietveld and Simons, 1998). Moreover lipid rafts have been 
reported to play a role in the pathogenesis of neuropsychiatric disorders 
including Alzheimer’s disease and Parkinson’s disease (Michel and Bakovic, 
2007).
It is quite interesting to note that the lipid profile of the hypothalamus was the 
most modified compared to the other brain regions of the FSL animals. This 
finding may be linked to depression. The hypothalamus is reported to be 
hyperactive in depression and this has been related to the disregulation of the 
HPA axis (Nestler et al., 2002). In humans, the hormonal end product of the 
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HPA axis is cortisol and this along with TXB2 has been shown to be increased 
in the plasma of depressed patients (Piccirillo et al., 1994). Interestingly, 
cholesterol is a precursor of steroid hormones such as cortisol, and thus its 
increased levels in the hypothalamus of the FSL rats may be related to the 
hyperactivity of the HPA axis in depression. Furthermore, the increased level of 
TXB2 in the plasma of depressed patients also suggests that fatty acid 
metabolising enzymes such as COX may play a role in depression. TXB2 is an 
AA derived lipid mediator generated via the COX pathway. Increased levels of 
AA in the FSL rat hypothalamus may therefore promote the upregulation of 
COX activity and subsequent production of prostanoids such as TXB2. 
These changes observed in the FSL brain regions are likely to induce structural 
and functional abnormalities. It has been demonstrated that there are brain 
structural and functional abnormalities in limbic and prefrontal cortical structures 
in depression (Drevets, 2000, Drevets et al., 2008). Changes in phospholipid 
composition and metabolism have been related to other aetiological hypotheses 
of depression including neurotransmitter receptor binding and function (Horrobin 
and Bennett, 1999, Peet, 2003). Additionally, functional impairment of central 
corticosteriod receptors has been reported in depression and is thought to be 
one of the hallmarks of HPA axis dysfunction [reviewed in (Swaab et al., 2005)]. 
The distortion in the structure of brain regions is also likely to influence the 
function of enzymes such as membrane bound enzymes such as PLA2 that are 
critical for phospholipid and fatty acid metabolism.
Furthermore, cholesterol and sphingomyeline form lipid rafts recently shown to 
be involved in brain serotonin transport (Magnani et al., 2004). This formation of 
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lipid rafts may also have a relevance to the pathogenesis of depression in the 
FSL animals. However, this hypothesis needs to be further investigated. It is 
worth pointing out that the hypothalamus also showed a significant increase in 
C18:0, one of the major saturated fatty acids found in mammalian cells 
(Christie, 1985). Saturated fatty acids are N-acylated to the sphingosine base of 
sphingolipids and are less fluid than essential fatty acids (Yehuda et al., 2002). 
Thus, this increase in C18:0 in the hypothalamus may be related to the increase 
in sphingolipids, which is likely to contribute to membrane microviscosity.
The FSL animal model has shown that alterations in brain lipid composition may 
accompany depression. However, more research is needed in other depressive 
animal models such as the WKY rat model, to further investigate these findings. 
This not withstanding, these findings may shed some light on the molecular 
mechanisms in the pathophysiology of depression and could help in predicting 
therapeutic targets and strategies.
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7.0 CONCLUSIONS AND FURTHER STUDIES
The present study evaluated the brain lipid profile in two models of 
neuroinflammation and one model of neuropsychiatric disorders and 
investigated the effects of atorvastatin on neuroinflammation. In an attempt to 
understand the modifications in lipid metabolism in neuroinflammation, we 
considered it important also to investigate the lipid profile of the liver of the 
same animals. The liver is a crucial organ for whole body lipid metabolism and 
is the target of statins that in addition to their inhibitory effects on cholesterol 
biosynthesis, also modulate fatty acid metabolism. 
Methodological evaluation
The lipidomic approach applied in this study was very informative. 1H-NMR 
spectroscopy is a non-destructive, highly reproducible method. It allowed the 
simultaneous identification and relative quantitation of choline and ethanolamine 
containing phospholipids, cholesterol, sphingolipids, sphingomyelin, 
plasmalogens, ether lipids, C18:2n-6, AA, DHA, n-3 PUFA, total saturated and 
unsaturated fatty acid chains and the degree of unsaturation of the unsaturated 
fatty acids, otherwise termed the unsaturation index in a crude lipid extract from 
the rat brain and liver. 1H-NMR provided initial information on the distribution of 
lipids in the brain and liver tissue. It showed the predominance of glycerol-
based phospholipids and cholesterol that where present in relatively similar 
amounts in the brain but lower amounts in the liver. 1H-NMR also showed global 
changes that occurred in the rat brain and liver lipid profile due to age, LPS 
challenge and depression, and treatment with atorvastatin. However, this 
analytical tool did not give detailed certain phospholipid species (namely PS 
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and PI) and fatty acid analysis. GC was used for detailed fatty acid analysis, 
and it was found that it also complemented the 1H-NMR analysis.
The examination of atorvastatin, and its metabolites para-hydroxyatorvastatin 
and ortho-hydroxyatorvastatin was necessary in order to gain more insight into 
the molecular mechanism of action of atorvastatin. A sensitive and selective 
method was therefore required for the examination of atorvastatin, para-
hydroxyatorvastatin and ortho-hydroxyatorvastatin in rat brain, liver and plasma. 
An LC/ESI-MS/MS assay was developed which permitted even very low 
concentrations of analytes to be detected.
Brain and liver lipid profile in age- and LPS-induced neuroinflammation 
In Chapter 4, it was demonstrated that age produced changes in the normal 
lipid profile of the brain and liver. The findings showed that quantitatively the 
brain and liver lipid compositions were different. In addition, the lipid 
compositions in these tissues were differentially modified by age. For instance 
in the brain, cholesterol was significantly increased, while phospholipids and n-3 
PUFA were significantly reduced with age. In the liver, age did not have any 
effects on cholesterol and phospholipids but n-3 PUFA was significantly 
increased. The liver supplies the brain with fatty acids, thus we attributed the 
increase in n-3 PUFA in the liver to a possible adaptative mechanism in an 
attempt to counteract the age-induced reductions in the brain. These findings 
also highlighted the importance of the liver as a site of total body lipid 
homeostatic regulation.
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In Chapter 5, LPS treatment was used to induce acute neuroinflammation in 
adult rats. Findings from brain and liver lipid profile analysis showed that the 
acute response of these tissues to inflammation also involves modifications in 
lipid metabolism. In both tissues, LPS did not induce any changes in the lipid 
classes but affected the concentration of monounsaturated fatty acids in the 
brain. Although it seemed that further elongation of C20:1n-9 was inhibited in 
the liver, this did not affect the total concentration of monounsaturated fatty 
acids in the liver. The findings in this study also showed that the liver was able 
to maintain its monounsaturated fatty acid metabolism and distribution more 
than the brain, in response to LPS treatment. 
A common finding in both age and LPS induced modifications in fatty acid 
composition is the significant increase in C18:1n-9 and total monounsaturated 
fatty acid composition. In age, this contributed to the significant increase in total 
unsaturated fatty acid concentration and may also be a compensatory 
mechanism occurring for the loss of n-3 PUFA. In the ageing human orbifrontal 
cortex, it has been reported that age induced a reduction in PUFA composition, 
including DHA and AA with a concomitant increase in stearoyl CoA desaturase 
expression and activity (McNamara et al., 2008). Additionally, it has been 
reported that C18:1n-9 and monounsaturated fatty acids have a fluidising effect 
on cell membranes (Barton and Gunstone, 1975, Ntambi, 1999) and C20:1n-9 
inhibits the formation of pro-inflammatory eicosanoids from AA (James et al., 
2000), so may be beneficial in n-3 PUFA deficit. 
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The modulatory effects of atorvastatin on age and LPS-induced 
alterations in brain and liver lipid profile
Findings from the aged study also showed that atorvastatin did not alter the 
cholesterol levels in the brain and liver of adult and aged animals. However, it 
modified some age related effects on fatty acids in the brain, like reversing the 
age-induced reduction in n-3 PUFA and increase in unsaturated fatty acid 
concentrations. It has been shown that treatment with n-3 PUFA may be able to 
improve neuronal membrane deficits in age (McGahon et al., 1999). In the liver 
also, atorvastatin reversed the increases in saturated and unsaturated fatty acid 
chains.
The effects of atorvastatin on the lipid profile of the liver in the LPS study were 
quite profound. Atorvastatin caused significant increases in cholesterol and total 
ethanolamine concentrations in both control and LPS-treated adult livers, as 
well as significant reductions in total choline phospholipids. These effects were 
not observed in the adult liver in the aged study. In the aged study, animals 
received atorvastatin in their diets for 8 weeks whilst in the LPS study, animals 
received atorvastatin in their diets for 3 weeks. It may therefore be proposed 
that the duration of administration (8 weeks versus 3 weeks) may have caused 
these differences in findings. The increase in rat liver cholesterol by atorvastatin 
may also be attributed to the paradoxical effect of statins in animals. The 
paradoxical effect of a drug occurs when the drug elicits an opposite effect to 
what is normally expected. The upregulation of HMG-CoA reductase and 
downregulation of cholesterol-7α-hydroxylase activities as demonstrated in 
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different studies using rats (Fujioka et al., 1995, Fujioka and Tsujita, 1997) may 
also contribute to this paradoxical effect.
We were able to detect some atorvastatin in the aged and adult rat brains. It 
can be infered from the findings in Chapters 4 and 5 that (i) age and LPS 
treatment altered the lipid profiles in brain and liver (ii) atorvastatin modulated 
the age and LPS induced lipid alterations and did not inhibit cholesterol 
biosynthesis (iii) these atorvastatin effects may contribute to its anti-
inflammatory and neuroprotective effects (iv) there may be short- and long- term 
effects of atorvastatin on cholesterol biosynthesis and that (v) atorvastatin may 
cross the blood brain barrier to reach the brain, although the mechanism by 
which this occurs is still unclear.
The profiling of brain lipids and fatty acids in the Flinders Sensitive Line 
rat model of depression
Chapter 6 explored the lipid profile of different regions of the FSL rat model of 
depression. The general finding in this investigation was the increased level of 
AA in the four brain regions of the FSL rats. This increase was suggested to be 
due to abnormalities in AA metabolism in the FSL strain and how this strain was 
developed and not due to diet. 
We showed for the first time that in the hypothalamus, in addition to the 
increased level of AA and reduction in DHA, ether lipids and total 
diacylglycerophospholipids were reduced while cholesterol and sphingolipids 
were increased. The increased level of cholesterol in the FSL rat hypothalamus 
may be related to the dysregulation of the HPA axis in depression (Nestler et 
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al., 2002). Neurons in the paraventricular nucleus (PVN) of the hypothalamus 
secrete corticotrophin-releasing factor (CRF), which stimulates the production 
and release of adrenocorticotropin (ACTH) from the anterior pituitary. ACTH 
stimulates the synthesis and release of glucocorticoids (cortisol in humans and 
corticosterone in rodents) from the adrenal cortex. Glucocorticoids modulate 
whole body metabolism and also affect behaviour through direct actions on 
brain regions such as the hippocampus and the amygdala. Cholesterol is a 
precursor of steroid hormones and may therefore contribute to the 
hypercortisolemia reported in depressed patients. Moreover, it has been 
suggested that a hyperactive HPA axis may contribute to depression not only 
through hypercortisolemia but also through enhanced CRF transmission in the 
hypothalamus and other brain regions that are innervated by PVN neurons 
(Nestler et al., 2002).
Cholesterol is known to reduce membrane fluidity with consequences on the 
activity of signal transduction, receptor function and dopamine release (Yehuda
et al., 2002). In addition, cholesterol forms lipid rafts with sphingolipids and lipid 
rafts are involved in neuronal signalling. Disordered cholesterol and sphingolipid 
metabolism are implicated in synapse loss and changes in nerve conduction 
(Colombaioni and Garcia-Gil, 2004). Fatty acids have differential effects on 
cholesterol metabolism. It is reported that n-6 PUFA redistribute cholesterol and 
n-3 PUFA actually reduce cholesterol concentration in neuronal membranes 
(Yehuda et al., 2002). DHA supplementation has been demonstrated to be 
beneficial in depression and DHA and EPA are known to inhibit the oxygenation 
of AA by COX thereby surpressing the production of pro-inflammatory 
eicosanoids and induction of pro-inflammatory cytokines (Corey et al., 1983, 
205
James et al., 2000). Furthermore plasmalogens have been reported to be 
reduced in neuropsychiatriic disorders such as Alzheimer’s disease and has 
been linked to the loss of DHA (Han et al., 2001). Alteration in phospholipid 
metabolism is also implicated in depression and some researchers have 
attributed this to abnormalities in the activities of enzymes involved in 
phospholipid remodelling such as PLA2 (Horrobin, 2001). 
Furthermore, in the prefrontal cortex we showed for the first time that total 
diacylglycerophospholipids was also reduced in parallel to an increase in AA 
concentration. It has been shown that major depression is associated with 
neuronal and glial cell loss in the prefrontal cortex (Cotter et al., 2002) and 
changes in glutamic acid release mediated by alterations in monoamine 
neurotransmission (Michael-Titus et al., 2000). In addition, a previous study 
showed that the level of the catecholamine, norepinephrine was increased in 
the prefrontal cortex, nucleus accumbens, hippocampus and median raphe 
nucleus of the FSL rats compared to Sprague-Dawley controls (Zangen et al., 
1999). AA has been shown to modulate neurotransmitter levels (Maida et al., 
2006). AA is one of the predominant PUFA at the sn-2 position of some 
phospholipids found in the brain such as PC and PI. It may be possible that due 
to an alteration in phospholipid metabolism via PLA2 free AA accumulates and 
thus available to modulate signal transduction. 
Future investigations
The findings from this study are not exhaustive. More research will be needed 
to address some of the issues raised from these results. 
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Although the analytical techniques employed in this study were informative, they 
did not provide information for the phospholipid molecular species. For instance 
in Chapter 5, it was observed that choline-containing phospholipids were 
significantly reduced and ethanolamine-containing phospholipids were 
significantly increased in the liver with atorvastatin treatment. This occurred 
concomitantly with a significant reduction in the concentration of AA in the 
control adult liver but not the LPS-treated liver. LC/ESI-MS/MS has been 
extensively used in lipidomic analysis and can provide information on 
phospholipid molecular species. Moreover, assessment of the results obtained 
from 1H-NMR and GC in this study with LC/ESI-MS/MS may further clarify the 
findings in this study. Analysis of the phospholipid molecular species of FSL rat 
brain regions is ongoing and some findings have been reported elsewhere. It 
may also be worthwhile to investigate the lipid composition of different brain 
regions in the models of neuroinflammation investigated in this study. This may 
give some insight on how different brain areas may respond to 
neuroinflammation.
It is still not clear whether atorvastatin can affect human brain cholesterol, it will 
be important to extend research in that area. Most studies have been based on 
animal models and findings may not be a true reflection of what could occur in 
humans. Moreover, statins inhibit cholesterol synthesis in the liver but in some 
animal species like rodents, this inhibition results in compensatory mechanisms 
that increase liver concenctration of cholesterol. It is therefore necessary to 
carry out this work on other animal models of neuroinflammation, especially 
those that respond to changes in cholesterol concentrations like humans. 
However, it is important to point out that this study did not investigate the 
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cholesterol lowering effects of atorvastatin in the liver or brain but investigated 
its anti-inflammatory effects in the brain with a view to understand the molecular 
mechanism of action. The rat models of neuroinflammation (aged and LPS-
treated rats) were investigated because it has been shown that atorvastatin
reduces neuroinflammation in rats. 
Species differences not withstanding, atorvastatin modified lipid and fatty acid 
metabolism in the normal adult rat brain and liver, thus care should be taken 
when using statins to treat not just central nervous system disorders but other 
diseases in which they have been found to be beneficial.
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IAppendix I
Composition of sunflower oil (Commission, 2005)
Fatty acid %
Palmitic acid 4-9
Stearic acid 1-7
Oleic acid 14-40
Linoleic acid 48-74
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Appendix II 
A typical 1H-NMR spectrum showing the diagnostic peaks used for lipid analysis
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Calculation of Fatty Acid Chains
Integral
Calculation of 
1H % mol
Total Chain: [0.80-0.98 ppm - 9xcholesterol]/3H (71.6 - 9 x 3.8)/3
[CH3 + omega-3]:    68.562 + 3.01 71.6 12.4 100
3.0/3 (1.0/12.4) x 100
omega-3 fatty acids (22:6, 22:5, 20:5, 18:3):[0.95 ppm/3H] 3.0 1.0 8.1
16.3/2
total chain from [2.3-2.35ppm/2H](fa esters) 16.3 8.1
0.3/2 (0.2/12.4) x 100
LIN: [2.75ppm/2H] 0.3 0.2 1.2
4.0/4 (1.0/12.4) x 100
DHA : [2.40ppm/4H] 4.0 1.0 8.1
2.2/2 (1.1/12.4) x 100
AR + EPA: [1.65-1.74/2H] 2.2 1.1 8.7
(35.0 - 2 x 3.8)/4 (6.8/12.4) x 100
unsaturated chains [1.90-2.15ppm - 2 x cholesterol]/4H 35.0 6.8 55.2
saturated chains [total chain - unsaturated chain]  100 - 55.2 44.8
22:5 + 20:5 + 18:3 [ 0.95ppm - 2.40ppm] 8.1 - 8.1 0.0
27.7 - 3.8/2
acyl chain double bonds[5.35ppm - 1 cholesterol/2H] 27.7 25.8
((27.7 - 3.8)/2)/12.4
unsaturation index [[5.35ppm-cholesterol]/2H]/total chain 1.0
Calculation of Phospholipids and Neutral Lipids
19.2/9 (2.1/9.8) x 100
total choline: [3.20 ppm/9H] 19.2 2.1 21.7
2.1 - 0.3 (1.9/9.8) x 100
PC: total choline-sphingomyeline 1.9 18.9
(0.3/9.8) x 100
sphingomyeline: ratioPC/SM:3.19ppm/3.21ppm 6.8 0.3 2.8
(2.0/9.8) x 100
total ethanolamine [3.10/2H] 4.1 2.0 20.6
(3.8/9.8) x 100
cholesterol: [0.69/3H] 11.5 3.8 38.9
(1.6/9.8) x 100
total sphingolipids: [ 5.70/1H] 1.6 1.6 16.4
(1.1/9.8) x 100
total ether lipids: [5.16/1H] 1.1 1.1 11.4
(1.0/9.8) x 100
plasmalogens: [5.92/1H] 1.0 1.0 10.2
(0.1/9.8) x 100
1-alkyl-2-acyl-GPL: [total ether-plasmalogens] 0.1 1.2
(3.3/9.8) x 100
DAGP (sn2): [5.22ppm/1H] 3.3 3.3 33.3
(1.4/9.8) x 100
PLA-b: [4.34 ppm/1H] 1.4 1.4 14.5
(3.7/9.8) x 100
total DAGPL: [4.43ppm/1H] 3.7 3.7 37.1
total lipids: total ether + sphingolipids + cholesterol + 9.8 100
 triglycerides + total DAGP
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CH
AA
DHA
PE
PC
EL
SPL
LA
1H-NMR spectrum of rat brain. EL: ether lipids, SPL: sphingolipids, PC: phosphatidylcholine, PE: phosphatidylethanolamine, CH: cholesterol, DHA: 
docosahexaenoic acid, AA: arachidonic acid, LA: Linoleic acid
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EL
SPL
LA
1H-NMR spectrum of rat liver. EL: ether lipids, SPL: sphingolipids, PC: phosphatidylcholine, PE: phosphatidylethanolamine, CH: cholesterol, DHA: 
docosahexaenoic acid, AA: arachidonic acid, LA: Linoleic acid
Appendix IV (B)
%
 R
el
at
iv
e
 a
b
un
d
an
ce
VI
Code Fatty acid % weight Retention 
time (min)
1 C4:0            butyric acid methyl ester 4 6.239
2 C6:0            caproic acid methyl ester 4 7.942
3 C8:0            caprylic acid methyl ester 4 9.896
4 C10:0          capric acid  methyl ester 4 12.095
5 C11:0          undecanoic acid methyl ester 2 13.436
6 C12:0          lauric acid methyl ester 4 15.051
7 C13:0          tridecanoic acid methyl ester 2 16.945
8 C14:0          myristic acid methyl ester 4 19.153
9 C14:1          myristoleic acid methyl ester 2 20.524
10 C15:0          pentadecanoic acid methyl ester 2 21.565
11 C15:1          cis-10-Pentadecenoic acid methyl ester 2 23.072
12 C16:0          palmitic acid methyl ester 6 24.191
13 C16:0          palmitoleic acid methyl ester 2 25.383
14 C17:0          heptandecenoic acid methyl ester 2 26.814
15 C17:1          cis-10-Heptadecenoic acid methyl ester 2 28.087
16 C18:0          stearic acid methyl ester 4 29.552
17 C18:1n-9t    eliadic acid methyl ester 2 30.157
18 C18:1n-9c   oleic acid tmethyl ester 4 30.595
19 C18:1n-7     vaccenic methyl ester Added a 30.801
20 C18:2n-6t     linolelaidic acid methyl ester 2 31.358
21 C18:2n-6     linoleic acid methyl ester 2 32.370
22 C18:3n-6     γ-Linolenic acid methyl ester 2 33.545
23 C18:3n-3     α-Linolenic acid methyl ester 2 34.507
24 C20:0          arachidic acid methyl ester 4 34.853
25 C20:1n-9     cis-11-eicosenoic acid methyl ester 2 35.850
26 C21:0          heneicosanoic acid methyl ester (Internal standard) 2 37.345
27 C20:2          eicosadienoic acid methyl ester 2 37.621
28 C20:3n-6     di-homo-γ-linoleic acid methyl ester 2 38.767
29 C204n-6      arachidonic acid methyl ester 2 39.581
30 C20:3n-3     cis- 11,14,17-Eicosatrienoic acid methyl ester 2 39.724
31 C22:0          behenic acid methyl ester 4 39.879
32 C22:1n-9     erucic acid methyl ester 2 40.985
33 C20:5n-3     eicosapentaenoic acid methyl ester 2 41.877
34 C23:0          tricosanoic acid methyl ester 2 42.495
35 C22:2          cis-13,16-docosadienoic acid methyl ester 2 42.930
36 C24:0           lignoceric acid methyl ester 4 45.367
37 C24:4n-6     docosatetrienoc acid methyl ester Added b 45.466
38 C24:1          nervonic acid methyl ester 2 46.723
39 C22:5n-3     docosapentaenoic acid methyl ester Added c 48.231
40 C22;6n-3     docosahexaenoic acid methyl ester 2 49.128
Appendix V (A) 
Composition of the fatty acid methyl ester (FAME) mixed standard used in this study
a = 20 μg/mlof C18:1n-7 was added
b = 20 μg/ml of C22:4n-6 was added
c = 20 μg/ml of C22:5n-3 was added
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A typical GC-FID chromatogram of rat brain fatty acids without internal standard.
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A typical GC-FID chromatogram of rat brain fatty acids with internal standard (IS).
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A typical GC-FID chromatogram of rat liver fatty acids without internal standard.
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A typical GC-FID chromatogram of rat liver fatty acids with internal standard (IS).
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XIII
weight of C21-Me in ng (IS) 939 (IS ng)
FATTY ACID AREA 1 AREA 2 AVERAGE AREA FAME ng % weight
(Average area/Average area of IS) x IS (ng) (FAME ng/Total FAME ng) x 100
C14 12.1 11.5 11.8 20.0 0.18
C15 11.6 11.3 11.4 19.5 0.18
C16 1173.4 1122.0 1147.7 1953.3 17.70
C16:1 14.0 13.6 13.8 23.5 0.21
C17 40.5 38.8 39.6 67.5 0.61
C17:1 16.7 15.6 16.2 27.5 0.25
C18 1428.1 1363.4 1395.7 2375.4 21.53
C18:1n-9c 624.3 596.3 610.3 1038.7 9.41
C18:1n-7 209.2 199.9 204.6 348.1 3.16
C18:2n-6t 0.0 0.0 0.0 0.00 0.00
C18:2n-6c 963.4 919.5 941.4 1602.24 14.52
C18:3n-3 19.7 18.9 19.3 32.82 0.30
C20:1n-9 10.0 9.2 9.6 16.27 0.15
C20:2 45.8 43.6 44.7 76.09 0.69
C20:3n-6 51.8 49.7 50.7 86.4 0.78
C20:4n-6 1518.0 1444.7 1481.4 2521.1 22.85
C20:5n-3 16.9 16.0 16.5 28.0 0.25
C24:0 37.5 36.4 36.9 62.9 0.57
C22:4n-6 31.3 30.2 30.7 52.3 0.47
C22:5n-3 66.0 62.9 64.4 109.6 0.99
C22:6n-3 344.1 329.0 336.6 572.8 5.19
IS 21:0. 564.8 538.7 939551.7 
(Average area of IS)
11034.0 (Total FAME ng) 100.00
Appendix VII 
Sample calculation of total fatty acid content
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